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Low birth weight is associated with cardiovascular disease and T2DM in later life. 
Paternal obesity and T2DM have been associated with an increased risk of fathering 
low birthweight offspring. Obesity is associated with epigenetic changes in blood, but 
few studies have replicated DNA methylation differences found in obese subjects. 
Animal studies have shown that obesity and insulin resistance are associated with 
DNA methylation changes in sperm, which in turn could mediate intergenerational 
effects. Such findings are lacking in humans. My PhD explored the association 
between paternal metabolic traits and the birth weight of his offspring. I then 
investigated whether DNA methylation signatures in spermatozoa of obese fathers 
could underlie any observed association with his offspring birthweight. 
First, I performed a prospective cohort study of 500 mother-father-offspring trios to 
identify paternal metabolic traits associated with an increased risk of fathering low 
birth weight offspring. Out of 390 trios, including 64 obese men and 48 growth-
restricted offspring, I did not discover any significant paternal metabolic traits 
associated with fathering low-birthweight offspring. However, I found that paternal 
(own) birth weight is associated with the birth weight of his offspring. This suggests 
that paternal genetic factors are more influential in determining his offspring’s 
growth in utero than are factors acquired during his lifetime. 
Second, I performed a systematic review of studies that had investigated DNA 
methylation in human sperm. From this review, I summarised current knowledge and 
generated recommendations for future research.  
I then performed the largest characterisation of matched human sperm and blood 
samples to date using the most comprehensive DNA methylation profiling array, the 
MethylationEPIC array. Results showed that the DNA methylomes of sperm and 
blood are highly discordant and in effect completely uncorrelated. Future studies of 
intergenerational effects will have to study germ cells, rather than blood. 
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Lastly, I attempted to validate previously-identified DNA methylation signatures 
associated with male obesity. Despite comparing 96 well-characterised obese men 
with 96 lean men, I was unable to replicate any previously identified differentially 
methylated CpG sites associated with obesity, in their blood. In a linear regression 
model, I identified two CpG sites, cg07037944 and cg26651978, as being suggestive 
of an association with BMI. These results will contribute to a larger cohort study of 
1000 obese and 1000 lean men that aims to identify a robust and reproducible DNA 
methylation profile associated with obesity. 
In conclusion, this thesis did not prove my pre-determined hypotheses. However, it 
does present findings which advance our understanding of the intriguing possibility 
that acquired parental metabolic phenotype may influence offspring birthweight 





Research presented in this thesis shows that a father’s Body Mass Index (BMI) around 
the time of conception has little impact on the birth weight of his offspring. However, 
other research has suggested that paternal BMI instead has a greater influence on 
the BMI of his offspring during childhood and later life. Research following on from 
this thesis will follow up the children born during my study to determine whether 
periconceptual paternal obesity sets a template for offspring obesity. Public health 
policies that target men at risk of obesity around the time of his partner’s pregnancy 
could have a beneficial impact on the health of the next generation and beyond. 
I found that paternal (own) birth weight is associated with the birth weight of his 
offspring, but that there is no such association between maternal (own) birthweight 
and offspring birthweight. This observation raises the intriguing possibility that 
paternal influences on offspring growth are predominantly genetic, whilst maternal 
influences are predominantly environmental. Furthermore, customised birthweight 
centiles for estimating fetal weight in utero may become more accurate if they 
included paternal (own) birth weight. This possibility needs to be tested in a future 
project.  
In the largest study of DNA methylation in matched sperm and blood samples 
performed to date, I show that the methylation profiles of sperm and blood are highly 
distinct and practically uncorrelated. These findings emphasise the necessity of 
studying germ cells, rather than proxy tissues, in analyses of intergenerational 
effects. They also question the validity of previous studies where blood has been used 
as a proxy tissue for sperm DNA methylation. 
This thesis contains the first systematic review of studies of DNA methylation in 
human sperm. From this, I summarise current knowledge in the field and set out a 
series of recommendations for future research. The systematic review will be of value 
for anyone interested in the epigenome of human germ cells, or designing studies of 
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the human sperm methylome. Such studies should aid our understanding of fertility, 
embryogenesis and the potential for the spermatozoal epigenome to be influenced 
by acquired traits. 
In terms of research methodologies that could be applied in future research, I have 
shown that bisulfite-PCR-sequencing represents a high-throughput, cost-effective, 
targeted alternative to reduced representation bisulfite sequencing in epigenome 
wide association studies. Results are well-correlated to those of DNA methylation 
profiling using the Illumina MethylationEPIC array. However, the methodology also 
has drawbacks, such as a generally lower read coverage. 
Future prospective studies to understand drivers of fetal growth that might be shared 
by a father and his offspring, may provide an early opportunity for the primary 
prevention of obesity in the next generation.  
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1.1 The Obesity Epidemic 
The obesity epidemic and related metabolic disease constitute major public health 
problems globally. Obesity, defined as a Body Mass Index (BMI) exceeding 30 kg/m2, 
is a major risk factor for comorbities such as Type 2 Diabetes Mellitus (T2DM), 
cardiovascular disease, chronic kidney disease, musculoskeletal disorders and some 
cancers, and surpasses smoking and alcohol consumption in its negative effects on 
health (1-3). Worldwide in 2016, 39% of adults, more than 1.9 billion people, were 
overweight (BMI >25 kg/m2), one-third of whom were obese (2). Since 1975, the 
worldwide prevalence of obesity has nearly tripled, and the trend is still increasing. 
Indeed, a recent pooled analysis of trends in body mass index, which collated results 
from studies with over 19 million participants in total, suggested that unless current 
trends are halted, the global prevalence of obesity will reach 18% in men and surpass 
21% in women by 2025 (4). In in low- and middle-income countries (LMICs), obesity 
increasingly occurs alongside persistent burdens of underweight, owing to changes 
in dietary habits and an increasingly sedentary lifestyle (5). 
In 2016, more than one in four UK adults (26.2%) were obese, and a further 35.2% 
were overweight (6). As a consequence, the UK prevalence of Type 2 Diabetes (T2DM) 
has risen dramatically, estimated at almost 9% of the UK adult population (7). The 
condition is more prevalent in people of black and Asian ethnicities and those in 
lower socioeconomic positions (8). In addition to its detrimental effect on quality of 
life, the rise in metabolic disease is associated with a significant economic burden. 
Indeed, recent estimates of the cost for treating obesity and related morbidity in the 
NHS amount to nearly £6 billion annually, whereas the annual cost for treating Type 
2 diabetes and its complications amounts to £14 billion pounds (3, 9). Together, 
healthcare spending for these two conditions account for approximately one sixth of 





Figure 1-1. Trends in obesity prevalence among UK adults 1993-2017. 
Data derived from annual Health Survey for England estimates of the prevalence of obesity among 
UK adult (over 16 years) men and women. Data points indicate three-year average values. Created 
using information available from (11). 
1.1.1 Health Consequences of Obesity 
Obesity and related disease constitute complex and heterogenous conditions 
resulting from an interplay of genetic, environmental and behavioural factors. 
Associated health risks are diverse, and include cardiovascular, pulmonary, 
endocrine, psychological and musculoskeletal conditions, as presented in Figure 1-2. 
Among the conditions most closely associated with obesity is the development of 
insulin resistance (IR) and T2DM. Although the exact pathophysiology of IR is 
heterogeneous and still a topic of research, lifestyle factors such as an atherogenic 
diet and physical inactivity are significant risk factors for its development. Enduring 
hyperglycaemia causes a compensatory high secretion of insulin from pancreatic b 
cells, which leads to diminishing insulin sensitivity of liver, skeletal muscle and 
adipose tissue. Eventually, pancreatic b cells fail to secrete high enough levels of 
insulin to maintain adequate glucose levels, and a pre-clinical condition of insulin 





Figure 1-2. Selected health risks associated with obesity. 
Figure created using information from (13, 14). 
Obesity, in particular central adiposity, forms one of the core diagnostic criteria of 
the Metabolic Syndrome. This describes a cluster of conditions that together are 
associated with a threefold increased risk of a cardiovascular event such as a 
myocardial infarction (12) (Figure 1-3). According to International Diabetes 
Federation criteria, a diagnosis of metabolic syndrome requires central obesity (waist 
circumference ³94 cm for Caucasian males) plus any two of the following: raised 
triglycerides (³1.7 mmol/L or specific treatment for high triglycerides), reduced HDL 
cholesterol (<1.03 mmol/L in males or specific treatment for this lipid abnormality), 
raised blood pressure (systolic blood pressure ³130 mmHg or diastolic blood pressure 
³80 mmHg or be treated for hypertension) or raised fasting plasma glucose (³5.5 




Figure 1-3. Diagnostic criteria for the Metabolic Syndrome according to the International Diabetes 
Federation (IDF) 2006. 
Figure created using information from (12). 
Obesity in pregnancy is associated with health risks both for the pregnant woman 
and the fetus. Thus, a pre-pregnancy BMI >40 kg/m2 significantly increases the risk of 
gestational diabetes mellitus, gestational hypertension, pre-eclampsia and 
thromboembolic events during pregnancy. Further, maternal obesity is associated 
with an increased risk of adverse intrapartum events, including emergency caesarean 
sections, wound healing complications following caesarean sections and admissions 
to intensive care units. Fetal and neonatal risks associated with maternal obesity 
include an increased risk of fetal malformations, intrauterine death and macrosomia, 
the latter of which is discussed further in section 1.2 (15). 
There is an estimated 4 million obesity associated deaths per year. Of these, 2.7 
million are estimated to occur as a consequence of cardiovascular events, 0.6 million 
from T2DM-related events, and the rest from causes such as cancer, chronic kidney 
disease, musculoskeletal disorders and adverse pregnancy outcomes associated with 
maternal obesity (13). 
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1.1.2 Obesity and Metabolic Disease: The Importance of Prevention 
Despite a nearly universal concern about the health risks associated with obesity and 
the enormous efforts that have gone into halting current trends in obesity 
prevalence, no national success stories have been reported (16). Indeed, once obesity 
is acquired, the probability of achieving and maintaining a normal body weight is low; 
an observational study using electronic primary care health records of over 150,000 
obese individuals with a nine year follow-up period showed that the annual 
probability of attaining a normal weight was 1 in 210 for men and 1 in 124 for women. 
The study further showed that the probability of attaining a normal weight decreases 
with increasing BMI category, and that even among individuals who initially managed 
a decrease in BMI category, the vast majority thereafter regained weight ( 
Figure 1-4) (17). 
Further, large-scale observational studies show that individuals born to obese 
parents have a significantly increased risk of themselves becoming obese as adults. 
Thus, in a pooled analysis of the annual Health Surveys for England carried out 
between 2001 and 2006, in total analysing data from 4,432 families, having two 
obese parents was associated with a significantly increased risk of childhood obesity 
(OR: 22.3; 95% CI: 10.3, 48.4; p < 0.01) independent of age, sex, socioeconomic status, 
and ethnicity (18). Childhood obesity is itself a strong predictor of adult obesity. 
Indeed, it has been estimated that when both parents are obese, about 80% of their 
children will be obese. This incidence falls to approximately 40% when one parent is 
obese, and to approximately 14% when both parents are lean (19). 
It is therefore clear that in order to halt the obesity epidemic and its devastating 
consequences, focus needs to be placed on primary prevention. As stated by the 
Department of Health in a 2011 report on tackling obesity in the UK: 
  
 27 
“ We need to adopt a life course approach – from pre-conception, through pregnancy, 
infancy, early years, childhood, adolescence and teenage years, and through to 
adulthood and preparing for older age” (20). 
 
Figure 1-4. Probability of individuals who initially decreased in BMI category to thereafter 
increase, maintain or decrease their weight. 
As visualised, approximately 60% of obese individuals who initially decreased their BMI category (to 
the category indicated on the x axis) thereafter increased their weight over the nine year follow up 





1.2 The Genetic Architecture of Obesity and Type 2 Diabetes Mellitus 
Obesity and T2DM are conditions characterised by high heritability estimates (21, 
22). Heritability describes the proportion of the phenotypic variance of a trait that is 
attributable to genetic factors (23). Classically, this has been estimated by collecting 
data from twin, adoption and family studies, which all attempt to separate the 
genetic versus environmental influences on a trait based on genetic relatedness of 
the individuals included in the study (24, 25).  
Studies in monozygotic twin pairs rely on the twins’ identical genetic makeup, making 
any difference in phenotypic variance between a twin pair attributable to unique 
environmental factors. In contrast, dizygotic twin pairs only share approximately 50% 
of their variable genetic make-up and can be assumed to have shared the same 
environment (24). One can assume that unique environmental factors contribute to 
a trait equally in monozygotic and dizygotic twin pairs. Therefore, it is possible to 
estimate the effect of the additional genetic similarity between monozygotic twin 
pairs by comparing the phenotypic correlation between monozygotic and dizygotic 
twins respectively. In adoption studies, the genetic contribution to a trait is estimated 
by comparing the risk of the trait to biological versus adoptive relatives of affected 
versus control adoptees. If the adoption study is of monozygotic twins that have been 
separated at birth and reared apart, any phenotypic correlation between the twin 
pair can be assumed to arise from genetic factors (24). Family studies frequently use 
estimates of the expected genetic relatedness between two individuals (e.g. 50% 
between full siblings and 12.5% between first cousins) (25). In family studies of binary 
traits, the concordance or discordance of disease status can be estimated using a 2 
by 2 contingency table. For continuous phenotypic traits, e.g. BMI, heritability can be 
estimated by the slope of the regression line, which approximates the heritability of 
a trait when the mean phenotypic value of the parents is used (24, 25). In summary, 
such pedigree analyses have allowed estimations of how much of the phenotypic 
variance in BMI and in the risk of T2DM can be attributed to genetic factors. 
In a meta-analysis of studies involving over 34,000 monozygotic twin pairs in total, 
the Discordant Twin (DISCOTWIN) Consortium estimated the heritability of T2DM to 
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be 72% (95% CI 61-78%) (21). Similarly, in the case of obesity, heritability estimates 
range from 40% to 70% (22). The high prevalence, heritability and considerable 
health consequences of T2DM and obesity have spurred intensive efforts into 
uncovering genetic variants that increase the risk of developing these conditions. 
The current understanding of the genetic basis of obesity and T2DM is similar to that 
of other common, complex diseases. Thus, in a small proportion of individuals, the 
condition occurs as a result of single gene variants with large effect sizes. However, 
in the vast majority of cases, the disease phenotype results from a complex 
interaction between lifestyle factors and a large number of disease risk conferring 
genetic variants, each with small effect sizes (26-28)(Figure 1-5).  
At least 10 gene variants have been associated with severe, monogenic obesity 
(typically defined as a BMI > 35 kg/m2) (29). These include single nucleotide 
polymorphisms (SNPs) in the gene for leptin (LEP), and in the Melanocortin 4 
Receptor (MC4R). Leptin is a hormone primarily produced by adipocytes and is 
involved in appetite regulation in part by suppressing the orexigenic peptides 
neuropeptide Y (NPY) and agouti-related peptide (AGRP) in the hypothalamus, thus 
reducing food intake (30). The melanocortin 4 receptor is a hypothalamic receptor 
involved in a leptin-targeted neural circuit of energy homeostasis (29). Indeed, the 
melanocortin 4 receptor, which is present in the hypothalamic arcuate nucleus, 
responds to levels of leptin, glucagon-like peptide 1 (GLP-1) and ghrelin (amongst 
others) and has a pivotal role in integrating these signals and regulating energy 
expenditure, satiety and growth accordingly (31). Individuals with an MC4R mutation 
typically present with severe obesity in childhood, lack of feelings of satiety, and have 
a higher fat mass ratio as adults (32). Studies in mice have further demonstrated that 
a targeted disruption of the MC4R gene is associated with increased food intake, 
obesity and hyperinsulinaemia (33). However, the most common form of these 
genetic variants, which is mutations in MC4R causing melanocortin 4 receptor 
deficiency, is only present in approximately 1% of adults with a BMI exceeding 30 





The vast majority of cases of obesity and T2DM are likely to have arisen from a complex interaction 
between a large number of disease-conferring alleles, each with small effect sizes, that together with 
lifestyle factors produce the disease phenotype. MAF = Mean Allele Frequency. Figure created with 
information from (28). 
From 2005 onwards, large-scale genome-wide association studies (GWASs) of obesity 
have aimed to uncover common SNPs, each with small additive or multiplicative 
effects, that together may explain a proportion of the heritability of the condition. 
From such analyses, over 300 SNPs associated with BMI, waist-to-hip ratio and other 
adiposity-related traits have been identified (35). Among the more robust and well-
replicated findings have been the association between BMI and SNPs in the fat mass 
and obesity associated (FTO) gene. Several of these SNPs are located in the first intron 
of the FTO gene, and each additional minor (risk) allele is associated with a 
0.39 kg/m2 higher BMI (36). Other obesity associated SNPs have more modest effect 
sizes of 0.06-0.33 kg/m2 per BMI-increasing allele, and SNPs identified to date can 
only explain a small proportion of the variance in BMI. For example, a meta-analysis 
of BMI-associated SNPs identified through GWASs and Metabochips (custom 
genotyping arrays for genetic studies of metabolic, cardiovascular and 
Figure 1-5. The genetic architecture of common conditions such as T2DM and obesity, and 





anthropometric traits) that included almost 340,000 individuals, identified 
approximately 100 loci, but these loci together accounted for only around 2.7% of 
variance in BMI (37). However, the variance explained by genetic known variants will 
likely increase; simulations based on whole-genome sequencing indicate that SNPs 
are able to explain approximately 27% of BMI variance (38). 
The genetic background of T2DM is similar to that of obesity. Thus, whilst a small 
proportion of individuals develop the disease as a result of rare variants with high 
penetrance, the majority of cases occur as a result of several variants, each with small 
effect sizes (39). 
One form of monogenic diabetes is maturity-onset diabetes of the young (MODY). 
This non-insulin dependent form of diabetes accounts for between ~ 1 and 4% of all 
cases of diabetes in those diagnosed under the age of 30 years, and is inherited in an 
autosomal dominant fashion (40). The disease can be caused by a mutation in one 
out of a number of different genes, several of which are involved in glucose and 
insulin signalling and function (41)(Figure 1-6). The majority of MODY cases arise as 
a result of a mutation in one of four genes: Glucokinase (GCK), Hepatocyte Nuclear 
Factor 1 Alpha (HNF1a), Hepatocyte Nuclear Factor 1 Beta (HNF1b) and Hepatocyte 
Nuclear Factor 4 Alpha (HNF4a) (42). Approximately one third of cases of MODY 
occur as a result of heterozygous mutations in GCK. Under normal circumstances, 
glucokinase acts as an intracellular glucose sensor such that as glucose enters 
pancreatic b cells, glucokinase catalyses the first step towards its conversion to ATP, 
which leads to downstream secretion of insulin (Figure 1-6). Mutations in GCK 
therefore reduce the potential of b cells to secrete insulin in response to glucose, 
resulting in fasting hyperglycaemia (41). 
The hepatocyte nuclear factors are transcription factors that have complex and wide-
encompassing roles in embryonic development and regulation of adult metabolism 
(43). They are expressed in a variety of adult human tissues, in particular the liver, 
kidney and pancreas (43). Among other cellular functions, HNF1a regulates 
transcription of insulin (INS) and glucose transporter 2 (GLUT2) a transmembrane 
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glucose carrier, in mature pancreatic β-cells (44). In line with this, HNF1a knock-out 
mice develop diabetes as a result of decreased insulin secretion (45). In humans, 
MODY caused by HNF1a mutations presents as fasting hyperglycaemia resulting from 
progressive β-cell dysfunction (43). HNF4a are thought to act in the same 
transcription pathway as HNF1a, and has a similar clinical phenotype as MODY 
caused by HNF1a mutations (43). MODY caused by HNF1b mutations, in contrast, is 
characterised both by β-cell dysfunction and insulin resistance, and commonly 
involve renal complications such as renal cysts (46). HNF1b is regulates transcription 
of HNF1a as well as GLUT2, exemplifying the interconnectedness of these key 




Figure 1-6. Schematic of a pancreatic b cell and genes implicated in Maturity Onset Diabetes of the 
Young (MODY). 
Genes implicated in MODY are depicted in red. 
The majority of cases of adult T2DM, however, have a polygenic basis, and numerous 
GWASs have attempted to uncover common genetic variants that through additive 
effects increase the risk of developing the condition (47-50). A recent study 
aggregated findings from 32 genome wide association studies of T2DM, allowing 
assessment of disease risk conferring genetic variants in almost 900,000 individuals, 
8% of which had T2DM (51). The greatly expanded sample size compared to the 
individual GWASs, combined with high-density imputation led to the identification of 
243 genome-wide significant loci, including rare (MAF<0.5%) but highly penetrant 
genetic variants with odds ratios as high as 8.05 (p<5x10-8) (51). Despite the large 
sample size and sophisticated bioinformatic approaches for detecting causal genetic 
variants, however, the combined effect of the identified loci could only explain 
approximately 18% of T2DM risk (51).  
In summary, the genetic contribution to obesity and T2DM is one in which a minority 
of cases result from rare genetic variants with high penetrance, whereas most cases 
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are due to several genetic variants, each with small effect sizes. However, there is at 
present still a considerable discrepancy between the relatively high heritability 
estimates for obesity and T2DM and the risk for these conditions attributable to 
known genetic variants (24). There are several potential underlying reasons for this 
“missing heritability”. One is that we are at present unable to detect rare genetic 
variants, in particular those in regions of low linkage disequilibrium (23). Another is 
our yet limited ability to assess the influence of gene-environment interactions on 
phenotypic traits. As study sample sizes increase and bioinformatic approaches 
improve, the genetic contributions to obesity and T2DM will become increasingly 
better characterised. However, in parallel to deciphering the underlying genetic 
landscape of these conditions, there is also value in understanding the 
developmental, gene-environment and environmental factors that contribute 
towards the disease phenotypes. 
1.3 Birth Weight and Adult Metabolic Health 
An individual’s risk of developing metabolic disease is influenced by their growth in 
utero (52, 53). It is well established that large for gestational age (LGA) infants, usually 
defined as a birth weight above the 90th centile for gestational age, have a higher 
risk of developing obesity and type 2 diabetes in later life (53). A meta-analysis of 20 
studies investigating the association between birth weight and adult obesity risk 
showed that infants born LGA, here defined as a birth weight > 4000 grams, were at 
significantly higher risk of developing obesity in adolescence and adulthood when 
compared to infants with a birth weight < 4000 grams (OR 2.07; 95% CI 1.91-2.24) 
(53). 
Maternal obesity and gestational diabetes mellitus (GDM) are major risk factors for 
giving birth to an LGA infant. Indeed, maternal obesity doubles the risk of LGA 
offspring (54). Gestational diabetes is loosely defined as any degree of glucose 
intolerance with its onset, or first diagnosis, during pregnancy (55). It usually resolves 
after delivery, but constitutes a risk factor for later development of T2DM in the 
mother (54). GDM affects approximately 5% of pregnancies worldwide, although this 
figure depends on maternal ethnicity, phenotype and the criteria for blood glucose 
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thresholds following a glucose tolerance test (GTT) (54). Unless adequately 
controlled, GDM is also significantly associated with increased offspring birth weight 
as well as an increased risk of diabetes in the next generation (56, 57). The 
mechanism behind this is thought that the increased glucose availability from the 
mother promotes fetal hypersecretion of insulin, which leads to fetal macrosomia 
(58, 59). 
At the other end of the birth weight spectrum, small for gestational age (SGA) infants 
are also at risk of developing metabolic syndrome in adulthood. In the late 1980’s, 
Barker and Hales noted a correlation between low birth weight and later 
development of lifestyle-related disorders, including impaired glucose tolerance, 
type 2 diabetes (T2DM), hypertension and cardiovascular disease (52). A key 
observational study was the Hertfordshire cohort study, which assessed birth weight 
records of 468 men born between 1920 and 1930 and found that the prevalence of 
impaired glucose tolerance, overt diabetes and hypertension at age 57-70 years fell 
progressively with higher birth weights such that the rate of T2DM was 40% if born 
at less than 2.5kg and less than 14% if born at more than 4.3kg (52). These and other 
findings led to the development of the ‘thrifty phenotype’ hypothesis (60). This 
hypothesis proposed that prenatal malnutrition leads to lifelong changes in insulin 
sensitivity, which together with lifestyle factors predisposes an individual to 
components of the metabolic syndrome in later life (60). The concept has been 
expanded to the “developmental origins of disease hypothesis” which broadly 
proposes that adult disease risk can be programmed by the perinatal environment 
(61). 
Further evidence that low birth weight is associated with an increased risk of adult 
metabolic disorders was provided by the Dutch Hunger Winter, a historical disaster 
that nevertheless has improved our understanding of the link between fetal growth 
and adult health. The Dutch Hunger Winter describes a period of extreme and acute 
food shortage in the West Netherlands between December 1944 and May 1945. This 
event occurred due to a German blockade against food shipments, resulting in daily 
food rations of only 400-800 kcal per day (62). This provided a key setting to study 
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the association between prenatal undernutrition and adult health because of several 
unique characteristics; 1) the famine was imposed on a previously well-nourished 
population, 2) detailed prenatal and birth records were kept throughout the period 
and 3) when the famine abruptly ended the population went back to normal 
nutritional intake. Birth weight was affected by the stage of gestation at which 
fetuses were exposed to maternal famine; if affected in late pregnancy they were 
lighter than those affected in early gestation (where the mother went back to normal 
nutritional intake towards late pregnancy). Even so, early nutritional deprivation had 
lasting effects on adult health. At age 50 and 58 years, individuals who had been 
exposed to famine early in pregnancy had a higher average BMI, a more atherogenic 
lipid profile and a higher prevalence of cardiovascular disease than unexposed 
individuals. Exposure to famine at any stage of gestation was associated with 
impaired glucose tolerance. Low birth weight was specifically associated with 
hypertension (62). 
More recently, large-scale meta-analyses have supported the association between 
low weight at birth and the risk of adult metabolic syndrome (63). A recent meta-
analysis that included a total of 7,646,267 participants showed that for each kilogram 
increment in birth weight, there was a 22% reduction in risk of later developing T2DM 
(OR ratio: 0.78, 95% CI: 0.70–0.87) (63) (Figure 1-7). The same study showed in a 
binary analysis that participants with a birth weight <2.5 kg experienced a 45% (OR: 
1.45, 95% CI: 1.33–1.59) higher risk of T2DM than those with a birth weight ≥2.5 kg 
(63). In addition, each kilogram increment in birth weight was associated with a 
16.5% reduction in risk of developing CVD (OR: 0.84, 95% CI: 0.81–0.86) (63). 
Studies of the association between low birth weight and adult risk of obesity has 
yielded more mixed results. Some observational studies suggest that low weight at 
birth is associated with an increased prevalence of adult obesity. Thus, in a cross-
sectional study of approximately 2,500 adults in the Swiss CoLaus cohort, a birth 
weight of £2.5 kg in women was associated with an increased risk of obesity in 
adulthood when compared to the reference birth weight category of 2.5-3.5 kg (p < 
0.001). However, this study failed to correct for gestational age at birth (64). Large-
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scale meta-analyses have contradicted such findings. For example, a meta-analysis 
by Zhao et al. that examined data from fifteen studies of low birth weight and adult 
obesity found no evidence for an association between a birth weight of <2.5 kg and 
adult obesity when compared to birth weights between 2.5-4 kg (OR = 1.17, 95% CI 
0.94, 1.46) (65).
 
The blue line represents point estimates of association, and the grey lines are the corresponding 95% 
CI. Data derived from (65). 
Part of the explanation for the mixed results may reside in the impact of accelerated 
postnatal ‘catch-up’ growth, typically described as low birth weight infants gaining 
weight within their first two years of life such that their age-adjusted centile for 
weight is significantly higher at age 1 or 2 years compared to that at birth. Catch-up 
growth is now considered to be particularly detrimental for adult risk of metabolic 
disorders, pointing towards an increased ‘metabolic vulnerability’ of low birth weight 
infants towards lifestyle-related disease (66). 
Figure 1-7. Dose-response relationship between birth weight and adult risk of T2DM from a meta-
analysis including a total of over 4,000,000 participants. 
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In summary, however, the consensus is that there is a U-shaped correlation between 
weight at birth and the risk of developing metabolic syndrome in adulthood, such 
that birth weights at both ends of the spectrum predispose to components of the 
metabolic syndrome. 
1.4 The Paternal Influence on Offspring Birth Weight 
Fetal growth in utero is determined by an interaction between the fetal genotype, 
where 50% of genes come from each parent, and the in-utero environment, which is 
wholly provided by the mother. As previously discussed, the intrauterine 
environment, for example the availability of glucose, is a crucial determinant of fetal 
growth. However, it has become increasingly evident that paternal factors also have 
an important influence on his baby’s birth weight. 
Magnus et al. examined the complete birth cohort of Norway 1967-98, which 
included nearly 70,000 mother-father-firstborn child trios, and demonstrated that 
paternal weight at birth was a significant determinant of offspring birth weight (67). 
There was an almost linear correlation between paternal birth weight and offspring 
birth weight within groups of maternal birth weight ( 
Figure 1-8). For example, if the mother had a normal birth weight of 3500-3999g but 
the father had a low birth weight of <2500g, the relative risk of their offspring being 
born with a low birth weight of <2500g was 2.0. If the father and mother had a normal 
birth weight of 3500-3999g, this risk drops to 1.1 (67). The authors conclude that 
there is a significant paternal genetic contribution towards offspring weight at birth, 




Figure 1-8. In a study of almost 70,000 mother-father-firstborn child trios, Per Magnus et al. found 
an almost linear increase in mean offspring birth weight according to paternal birth weight group. 
The differently coloured lines indicate groups of maternal weight at birth as detailed in the legend. 
Maternal and paternal birth weights are placed into 250g groups such that birth weight group 2500 = 
2500-2749, 2750 = 2750-2999, 3000 = 3000-3249 etc. Data derived from (67). 
More recent research has suggested that not only genetic, but also acquired paternal 
traits, including obesity and insulin resistance, have the potential to influence fetal 
growth and weight at birth. A nested cohort study by McCowan et al. involving 2002 
couples in the prospective Screening for Pregnancy Endpoints (SCOPE) cohort, found 
that men who fathered SGA infants, defined as a birth weight <10th customised birth 
weight centile, were more likely to be obese compared with men who fathered 
normally grown infants (adjusted OR 1.50, 95% CI 1.05-2.16) (68). The study adjusted 
for maternal factors such as age, ethnicity, BMI, smoking status and maternal birth 
weight. Fathers of SGA offspring were also more likely to have central adiposity, 
defined as a waist circumference >102 cm (68). In line with the study by Magnus et 
al. discussed above, men who fathered SGA infants were found to have had a lower 
birth weight themselves (mean 180g lighter, p < 0.0001), supporting a self-
perpetuating cycle of low birth weight, adult obesity and an increased risk of 
fathering SGA offspring.  
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A study by Hillman et al. provided further support for the association between 
paternal metabolic syndrome and low birth weight offspring. This case-control study 
compared metabolic parameters of men who had recently fathered pregnancies 
affected by SGA (n = 42, mainly FGR) with men who fathered appropriately grown 
neonates (n = 77). Insulin resistance was determined by comparing homeostatic 
model assessment of insulin resistance (HOMA-IR) values, which evaluates insulin 
resistance based on fasting blood glucose and insulin levels, between the two groups 
of fathers. Fathers of SGA offspring were more likely to be sub-clinically insulin 
resistant (OR 7.68 of having a 1 unit higher log HOMA-IR value; 95% CI 2.63–22.40; p 
= <0.001), and were also more likely to smoke (OR 3.39; 95% CI 1.26–9.16; p = 0.016), 
when controlling for factors such as maternal disease, age, BMI, ethnicity, and parity 
(69). In line with previous research discussed above, this study also found that fathers 
of SGA offspring were more likely to themselves have been light at birth (birth weight 
3127±597g for fathers of SGA offspring, versus 3506±380g for fathers of AGA 
offspring, p = 0.0045). 
Observational studies therefore suggest that whereas maternal obesity and insulin 
resistance is associated with LGA offspring, paternal metabolic syndrome may be 
associated with an increased risk of fathering SGA offspring (65, 68, 69). 
1.5 The Genetic Association between Paternal Insulin Resistance and Offspring 
Birth Weight 
Clues towards the mechanism behind the epidemiological association between 
paternal insulin resistance and low offspring birth weight may be provided by the 
influence of forms of monogenic diabetes on the birth weight of an infant whose 
father has the condition. Indeed, GCK mutations in MODY provide an example of a 
genetic variant that confers insulin resistance in a father as well as predisposes his 




As discussed in section 1.2, glucokinase (GCK) mutations lead to defective glucose 
sensing and insulin secretion. Women heterozygous for a GCK mutation are typically 
asymptomatic until screened for gestational diabetes, when they are found to have 
fasting hyperglycaemia. This glucose overload stimulates fetal insulin secretion and 
women with a GCK mutation, therefore, tend to give birth to LGA infants, provided 
that the fetal genotype is normal. If there is ultrasound evidence of macrosomia in 
pregnancies of women with GCK mutations, therefore, they should be offered insulin 
treatment during pregnancy (71). The effect is large; infants born to women with GCK 
heterozygosity are on average 601g heavier at birth than AGA infants (p = 0.001) (72). 
In cases where a fetus is heterozygous for a GCK mutation and the mother has a 
normal genotype, i.e. where the fetus has inherited the condition from the father or 
developed it de novo, the fetus will fail to secrete enough insulin in response to 
glucose, and will be SGA. Indeed, the average birth weight of these infants is 
decreased by as much as 533g (p = 0.002) (72). If both the mother and the fetus are 
heterozygous for a GCK mutation, the effects of the hyperglycaemic environment and 
the low insulin secretion in the fetus effectively cancel each other out, resulting in 
normal birth weight infants. 
In summary, there are genetic variants that both predispose a fetus to poor 
intrauterine growth and to an increased risk of adult diabetes. This concept is known 
as the fetal insulin hypothesis (70).
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 Figure 1-9. Birth weight centile distribution in 58 offspring in families with GCK mutations 
according to maternal and fetal GCK genotype. 
M+F- denotes a maternal GCK mutation and a normal fetal genotype, M+F+ denotes a maternal and 
a fetal GCK mutation, M-F- denotes a normal maternal and fetal genotype and M-F+ denotes a 
normal maternal genotype and a fetal GCK mutation. Figure created using data from (70). 
Single gene mutations like MODY provide an example of the link between parental 
insulin resistance and offspring growth. However, most cases of diabetes are a result 
of additive effects from a large number of genetic variants, each with small effect 
sizes (section 1.2). From this follows that there would be an overlap between genetic 
variants identified in large cohorts of individuals with T2DM and genetic variants 
identified in large cohorts of low birth weight infants. A GWAS meta-analysis of birth 
weight in over 150,000 individuals identified 60 SNPs that were significantly 
associated with birth weight at a genome-wide level (p < 5 x10−8) (73). Nine of these 
had previously been associated with adult T2DM (73). However, taken together, the 
60 birth weight loci could only explain approximately 2% of variance of birth weight. 
This indicates either that increasingly large sample cohorts are required to detect 
underlying genetic effects, or that other factors, such as gene-environment 
interactions, underlie part of the epidemiological association between low weight at 
birth and an increased risk of metabolic syndrome in adulthood (73, 74). 
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1.6 Bridging the Gap: Epigenetic Inheritance and Fetal Growth 
At present, only a small proportion of the epidemiological association between 
paternal metabolic disorders, e.g. obesity and T2DM, and fetal growth can be 
explained by genetic associations. Although improvements in methodology and 
increased sample sizes are likely to identify a larger number of genetic variants 
predisposing to both dysregulated fetal growth and adult risk of diabetes in the years 
ahead, the strong impact of environmental and lifestyle-related factors on the 
pathogenesis of T2DM makes a plausible case for gene-environment, or epigenetic, 
changes, to explain part of the impact of paternal health on fetal growth. 
Epigenetics is generally defined as ‘the study of changes in gene function that are 
mitotically and/or meiotically heritable and that do not entail a change in DNA 
sequence’ (75, 76). In other words, epigenetics refers to regulation of gene 
expression that do not involve changes in the underlying genetic code. As such, while 
the genetic code is preserved in all human cell types, epigenetic alterations allow 
gene expression to be regulated in a tissue- cell- and developmental stage specific 
manner (77). Epigenetic changes are dynamic, allowing organisms to alter their gene 
expression in response to factors such as environmental conditions, tissue specific 
requirements and nutrient availability (78, 79). In broad terms, epigenetic 
mechanisms act by altering the accessibility of chromatin towards the transcriptional 
machinery, and by regulating gene expression at a post-transcriptional level (80, 81). 
There are three distinct but interrelated epigenetic mechanisms (Figure 1-10): 
(1) DNA methylation: the addition of a methyl group to the 5-carbon of cytosine, 
forming 5mC,  
(2) posttranslational modifications of histones, including methylation, 
acetylation, phosphorylation and sumoylation, and  
(3) noncoding RNAs (ncRNAs) 
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Figure 1-10. Overview of epigenetic mechanisms. 
Epigenetics is generally taken to include three distinct but interrelated mechanisms; DNA 
methylation, posttranslational modifications of histones, and non-coding RNA.  
lncRNA = long non-coding RNA. 
(1) Methylation of mammalian genomes occurs predominantly at cytosines next 
to guanines (‘CpG sites’). DNA methylation at gene promoters and enhancers 
is generally associated with transcriptional silencing, whereas DNA 
methylation in the gene body tends to be associated with active gene 
expression, although there are exceptions (79). Removal of DNA methylation 
can occur both by passive and active mechanisms. Passive demethylation of 
DNA occurs in the absence of maintenance methylation of newly synthesised 
DNA strands during replication (82). The active process involves enzymes such 
as ten eleven translocation (TET) enzymes. TET enzymes can oxidise 5mC to 
yield 5-hydroxymethylcytosine (5hmC) (82). Further oxidation, again by TET 
enzymes, generates 5-formylcytosine (5fC) and 5-carboxylcytosine (5caC) 
(82). 5fC and 5caC can be cleaved by thymine-DNA glycosylase (TDG) and then 
recognised by the base excision repair system in which they are replaced with 
an unmethylated cytosine (82). 
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(2) Histone methylation can either repress or activate transcription, depending 
on which lysine is methylated. For example, trimethylation of histone H3 at 
lysine 4 (H3K4me3) is associated with active gene transcription, whereas 
dimethylation of histone H3 at lysine 9 (H3K9me2) is associated with 
transcriptional silencing (83). Unlike methylation, acetylation of histones 
potentiates and deacetylation suppresses gene expression (83) 
 
(3) Non-coding RNAs, including microRNAs (miRNAs), PIWI-interacting RNAs 
(piRNAs), and long non-coding RNAs (lncRNAs), can affect RNA silencing and 
post-transcriptional regulation of gene expression and be transmitted 
independently of the genetic sequence and are thus also considered part of 
the epigenetic machinery (84).  
1.7 Overview of Epigenetic Profiling 
Regulation of epigenetic processes is fundamental to normal mammalian 
development and its dysregulation has been linked to a wide range of disease 
processes (79). Thus, the last couple of decades have seen increasingly sophisticated 
methods of characterising epigenetic signatures associated with a range of human 
traits and diseases. Characterisation of epigenetic signatures of disease can aid the 
understanding of disease pathogenesis, develop biomarkers for disease progression 
and identify therapeutic targets (85). The majority of studies thus far have focussed 
on DNA methylation, which will also form the focus of the methods of epigenetic 
profiling discussed below. 
1.7.1 Overview of DNA Methylation Profiling 
DNA methylation is fundamental in biological processes such as X chromosome 
inactivation, silencing of retroviral transposable elements and long-term regulation 
of gene expression (86). DNA methylation is the most studied epigenetic mark in 
human health and disease to date (79). This is partly owing to it being more stable 
than non-coding RNA and histone modifications, and to the availability of 
commercial, cost-effective methylation analysis platforms that allow single base 
resolution profiling of targeted CpG sites using probes on a microarray. 
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The current gold standard technique for analysing DNA methylation is whole-genome 
bisulphite sequencing (WGBS). This technique commences with the treatment of 
genomic DNA with sodium bisulfite, which converts unmethylated cytosines (C) to 
uracil (U), while leaving methylated cytosines unchanged. During subsequent whole 
genome amplification, uracil is amplified to its complementary base thymine (T). 
These steps effectively transform the DNA methylation analysis into a genotyping 
assay, as the initially methylated CpG sites can be identified through determining the 
presence of C versus T. Bisulfite treatment and whole genome amplification is 
followed by whole-genome highly parallel sequencing. 
WGBS has been successfully applied to create a complete map of the ~ 28 million CpG 
sites in the human genome using a variety of tissues and cell types (87). However, 
due to the high cost per sample and expertise required to analyse WGBS data, this 
technique is not always the most practical. Thus, microarray-based technologies that 
enable the interrogation of a large number of DNA fragments in a highly parallel 
fashion have become widely used and have allowed the completion of large-scale 
epigenome-wide association studies into multiple complex human conditions. 
Among microarray-based technologies, the lllumina BeadChips are among the most 
extensively employed, and consist of three-micron silica beads on a solid surface, 
each bead covered with hundreds of thousands of copies of a specific 
oligonucleotide, which act as the capture sequences in a given Illumina assay. 
The first Illumina Methylation BeadChip, the HumanMethylation27K (HM27), was 
introduced in 2008. The array interrogated methylation across >25,000 CpG sites, 
mainly within promoter regions of well-described genes. The HM27 allowed the first 
epigenome-wide association studies (EWASs) to be performed, for example leading 
to an improved understanding of the role of aberrant DNA methylation in 
carcinogenesis and its association to ageing and smoking (88, 89). 
The HM27 was superseded by the Illumina HumanMethylation450 (HM450) in 2011. 
The HM450 allowed investigation of >485,000 CpG methylation sites across the 
genome, including CpG islands, shores and shelves, 5’ UTR, 3’ UTR and bodies of 
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RefSeq genes, the MHC region and some enhancer regions (87). The HM450 
represented a significant improvement compared to its predecessor, and rapidly 
became the most widely used platform to study DNA methylation and its association 
to a broad range of conditions, including several forms of cancer, immune related 
disorders such as rheumatoid arthritis and the effect of maternal smoking in 
pregnancy on the neonate (90-93).  
However, the HM450 was not without issues. For example, in the years since the 
HM450 was introduced, the importance of DNA methylation in the regulation of 
transcriptional activators binding to genomic enhancer regions was increasingly 
recognised (87). It was therefore problematic that CpGs from only a small proportion 
of enhancer regions were represented on the array (86). Enhancer regions, which 
may be located hundreds of thousands base pairs away from the transcription start 
site, allow transcriptional regulation by binding to transcriptional activators, which 
enhance the activity of the promoter e.g. by stabilising interactions between 
transcription factors and the transcription machinery (Figure 1-11)(86). 
The most recent of the Illumina DNA methylation arrays is the Illumina 
MethylationEPIC Array (EPIC), which was introduced in 2015. The EPIC array was 
specifically designed to interrogate potential enhancer regions as well as 90% of the 
CpG sites assayed by the HM450 (79). The Illumina MethylationEPIC Array is 




1.7.2 Overview of Histone Modification Profiling 
There is a range of methods for detecting targeted, global and genome-wide post-
translational modifications (PTMs) of histones. Among the most widely used methods 
of histone profiling is chromatin immunoprecipitation (ChIP). Briefly, this involves 
cross-linking DNA-histone interactions with formaldehyde followed by fragmentation 
of the DNA (bound to histones). Antibodies are then targeted towards the specific 
histone modification of interest and the DNA bound to the isolated histone can be 
analysed e.g. by quantitative PCR (ChIP-PCR), microarray-hybridisation (ChIP-chip) or 
next generation sequencing (ChIP-seq) (94). 
More recently, issues such as antibodies cross-reacting with similar modifications on 
the same histone protein, or on a different histone protein, as well as the 
requirement for a prioi knowledge about the type of modification of interest, have 
made approaches such as mass spectrometry more widely used for studying histone 
modifications. Mass spectrometry, in contrast to antibody-based methods, allows 
unbiased profiling of several PTMs simultaneously (95). 
Figure 1-11. Transcriptional regulation via enhancer regions. 
TATA box = genomic region containing a high density of T and A and which forms part of the 
promoter region. TFIID = Transcription Factor II D. 
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1.7.3 Overview of Profiling non-coding RNA 
Non-coding RNA species are RNA species that do not encode for proteins. They 
constitute a diverse set of RNA molecules which includes long non-coding RNAs 
(lncRNAs), transfer RNAs (tRNAs), ribosomal RNAs (rRNAs) as well as several types of 
small RNA species such as microRNAs, small interfering RNAs (siRNAs) and piwi-
interacting RNA (piRNAs). 
The gold standard for RNA profiling is next generation RNA sequencing. This method 
is replacing previously popular hybridization-based microarray methods, and allows 
an unbiased assessment of the presence and quantity of RNA molecules in biological 
samples (96). In brief, the method involves extracting messenger RNA (mRNA) from 
the organism, tissue or cell of interest, fragmenting the mRNA, and generating double 
stranded complementary DNA (cDNA) using reverse transcriptase. The cDNA 
molecules are then amplified, fragmented and sequenced based on a reference 
genome. Aligning the RNA-seq reads against a reference genome also allows mapping 
them into genomic positions. For sequencing of small RNA species, the cellular RNA 
is size selected prior to generation of cDNA, e.g. with a size exclusion gel of size 
selection magnetic beads. 
1.8 Epigenetics and Metabolic Syndrome 
The rapid rise in the prevalence of obesity cannot be explained by genetics alone, but 
more adequately by a combination of genetic susceptibility, environmental factors 
and gene-environment interactions. This observation has spurred intensive efforts 
into uncovering which, if any epigenetic variants are associated with the disease 
phenotypes (24). 
In non-human mammals, there are convincing examples of how specific epigenetic 
perturbations can not only be associated with metabolic phenotypes, but also be 
causal (97). For example, knockout of the H3K9-specific demethylase Jhdm2a leads 
to obesity and hyperlipidaemia in mice (98). Mechanistically, it was shown that that 
this single epigenetic factor deficiency decreased the physiological ability to respond 
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to β-adrenergic stimulation via two key regulators of metabolism; uncoupling protein 
1 (UCP1) and peroxisome proliferator-activated receptor alpha (PPARα) (98). 
In humans, however, intervention studies are less feasible from an ethical and 
methodological perspective. Instead, most studies have been increasingly large-scale 
epigenome-wide association studies (EWASs) of DNA methylation in obesity and 
T2DM. The underlying hypothesis has been that the epigenetic architecture of these 
conditions is equivalent to their genetic counterpart, i.e. that in the majority of cases, 
several epigenetic variants, each with small effect sizes, contribute towards the 
phenotype. In the discussion below, I have specifically focused on DNA methylation 
signatures of obesity as opposed to those of T2DM. This was partly to limit the scope 
of the discussion, but also because the review of studies investigating DNA 
methylation in obesity formed the basis of a validation experiment aimed to generate 
a robust and reproducible DNA methylation profile described in Chapter 6. 
1.8.1 DNA Methylation in Human Obesity 
Early studies of DNA methylation in human obesity frequently focussed on candidate 
genes. These included imprinted genes with known involvement in growth 
regulation, e.g. IGF2/H19, and genes with known functions in appetite regulation, e.g. 
pro-opiomelanocortin (POMC) (99). However, such hypothesis-driven approaches 
yielded inconsistent results. Since the introduction of array-based DNA methylation 
analyses tools, studies have progressed to a less biased interrogation of the 
methylome as well as to include increasingly large sample cohorts. In order to 
summarise the current understanding of the association between DNA methylation 
and human obesity, I performed a review of studies using the PubMed database in 
June 2019. The following selection criteria were employed: 
• Analysis of DNA methylation in association to human obesity or BMI 
• Minimum sample size of 1000 participants (discovery and replication cohorts 
combined) 




Nine studies were identified using the above criteria and are summarised in Table 
1-1. All studies analysed blood or blood components. The minimum cut-off of 1000 
participants was chosen to limit the scope of the review, and because the robustness 
of findings from EWASs is closely related to its sample size. Indeed, among the studies 
included in this review, there was a clear correlation between the size of the 
discovery cohort and the number of genome-wide significant CpG sites identified in 
the EWAS (R2 = 0.765, p = 0.001) (Figure 1-12).
  
Figure 1-12. Correlation between number of participants in obesity EWAS discovery cohorts and 
number of CpG sites identified after correcting for multiple testing. 
R2= 0.765, p = 0.001. For references to the original publications see Table 1-1. 
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 Author, year, 
reference 
 




Dick et al., 
2014 
Discovery cohort 459 BMI Whole blood 5 (FDR) Caucasian Cardiogenics Consortium 
 (100) Replication cohort 339 BMI Whole blood 3 (Bonf.) Caucasian MARTHA 
  Replication cohort 2 1789 BMI Whole blood 3 (Bonf.) Caucasian KORA 
Aslibekyan et 
al., 2015 
Discovery cohort 991 BMI CD4+ T cells 8 (Bonf.) European Americans GOLDN 
 (101) 
 
  WC   5 (Bonf.)   
 
  Replication cohort 1 2105 BMI Whole blood 2 (Bonf.) European Americans FHS 
      WC   3 (Bonf.)   
 
  Replication cohort 2 1935 BMI Whole blood 4 (Bonf.) African Americans ARIC 
  Meta-analysis 5031 BMI Whole blood 8   
 




Discovery cohort 2097 BMI PBLs 76 (Bonf.) African Americans ARIC 
 (102)     WC   164 (Bonf.)   
 
  Replication cohort 3368 BMI Whole blood/ 
CD4+ T cells 
37 (Bonf.) European Americans FHS + GOLDN 
    991 WC CD4+ T cells 8 (Bonf.) European Americans GOLDN 
Al Muftah et 
al., 2016 
Discovery cohort 123 BMI Whole blood None Arab Quatari family study 
 (103)     T2DM   1 (Bonf.)   
 
  Replication cohort 810 BMI Whole blood None Caucasian TwinsUK 
      T2DM   None   
 
  Meta-analysis* 123 + 810 BMI Whole blood None 
  






Discovery cohort 3743 BMI Whole blood 135 (Bonf.) European Americans + 
Caucasian 
FHS + LBCs 
 (104) Replication cohort 4055 BMI Whole 
blood/CD4+ T 
cells 
83 (Bonf.) African Americans + 
European Americans + 
Caucasian 
ARIC + GOLDN + PIVUS 
Sayols-
Baixeras et al., 
2017 
(105) 
Discovery cohort 641 BMI Whole blood 94** (Bonf.) European REGICOR 
  Replication cohort 2515 WC Whole blood 49** (Bonf.) European Americans FOS 
Wahl et al., 
2017 
(106) 
Discovery cohort 5387 BMI Whole blood 278 (Bonf.) European + Indian-
Asian 
EPICOR + KORA + LOLIPOP 
  Replication cohort 4874 BMI Whole blood 187 (Bonf.) European + Indian-
Asian 
ALSPAC + EGCUT + Leiden 
Longevity + LifeLines Deep 
+ LOLIPOP + RS-BIOS + RS-
III + TwinsUK 
Dhana et al., 
2018 
(107) 
Discovery cohort 1450 BMI Whole blood 14 (Bonf.) European Rotterdam Study 
      WC Whole blood 26 (Bonf.)   
 
  Replication cohort 2097 BMI Whole blood 12 (Bonf.) African Americans ARIC 
      WC Whole blood 13 (Bonf.)   
 
Wang et al., 
2018 
(108) 
Discovery cohort 700 BMI 
(obese vs 
lean) 
PBLs 76 (Bonf.) African Americans 
(14-36 years) 
EpiGO, LACHY, BP Stress 
Study 
 
Replication cohort 2097 BMI PBLs 54 (FDR) African Americans ARIC 
  Replication cohort 188 Obese vs 
lean 
Neutrophils 37 (FDR) African Americans Subgroup of EpiGO 
Table 1-1. EWASs of obesity associated genome-wide CpG methylation.  
Legend continued on the following page.
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Table 1.1. Analyses of DNA methylation associated with obesity 
* Study replicated 1 out of 8 T2DM and 7 out of 39 BMI findings from previous EWASs in the Quatari 
discovery cohort. The meta-analysis was performed on these 8 replicated loci 
** Results are from a meta-analysis of discovery and replication cohorts. 
WC = Waist Circumference, PBL = Peripheral Blood Leukocyte, FDR = False Discovery Rate, Bonf = 
Bonferroni, ARIC = Atherosclerosis Risk in Communities, MARTHA = MARseille THrombosis 
Association Study, KORA = Cooperative Health Research in the Augsburg Region, GOLDN = Genetics 
of Lipid Lowering Drugs and Diet Network, FHS = Framingham Heart Study, PIVUS = Prospective 
Investigation of the Vasculature in Uppsala Seniors, REGICOR = Girona Heart Registry, EpiGO = 
Epigenetic Basis of Obesity-Induced Cardiovascular Disease and Type 2 Diabetes, FOS = Framingham 
Offspring Study, LOLIPOP = London Life Sciences Population Study, ALSPAC = Avon Longitudinal 
Study of Parents and Children, EGCUT = Estonian Genome Center of the University of Tartu, RS-BIOS 
= Rotterdam Study Bios Cohort, RS-III = Rotterdam Study-III, LACHY = Lifestyle, Adiposity, and 
Cardiovascular Health in Youth.
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A general observation is that there is considerable overlap in the study cohorts that 
have been analysed in these EWASs. For example, the Atherosclerosis Risk in 
Communities (ARIC) cohort has been included as a discovery cohort in one study, but 
as a replication cohort in a further four studies. The Framingham Heart Study (FHS) 
cohort has been studied as a discovery cohort in one study and a replication cohort 
in a further two studies. It is therefore possible that findings that appear to be robust 
and reproducible partly arise from studies that sample the same cohorts as previous 
researchers have done. 
The first large scale obesity EWASs was published in 2014 (100). The study identified 
3 CpG sites that were associated with BMI on a genome-wide level in both the 
discovery and replication cohorts (100). Interestingly, all three of these probes 
mapped to intron 1 of Hypoxia Inducible Factor 3 Subunit Alpha (HIF3A), a 
transcription factor that is involved in regulating cellular responses to hypoxia. The 
same study found that one of the significant probes, cg22891070, was also associated 
with BMI in adipose tissue, but not in skin (p = 1.72 x 10-5 and p = 0.882 respectively). 
Demerath et al. similarly identified an association between methylation of HIF3A and 
BMI and waist circumference in a cohort of over 2000 adults (102). Notably, these 
studies included cohorts with different ethnic backgrounds as discovery cohorts, 
suggesting that the association may be relatively independent of underlying genetic 
architecture. Subsequent research has supported the involvement of HIF3A 
methylation in the development of obesity. Thus, Pfeiffer at al showed that HIF3A 
methylation at cg22891070 was significantly higher in visceral adipose tissue 
compared to subcutaneous adipose tissue, and that its methylation level correlated 
with BMI (109). 
There is, however, an overall lack of concordance of findings. The two largest studies 
to date found 187 obesity-related CpGs (Wahl et al) and 83 CpGs  (Mendelson et al), 
but only 37 CpGs overlapped between the two studies (104, 106). Discrepancies 
could in part be explained by studying populations of different ethnicities or ages. 
However, in the context of deciphering disease pathophysiology and identifying 
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biomarkers for disease progression, the current lack of a robust, reproducible 
epigenetic signature of obesity presents a hindrance. 
Despite the paucity of concordance between some study results, there are individual 
findings that have been convincingly replicated. These include CpG sites annotated 
to carnitine palmitoyltransferase 1A (CPT1A). In a study of 991 participants in the 
Genetics of Lipid Lowering Drugs and Diet Network (GOLDN) cohort, Aslibekyan et al. 
found that methylation of intron 1 of CPT1A was significantly associated both with 
BMI and waist circumference (101). This finding was replicated in both a Quatari and 
a UK cohort (103). Further, Demerath et al. identified CPT1A methylation as 
associated with BMI and waist circumference, and showed that that CPT1A 
methylation is associated with BMI in adipose tissue (102). Similarly, in the largest 
obesity EWAS performed to date, Wahl et al. found that CPT1A methylation is 
significantly associated with BMI (106). With the caveat that some of these studies 
had partially overlapping study cohorts, it thus seems that CPT1A methylation is 
robustly associated with BMI and related traits. The gene product of CPT1A, carnitine 
palmitoyltransferase 1A, is involved in the transport of fatty acids across the 
mitochondrial inner membrane (102). Indeed, deficiency of carnitine 
palmitoyltransferase results in a decreased rate of fatty acid beta-oxidation (110). 
Therefore, epigenetic dysregulation of CPT1A appears to be involved in the 
pathogenesis of obesity (103). 
Another significant and replicated finding from obesity EWASs is differential 
methylation of probes annotated to Sterol Regulatory Element Binding Transcription 
Factor 1 (SREBF1). This transcription factor, sometimes called the ‘master regulator 
of lipid homeostasis’, regulates expression of the low density lipoprotein receptor 
and other genes involved in cholesterol synthesis (102, 111). Multiple studies have 
shown that individuals with obesity have differential DNA methylation at CpG sites 
associated with SREBF1 (102-107). Dysregulated expression of the SREBF1 gene 
product has consistently been linked to conditions such as non-alcoholic fatty liver 
disease (NAFLD) and insulin resistance in humans and mice (112, 113). In a large-scale 
meta-analysis of GWASs investigating T2DM, which included over 70,000 individuals, 
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independent SNPs at SREBF1 reached study-wide significance (p<2.4x10-6) (114). 
These results suggest that genetically and/or epigenetically dysregulated expression 
of SREBF1 could be a relatively common feature of metabolic syndrome. 
1.8.2 DNA Methylation in T2DM 
Early studies of the epigenetics of T2DM typically employed a candidate gene 
approach. Such studies included analysing the insulin gene itself (INS) and other 
genes with known roles in insulin signalling, e.g. the glucagon-like peptide-1 receptor 
(GLP1R) (110). However, these approaches have now been largely replaced by 
genome-wide interrogations of CpG methylation. 
There is overlap between CpG sites identified as significantly associated with T2DM 
and obesity. For example, the fat mass and obesity associated (FTO) gene, which is 
linked to obesity development, was identified as differentially methylated in the first 
large-scale EWASs of T2DM (115). Also, in a recent study where previously identified 
T2DM associated CpG sites were replicated in a novel cohort of 100 type 2 diabetics 
and 100 controls, only five out of 15 initially significant replicated sites remained 
significant after controlling for BMI (116). 
A recent systematic review of EWASs of T2DM indicated that just over 100 CpG sites 
have been significantly associated with T2DM in studies of blood (116). EWASs of 
tissues directly relevant to T2DM, such as pancreatic tissue, have been less fruitful, 
yielding a total of 18 significant CpG sites to date. However, this is likely due to small 
sample cohorts (the largest one including a total of 35 individuals with T2DM) (116). 
1.8.3 Histone Modifications and Non-Coding RNA in Obesity and T2DM 
Further technological advancements are required before post-translational 
modifications (PTMs) to histones and ncRNA species associated with obesity and 
T2DM can be studied in a cost-effective way on a large scale. There is also a need for 
development of high-throughput methods of analysing cross-talk between 




Nevertheless, there are indications that histone modifications and their 
dysregulation are likely to be involved in T2DM. For example,  several histone 
deacetylases called sirtuins (SIRT1-7) have been repeatedly identified as involved in 
insulin resistance, metabolic processes and inflammation (117, 118). One of the 
sirtuins, SIRT1, suppresses inflammation in both adipocytes and macrophages and 
improves glucose tolerance and reduces hyperinsulinaemia (119). 
Recent research has also begun to disentangle the role of ncRNA species in obesity 
and T2DM. Case-control studies have demonstrated down- or upregulation of 
specific miRNAs in obesity and T2DM, some of which could emerge as useful 
biomarkers for disease progression (120). The roles of ncRNAs have also been 
demonstrated in studies on non-human mammals. For example, in a murine model, 
the brown fat long non-coding RNA (Blnc1) forms a core component of hepatic 
lipogenesis via the LXR/SREBP1c pathway, which is implicated in the development of 
NAFLD (121). In another murine model, obesity was associated with significantly 
elevated levels of the lncRNA Lnc-leptin, which is transcribed from an enhancer 
region upstream of leptin and which is required for leptin synthesis (122). 
1.8.4 Conclusions from Epigenomic Profiling of Obesity and T2DM to date 
The majority of large-scale EWASs of complex conditions so far have been performed 
on components of blood. As epigenetic signatures are highly tissue- and even cell-
specific, the results of such analyses need to be interpreted with caution. In the 
context of obesity and T2DM, more relevant tissues to study are the liver, pancreas, 
hypothalamus and adipose tissue. Some studies have addressed this issue by 
attempting to replicate findings from EWASs performed in blood in more relevant 
metabolic tissues. One large epigenome-wide association study used the 450K 
human methylation array to identify 187 differentially methylated CpG sites 
associated with BMI in blood (106). They then found that methylation levels at these 
187 loci correlated moderately to strongly between blood and metabolically relevant 
tissues, including included subcutaneous and omental fat, liver, muscle, spleen and 
pancreatic tissue (106). There was directional consistency in 120 out of the 187 sites 
for an association with BMI in both adipose tissue and blood (p < 0.05 after 
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Bonferroni correction). The authors suggest that the CpG sites identified in blood are 
therefore a reasonable reflection of their methylation levels in adipose tissue. 
Similarly, in liver, 114 of the 187 CpG sites showed directional consistency for 
association with BMI compared to blood (p = 0.001). It should be noted, however, 
that the overall correlation between methylation levels of the 187 CpG sites 
identified in blood compared to the other tissues ranged widely (R = 0.37− 0.93, p = 
8.9 x 10−8 to 1.9 x 10−82). Perhaps such inconsistency between tissues could serve as 
a cautionary note for future epigenetic investigations where blood is used as a 
surrogate for a tissue more relevant to the disease phenotype. Further, the fact that 
there was a correlation between findings in blood and other (more disease-relevant) 
tissues should have spurred investigation into whether the correlation could be 
explained by underlying genetic variation rather than BMI. Thus, there could be 
genetic variants, either at the at the CpG site itself or elsewhere in the probe 
sequence, that influenced CpG methylation at the sites of interest without being 
associated with BMI. 
A significant challenge in interpreting results from EWASs is determining causality, 
i.e. whether a phenotype has occurred due to epigenetic alterations, or whether a 
phenotypic change has induced epigenetic change. Recent studies have begun to 
address this issue by using methods like Mendelian randomisation. The approach 
relies on the natural randomisation of genetic variants that occurs at conception and 
frequently uses SNPs identified through GWASs to infer causality as to whether 
particular CpG methylation signals identified in EWASs are likely to be a cause or 
effect of the phenotype of interest (123). This method was employed by Wahl et al. 
to investigate the potential causal relationships between DNA methylation in blood 
and BMI. A weighted genetic risk score was first calculated from a previously 
published GWAS of BMI, and then for each of the 187 identified significant CpGs, the 
effect of genetic risk score on methylation predicted through BMI was compared to 
the directly observed effect of genetic risk score on the CpG. An overall strong 
correlation between observed and predicted effects was seen (R2 = 0.81, p = 4.7 x 10-
44). This suggests that for the majority of the CpG sites, methylation in blood is the 
consequence rather than the cause of BMI variance (106). 
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A pertinent question in this context is what proportion of phenotypic variance could 
be attributable to epigenetic alterations. In a meta-analysis of 94 CpG sites identified 
as associated with BMI in a total of approximately 3000 individuals, it was estimated 
that the collective effect of methylation of these sites explained between 14-26% of 
the observed variation in BMI (105). Such estimates are likely to be refined as sample 
sizes increase and bioinformatic analyses improve. Still, these figures suggest that 
obesity is associated with substantial differences in DNA methylation. 
In addition to those mentioned, there are several other caveats with results from 
EWASs of obesity and T2DM performed to date. For example, the Illumina HM450, 
which has been used in all large-scale obesity EWASs performed to date, only 
captures approximately 1.7% of the ~ 28 million CpG sites in the genome, and is 
heavily biased towards promoter regions. Future studies should use methylation 
arrays with improved coverage of enhancers and other regulatory regions, e.g. the 
MethylationEPIC array, until WGBS becomes a cost-effective alternative. Further, 
there should be increased interrogation into whether genetic variants could have 
influenced EWAS results, such as in studies of the correlation of epigenetic markers 
between tissues. Well-powered longitudinal analyses are likely to be key in this 
regard, and have the potential to detect biomarkers and epigenetic perturbations 
related to disease complications before the complications develop, allowing tailored 
interventions. 
In summary, epigenome-wide association studies of components of the metabolic 
syndrome have largely focussed on CpG methylation in common conditions such as 
obesity and T2DM. The vast majority of studies thus far have been cross-sectional 
and thus unable to definitively determine causality. Studies have generally been 
performed on blood, and only a small proportion of CpG sites identified have been 
robustly replicated across cohorts. Despite these caveats, it seems that there are 
epigenetic variants associated with obesity or T2DM. Continued elucidation of these 
would improve our understanding of disease pathogenesis and identify biomarkers 
for disease progression. 
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1.9 Inheritance of Epigenetic Marks through Gametes 
Paternal genetic factors influence fetal growth, but can paternal epigenetic marks 
acquired through the development of metabolic traits, be transmitted from father to 
offspring (67, 124)? This phenomenon is known as inter- and transgenerational 
epigenetic inheritance. Intergenerational effects occur when a fetus is exposed in 
utero, which can affect both the F1 and F2 generation (on the maternal side). On the 
paternal side, intergenerational effects refer to acquired or environmental changes 
to his germ cells that impact the F1 generation (125, 126). In strict terms, 
transgenerational effects refer to when epigenetic information is transmitted to the 
F2 generation (on the paternal line or in a maternal line in which exposure occurred 
only before conception) or F3 (on the maternal line when exposure occurs during 
pregnancy) generation and beyond (125). To convincingly show that germ cell 
alterations induce phenotypic changes in his offspring, several confounders need to 
be accounted for. These include changes in factors such as the composition of 
seminal fluid, the maternal reproductive tract at conception, the in utero 
environment and parental behavioural factors (127). 
Transgenerational epigenetic inheritance in humans is controversial, in part due to 
the extensive epigenetic reprogramming that mammalian germ cells and 
preimplantation embryos undergo in order to generate an epigenetic state 
competent for totipotency (128). In other words, because a zygote requires the 
potential to differentiate into every tissue in the human body, its epigenetic makeup 
is reset between generations. Two distinct waves of epigenomic erasure occur; one 
shortly after fertilisation, during preimplantation development in the pronuclear 
zygote, and one in primordial germ cells (PGCs), during gonadal formation. 
Reprogramming of human primordial germ cells (hPGCs), including erasure of 
imprinting and epimutations, restores full germline totipotency (128) (Figure 1-13). 
DNA demethylation occurs both through passive loss of methylation during DNA 
replication, in the absence of methylating enzymes, and through active removal of 
methylation (129). Alongside demethylation, hPGCs undergo chromatin 
reorganisation and X reactivation (128). These processes mean that methylation 
levels in hPGCs are at basal level around week 5-7 of embryonic development (128). 
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In the peri-implantation period, the genome is re-methylated in a sex-, cell- and 
tissue-specific manner, allowing for lineage commitment, X-inactivation and 
establishment of imprinting. Recent research suggests that some loci escape the 
described genome-wide demethylation process, both in mouse and in human PGCs 
(128, 130). Notably, these ‘escape loci’ are preferentially found in genes controlling 
neurological and metabolic processes and are enriched for in gene bodies and 
regulatory regions (128). This implies a potential mechanism for environmentally 
acquired traits to be transmitted from one generation to the next. 
In men, a third period of epigenetic reprogramming occurs with the onset of 
spermatogenesis and spans from puberty to adulthood (131). This may explain how 
changes in adult health and metabolism could impact on the sperm epigenome and 
gene expression in future generations. 
hPGCs undergo the most comprehensive wave of global DNA demethylation shortly following 
fertilisation. A second wave of demethylation occurs in the primordial germ cells during gonadal 
development in the developing embryo. Adapted from (128). 
Figure 1-13. Schematic showing the dynamics of preimplantation and germline epigenetic 




1.10 Paternal Metabolic Syndrome, Epigenetic Inheritance and Fetal growth: 
Studies in Animals 
Studies in non-human mammals have demonstrated that the sperm methylome can 
be altered by environmental and physiological change, including dietary alterations, 
toxins and even psychological stress (132-137). However, simply showing that an 
environmental factor is associated with germline epigenetic changes does not mean 
this change influences the next generation. Further, such associations are of little 
value in the context of intergenerational inheritance unless they also account for the 
widespread demethylation process that occurs between generations. More 
convincingly, other studies have suggested that acquired paternal traits may 
influence his offspring via alterations in his germ cells. 
A seminal study by Ng et al. 2010 showed that a paternal high fat diet can induce 
lasting physiological changes in his offspring (138). Interestingly, only the female 
offspring of the HFD fed fathers were lighter at birth compared with offspring of 
fathers fed a control diet (CD). Furthermore, these F1 daughters had altered gene 
expression patterns in several hundred pancreatic islet cell genes and metabolic 
dysfunction at 6 and 12 weeks of age (138). 
Further evidence that the effect of parental metabolic phenotype is gamete-driven 
comes from a clever in vitro fertilisation (IVF) study of genetically identical male and 
female mice fed combinations of a high fat diet (HFD), normal chow (NC) and low fat 
diet (LFD) as illustrated in Figure 1-14. Sperm and oocytes were isolated from F0 mice 
at the end of the dietary exposure and used for in vitro fertilization (IVF). The two-
cell embryos obtained were transferred into healthy surrogate females to generate 
offspring (F1) from different parental combinations (127). The F1 pups were then all 
subjected to a high fat dietary challenge, and were followed up with regards to 
weight and metabolic health. In the F1 generation, female mice whose parents both 
had been subjected to an HFD were both heavier and more insulin resistant than 
those whose parents had been fed a CD (Figure 1-15). Indeed, they exhibited a blood 
glucose levels in response to an intraperitoneal glucose challenge and had a higher 
level of fat mass. Interestingly, F1 mice with only one parent subjected to a HFD 
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exhibited a similar, albeit tempered, metabolic dysfunction (139). These results show 
that the effect of diet induced metabolic dysfunction in both parents seems, at least 





Two cell embryos from the parental IVF combinations marked with an ‘X’ above were transferred to 
lean, healthy surrogate females to limit the impact of intrauterine effects on the offspring 
phenotype. 
HFD = High Fat Diet, LFD = Low Fat Diet, NC = Normal Chow. Data derived from (127) 
HFD = High Fat Diet, LFD = Low Fat Diet, NC = Normal Chow. Data derived from (127). 
 
Figure 1-14. Schematic showing combinations of mating investigated in the study by Huypens et al. 
 
Figure 1-15. Body weight trajectories of female F1 mice during an HFD challenge between 9 and 15 
weeks of age.  
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In another experiment, prediabetes was induced in male mice by feeding them a HFD 
and injecting them with a low-dose streptozocin before mating them with female 
mice fed a control diet CD (140). The offspring exhibited glucose intolerance and 
insulin resistance, and showed altered expression patterns of several hundred genes 
in pancreatic islet cells (140). Analysis of pancreatic islet cells identified changes in 
cytosine methylation at several insulin signalling genes, and these changes correlated 
with their expression patterns (140). Notably, analysis of paternal gametes showed 
an extensive overlap in the regions that were differentially methylated in offspring 
pancreatic islets and in sperm. It is possible that the phenotypic changes seen in 
offspring could be transmitted by other means, such as changes in seminal fluid or 
differences in mating behaviour. Nevertheless, this study supports the concept that 
it is possible for an environmentally-induced epigenetic signatures to be inherited 
through the paternal germline and alter offspring phenotype. 
Martinez et al similarly identified an epigenetic signature on paternal gametes that 
was also present in metabolically important tissues in the offspring. In this study 
pregnant (F0) mice were fed a half-normal caloric intake in late gestation, which 
resulted in growth-restricted offspring (IUGR-F1) (141). The IUGR- F1 mice developed 
obesity, mild hyperglycaemia and glucose intolerance in adulthood; an 
intergenerational effect. When the IUGR- F1 males were mated with females fed a 
control diet, their resultant offspring (IUGR-F2) also exhibited features of metabolic 
syndrome, including hyperglycaemia and hypercholesterolaemia. Further, 
expression profiles of IUGR-F2 livers revealed 172 differentially expressed genes 
compared to control F2 mice, several of which are implicated in lipid biosynthesis. 
Analysis of upstream transcription factors regulating these lipogenic genes showed 
that the liver X receptor alpha (LXRA) was down-regulated in the livers of IUGR-F2 
mice as a result of hypomethylation of 5’ regulatory regions of the gene. Notably, the 
researchers then found this specific epigenetic signature in the spermatozoa of IUGR-
F1 males as well as in IUGR-F2 fetal livers. In adult IUGR-F2 mice, the signature was 
also present in white adipose tissue and pancreatic islet cells, but absent in skeletal 
cells, suggesting tissue specific postzygotic epigenetic reprogramming. Functional 
analyses of Lxra using knockout models supported that decreased levels of Lxra has 
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downstream effects such as those observed in adult IUGR-F2 mice, including 
moderate hypertriglyceridemia and increased hepatic free cholesterol levels (141). 
In summary, there are at least two studies in mammals where distinct diet-induced 
epigenetic signatures are found both in paternal gametes and in metabolically 
relevant tissues in his offspring. The lack of concordance of results in these studies 
may reflect differences in timing and type of dietary insult to the parent, different 
strains of mice or different methods of epigenomic investigation. However, these 
findings also raise several questions. How did the epigenetic mark seen in paternal 
gametes either escape the extensive demethylation process that follows fertilisation, 
or become re-established post-fertilisation? And if the mark does escape this process, 
then why is it not present in all offspring tissues? 
It should also be said that few of the studies discussed above have been convincingly 
replicated, and that some researchers suggest that stochastic epivariation rather 
than generational effects of diet may underlie the observed phenotypic effects (142, 
143). Further, the role of DNA methylation in the context of intergenerational 
epigenetic inheritance has been challenged by recent research indicating that small 
RNA species may be more instrumental in generational effects (144, 145). 
1.11 Paternal Metabolic Syndrome, Epigenetic Inheritance and Fetal growth: 
Studies in Humans 
The evidence for epigenetic inheritance through gametes in humans is sparse at best. 
However, several studies point towards the possibility that the sperm epigenome is 
dynamically remodelled during an individual’s lifetime. One study found that 
spermatozoa of obese men carry a distinct epigenetic signature compared to that of 
lean men (146). Differences principally affected genes involved in the central control 
of appetite. Following extreme weight loss by bariatric surgery, this epigenetic profile 
was altered (147). However, this study can be criticised for only including 5 men 
without a control group. Furthermore, none of the epigenetic changes following 
weight loss met the threshold for epigenome-wide significance after correcting for 
multiple testing. Two longitudinal studies have indicated that 3 months of aerobic 
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exercise could be associated with remodelling of the human sperm methylome (148, 
149). These studies were small-scale and there was little overlap between their 
results. Nevertheless, they point towards the potential for dynamic gamete 
remodelling in response to metabolic alterations in a tissue that has the potential to 
influence the next generation. 
If epigenetic change in gametes underlie the association between paternal obesity 
and T2DM, and in-utero growth of his offspring, then infants born to obese or 
diabetic fathers would be expected to carry epigenetic profiles that are distinct from 
those of appropriately grown offspring. In support of this hypothesis, infants affected 
by fetal growth restriction (FGR), are more likely to have insulin-resistant fathers, and 
have a distinct DNA methylation profile in umbilical cord blood relative to 
appropriately grown offspring (150). Further, in a cohort of 1,046 infants from the 
Norwegian Mother and Child Cohort Study (MoBa), there was differential 
methylation of 19 CpGs in cord blood DNA associated with birth weight (151). 
Differential methylation of 2 CpGs on ARID5B (AT-rich interactive domain 5B), a gene 
associated with low birth weight and decreased adipose tissue in mice, were inversely 
correlated with birth weight (151). 
Offspring born to parents exposed to caloric restriction during the Dutch Hunger 
Winter (see section 1.2), had 181 differentially methylated regions (DMRs) in an epi-
genome-wide DNA methylation analysis of their whole blood compared with their 
same-sex siblings not conceived during the famine (152). Gene ontology analyses of 
these regions revealed enrichment for pathways involved in positive regulation of 
growth and lipid and cholesterol metabolism, consistent with the more atherogenic 
lipid profile in these individuals (152). Whether epigenetic differences in offspring 
affected by the Dutch Hunger Winter are a consequence or cause of altered 
metabolic phenotype is unclear. 
In summary, there is only circumstantial and not conclusive evidence of 
intergenerational inheritance of acquired paternal epigenetic changes influencing 
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fetal growth and birth weight of his offspring. Prospective studies in humans are 
lacking, but hard to conduct. 
1.12 The Human Sperm Epigenome 
The human sperm epigenome is less well characterised than more readily available 
somatic tissues, such as blood. As human semen is only routinely analysed in 
reproductive medicine settings, most research has focused on the human sperm 
methylome in relation to fertility. There has been a general lack of robust, 
reproducible findings across studies. Sperm represents the most relevant tissue to 
study when investigating the potential for acquired paternal traits to impact the next 
generation. 
Blood is the most commonly studied surrogate tissue when sperm is not available. 
For example, Soubry et al. investigated the association between paternal obesity and 
methylation status of seven imprinted genes in offspring cord blood (153). They 
showed that periconceptual paternal obesity was significantly associated with 
altered methylation status of three of the genes studied (153). However, as the study 
analysed paternal blood rather than germ cells, it is difficult to draw conclusions 
regarding the mechanism behind the identified epigenetic effects. In spite of this, the 
authors suggest that the results likely indicate that paternal obesity alters the DNA 
methylation profile of his germ cells such that it may impact the phenotype of the 
next generation: 
“… The significant and independent association between paternal obesity and the 
offspring’s methylation status suggests the susceptibility of the developing sperm for 
environmental insults. The acquired imprint instability may be carried onto the next 
generation and increase the risk for chronic diseases in adulthood.” (153) 
Such conclusions are tentative owing partly to the highly tissue-specific nature of 
epigenetic signatures, and partly to the widespread demethylation process that 
occurs between generations (section 1.9). Future research would thus be aided by 
either investigating paternal germ cells directly, or, as an intermediate approach, to 
better characterise the epigenetic correlation between surrogate tissues such as 
blood and spermatozoa.  
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1.12.1 Candidate Gene Analyses of DNA Methylation in Human Spermatozoa 
Early studies of the human sperm methylome followed epidemiological reports of an 
association between assisted reproductive technologies (ART) and an increased risk 
of imprinting disorders in the offspring (154). It was hypothesised that spermatozoa 
from males with abnormal semen parameters who conceived with the aid of ART 
could harbour a greater frequency of abnormally imprinted genes that would impact 
on the phenotype of the offspring. In this regard, several candidate gene studies were 
directed towards the imprinted gene clusters. These included 15q11-q13, implicated 
in the Prader-Willi and Angelman syndromes, and the H19/IGF2 locus, which is 
implicated in the Beckwith-Wiedemann and Silver-Russell syndromes (155-159). 
Other candidate gene analyses focused on genes involved in spermatogenesis, early 
embryogenesis and DNA methylation (160-162). Whilst some of these studies 
suggested that imprinting disorders were more frequent in sperm from subfertile 
men, other studies found no evidence between imprinting disorders and the 
outcome of ART (157, 158). 
The cost-effectiveness of candidate gene studies has made them an attractive 
approach to studying small numbers of genes thought to be involved in a particular 
biological process. However, these hypothesis-driven approaches suffer from several 
methodological limitations. These include publication bias (as negative results from 
a small-scale study are less likely to be published), incomplete understanding of the 
biological pathways and lack of power to detect modest effects. 
1.12.2 Genome-wide Analyses of DNA Methylation in Human Spermatozoa 
Epigenome-wide array-based methods have interrogated CpG methylation across 
the spermatozoal methylome, typically in case-control studies of fertile versus 
infertile/subfertile males (163-167). As the majority of participants in these studies 
have been recruited from reproductive medicine settings, the results may not be 
broadly relevant. 
It is unlikely that studies similar in magnitude to EWASs performed on blood in the 
context of obesity and T2DM will ever be performed on spermatozoa. An 
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intermediary step in understanding how metabolic syndrome in humans could affect 
the epigenetic make-up of sperm would be to perform a detailed characterisation of 
the epigenetic covariation between the two tissues. This would allow findings 
obtained from analyses in blood to be compared with the relevant CpG sites in sperm. 
For example, if paternal obesity is robustly associated with the methylation status of 
an individual CpG site in both blood and sperm, intergenerational effects of acquired 
paternal obesity become more likely, compared with a lack of tissue correlation. 
The largest study to characterise DNA methylation co-variation in matched human 
sperm and blood components (B cells) included just eight males (168). This study 
demonstrated large-scale differences between the DNA methylome of sperm and 
blood, such that spermatozoa displayed methylation levels towards the extremes, i.e. 
methylation levels below 20% or above 80%. This observation already questions 
whether analyses of blood can be used to infer DNA methylation signatures of germ 
cells. The analysis further convincingly contradicted some earlier candidate gene 
studies that had, for example, indicated that abnormal spermatozoa exhibit 
epigenetic dysregulation of the Deleted in Azoospermia-Like (DAZL) gene, and that 
abnormal spermatozoa frequently exhibit imprinting abnormalities (161, 169). Thus, 
in spite of its small sample size, this study provided a valuable contribution to the 
field, and highlighted the need for larger-scale, genome-wide analyses of germ cells 
and matched somatic cells in future research.  
1.13 Rationale for my PhD Project 
Small for gestational age infants are at increased risk of developing metabolic 
disorders, including T2DM and cardiovascular disease, in adulthood (52, 65, 170). 
Epidemiological studies suggest that paternal obesity and/or insulin resistance 
predisposes his offspring both to poor growth in utero and future metabolic disorders 
(68, 69). Genetic association studies have identified an overlap between genetic 
variants that predispose to birth weight and risk of T2DM (171). However, SNPs only 
explain a small proportion of the variance of these traits, suggesting that gene-




Large-scale epigenome-wide association studies have identified CpG sites that are 
differentially methylated between lean and obese individuals (104-106). However, 
most studies have been performed using blood samples, which are of questionable 
importance in the context of intergenerational inheritance. Further, most identified 
CpG sites to date remain unreplicated across study cohorts. 
Animal studies suggest that the association between paternal obesity and T2DM and 
fetal growth could be mediated through epigenetic changes to spermatozoa that are 
passed from a father to his offspring and affect metabolism in the developing fetus 
(140, 141). Such studies are lacking in humans. Indeed, epigenetic studies of human 
spermatozoa have largely been focussed around fertility, and the knowledge of how 
acquired traits could influence the human spermatozoal methylome is patchy. A 
systematic review and summary of studies of DNA methylation in human 
spermatozoa would provide a useful resource for understanding how the human 
spermatozoal methylome could be influenced by acquired traits and their potential 
to affect the next generation.  
Studies of the human sperm methylome thus far have frequently been hampered by 
biased approaches and small sample sizes. A comprehensive, unbiased 
characterisation of the human sperm methylome in healthy, fertile males would 
provide novel insights into the epigenetic profile of the tissue that is most relevant in 
understanding generational effects of acquired paternal traits. Further, a comparison 
between the human sperm methylome and that of matched blood samples would 
improve our understanding of the circumstances under which surrogate tissues such 
as blood could be used for studies of intergenerational inheritance. Also, to analyse 
whether the covariation between DNA methylation in sperm and blood is influenced 
by obesity would yield insights into the potential for acquired paternal traits to 
influence his germ cells. 
Overall, an improved understanding of the association between paternal metabolic 
syndrome and his offspring’s growth in utero, and the mechanisms behind this 
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association, has the potential to improve the primary prevention of obesity and 
T2DM, which are major global public health concerns. 
1.14 Hypotheses 
1) Paternal obesity and/or insulin resistance increases the risk of fathering small 
for gestational age (SGA) offspring 
 
2) A.  The human sperm epigenome displays large-scale overall differences 
compared with matched somatic tissues such as blood 
B.  At a select number of CpG sites, there is a high DNA methylation 
correlation between the tissues 
 
3) Obesity influences the sperm DNA methylome 
 
4) Obesity is associated with a robust, reproducible DNA methylation profile in 
blood 
1.15 Thesis Aims 
1) To identify paternal metabolic risk factors for low birth weight offspring in a 
prospective cohort study of 500 mother-father-offspring trios 
 
2) To systematically review and summarise current knowledge of the human 
sperm methylome and its potential for being influenced by acquired traits 
 
3) To perform the largest to date characterisation of the DNA methylome in 
matched samples of human sperm and blood 
 
4) To identify specific CpG sites that show a high degree of DNA methylation 
correlation between blood and sperm in order to inform future research of 




5) To undertake a case-control study of DNA methylation covariation in sperm 
and blood between lean and obese males in order to investigate whether 
obesity is associated with an altered DNA methylation profile in male germ 
cells 
 
6) To generate a robust, replicable obesity associated DNA methylation profile 
in blood by replicating CpG sites previously identified as significantly 












In order to test the hypotheses stated in section 1.14, I carried out four separate but 
linked investigations. 
First, I performed a prospective cohort study, hereafter referred to as ‘The Dad’s 
Health Study’, where I recruited couples due to have a child at UCLH in order to 
investigate the association between paternal metabolic disease and offspring birth 
weight. The parents were phenotyped with regards to metabolic health, and the 
pregnancies were followed up with regards to pregnancy outcome and offspring 
weight at birth. This study is described in sections 2.3-2.8. 
Second, I performed a systematic review of studies investigating DNA methylation in 
human spermatozoa following established guidelines. This allowed me to summarise 
current knowledge, generate recommendations for future research, and inform the 
next stages of my project. The methods of performing the systematic review are 
discussed in section 2.9. 
Third, I investigated whether any observed association between paternal metabolic 
health and offspring birth weight could be mediated by spermatozoal DNA 
methylation changes passed from the father to his offspring. With this aim, I 
performed an extensive characterisation of the spermatozoal DNA methylome and 
compared it to that of matched blood samples. I characterised this sperm-blood 
methylation covariation both in lean, fertile males and in overweight/obese, fertile 
males. I then compared the sperm-blood DNA methylation covariation profiles of 
lean and obese males. This study is described in sections 2.10-2.12. 
Lastly, I aimed to establish whether obesity is associated with a robust, replicable 
DNA methylation signature in blood. With this aim, I compiled results from previous 
studies investigating genome-wide CpG methylation in obesity and validated these 
results using a multiplex bisulfite-PCR-sequencing microfluidics based assay in 
peripheral blood from a novel cohort of lean and obese males. This study is described 




Recruitment and sample collection for the Dad’s Health Study was performed by 
myself and research midwife Anna Greco. Sample processing and DNA extraction was 
also performed by myself and research midwife Anna Greco. Statistical analyses were 
carried out by myself under guidance from Jim Tyson, Senior IT Trainer at UCL, and 
Professor Aviva Petrie at the UCL Eastman Dental Institute. 
For the systematic review of studies of DNA methylation in human sperm, the search, 
filtering of results and summarising of studies was first performed by myself. The 
search was then repeated independently by Dr Amy Danson, Queen Mary University 
London (QMUL). Dr Amy Danson also added to the grading of studies and we together 
discussed overall conclusions and recommendations for future research. Dr Sarah 
Marzi, QMUL, had an advisory role in the search process and evaluation of evidence. 
For the study of DNA methylation covariation of sperm and blood, I collected and 
processed the sperm and blood samples together with research midwife Anna Greco. 
Bisulfite conversion of DNA from blood and sperm samples was performed by myself 
and Ama Brew, research technician at the Blizard Institute, QMUL. The Illumina 
MethylationEPIC array was processed by Yasmin Panchbhaya at UCL Genomics, Great 
Ormond Street Institute of Child Health. Methylation data preprocessing and analysis 
was performed by Dr Sarah Marzi at the Blizard Institute, QMUL. 
For the analysis of obesity associated CpG sites in blood, I and research midwife Anna 
Greco collected the blood samples and phenotyped participants. Blood samples were 
also collected by Dr Donna Santillan at the Women’s Health Tissue Repository, 
University of Iowa Health Care. DNA extraction from all blood samples was 
performed by myself and Research Midwife Anna Greco. Primers for the multiplex 
bisulfite PCR sequencing microfluidics-based assay were identified from previous 
research by Dr Michelle Holland and Dr Sarah Marzi at QMUL under guidance of 
Professor Vardhman Rakyan. Primers were tested for efficacy and specificity by 
Adrian Signell at Kings College London under supervision from Dr Michelle Holland. 
Bisulfite conversion of blood samples was performed by Theodoros Xenakis at QMUL. 
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The multiplex bisulfite-PCR-sequencing microfluidics based assay, library preparation 
and subsequent Next Generation Sequencing (NGS) was performed at the Genome 
Centre Facility at QMUL. Methylation data preprocessing and analysis was performed 
by Dr Sarah Marzi at the Blizard Institute, QMUL. 
2.3 The Dad’s Health Study 
A prospective cohort study known as ‘the Dad’s Health Study’, detailed in sections 
2.3-2.8, was performed to investigate the association between paternal metabolic 
health and offspring birth weight. Parental and offspring phenotypic measurements 
were recorded as described in sections 2.6 and 2.7. 
DNA was extracted from buffy coat from parental blood samples and offspring cord 
blood samples as described in section 2.8. Paternal semen samples were collected 
and analysed as described in section 2.9. DNA methylation was analysed using the 
Illumina MethylationEPIC array as described in 2.11. 
2.3.1 Study Design 
A prospective cohort study, The Dad’s Health Study, was undertaken of lean, 
overweight and obese fathers and their female partners (the mothers) to investigate 
the association between paternal metabolic health and offspring birthweight. The 
study was carried out at University College London Hospital between May 2016 and 
May 2019. Favourable ethical approval for the study was granted from the South East 
Coast - Surrey Research Ethics Committee on 28 September 2015 (REC reference 
number 15/LO/1437, IRAS project ID 164459). The study was also registered with the 
UCLH Joint Research Office (Project ID 15/0548). All participants provided written, 
informed consent.  
2.3.2 Pilot Study 
A pilot study of matched blood and semen samples from eight healthy male 
volunteers was performed in October-December 2015, prior to commencing 
recruitment for The Dad’s Health Study. The pilot study sought to confirm that the 
techniques for processing of and DNA extraction from blood and semen, detailed in 
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sections 2.8 and 2.9 were adequate to 1) yield purified samples of human semen such 
that only the motile portion of sperm was used for DNA extraction while 
contaminating cells and seminal fluid was discarded and 2) yield sufficient quantities 
of high quality DNA from blood and semen for downstream epigenetic analyses. 
Recruitment for The Dad’s Health Study commenced following successful completion 
of the pilot study. 
2.3.3 Statistical Methods 
Statistical analyses were carried out using RStudio version 1.1.456. Results were 
independently verified by Dr Aviva Petrie at the UCL Eastman Dental Institute 
Biostatistics Unit using STATA 15 (StataCorp LLC, Texas USA). 
Lean, overweight and obese male participants were assessed for comparability with 
simple descriptive statistics. Baseline characteristics of the three groups of male 
participants and their female partners (the mothers) were summarised with means 
and 95% confidence intervals. For categorical variables, frequency counts and 
percentages were given. When comparing the means of two variables an unpaired t-
test was used for continuous variables and a 2x2 table for categorical data. Two tailed 
P-values <0.05 were considered statistically significant. 
Multivariable logistic regression was used to analyse the impact of paternal 
metabolic profile on offspring birth weight. Prior to study recruitment, the primary 
paternal variable hypothesised to be associated with offspring birth weight was BMI. 
Secondary variables to be explored were other components of the metabolic 
syndrome, including paternal insulin resistance measured using HOMA (detailed in 
section 2.7), waist circumference, blood lipid levels, blood pressure as well as 
paternal smoking (12, 69). 
2.3.4 Sample Size Calculations 
Sample size calculations were undertaken using ‘Sample Size Tables for Clinical 
Studies, 3rd Edition’ (172). Paternal obesity was hypothesised to either be associated 
with an overall reduction in mean offspring birth weight, or with an increase in the 
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proportion of offspring born small for gestational age (SGA). Thus, two different 
approaches to determining an adequate sample size were employed. 
In the first scenario, assuming that the smallest difference in birth weight that is 
clinically significant is a reduction of 150 g, obese paternity would be associated with 
an overall mean offspring birth weight of 3350 g compared with 3.5 kg for offspring 
born to lean fathers (standard deviation 400 g) (173). If using a two-sample t-test to 
compare the means of offspring birth weights, this would require the recruitment of 
151 obese and 151 lean fathers, i.e. a total sample size of 302, to achieve 90% power 
at 5% significance. 
Alternatively, paternal obesity could be associated with an increased proportion of 
offspring born SGA. Previous research has indicated that paternal obesity (BMI ³ 30 
kg/m2) may be associated with a 24.8% (50/321) risk of fathering small for gestational 
age offspring, compared to a 9.8% (159/1631) risk of fathering a small for gestational 
age offspring among lean men (BMI <25 kg/m2) (68). Assuming that the smallest 
difference in the proportion of offspring born SGA between the two groups of fathers 
(obese versus lean) that is clinically significant is 10%, and assuming that paternal 
obesity would be associated with a 20% risk of fathering offspring below the 10th 
customised centile whereas 10% of offspring born to lean fathers would be born SGA, 
219 fathers in each group (438 in total) would be required to detect a 5% difference 
with 80% power. 
A proportion of those recruited would not be included in analyses of the impact of 
paternal metabolic health on offspring birth weight for reasons such as miscarriage, 
multiple pregnancy that was unknown at the time of recruitment and transfer of care 
to other hospitals. Allowing for these and other causes of participant drop-out, a total 
recruitment target of 500 male participants (250 lean versus 250 obese) was felt to 
be justified. 
In an audit performed at UCLH antenatal clinics in 2015 prior to recruitment, it was 
identified that a significant group of otherwise eligible participants were of an 
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intermediate (overweight) BMI of 25-30 kg/m2. In order to investigate whether there 
was a linear, reverse correlation between paternal BMI and offspring birthweight as 
well as achieve a sample population that was more reflective of the male population 
as a whole, it was decided to include overweight men as a separate group in addition 
to those with a lean and obese BMI.  
2.4 Feasibility of Recruitment 
An audit performed in UCLH antenatal clinics in 2015 showed that approximately 40% 
of fathers were lean (BMI 18-25 kg/m2), 40% of fathers were overweight (BMI 25-30 
kg/m2) and 20% of fathers were obese (BMI ³ 30 kg/m2). Around 6500 babies are 
delivered at UCLH each year (174). Assuming that 1 in 10 of obese fathers (130 per 
year) and 1 in 20 lean fathers (130 per year) would take part in the study, a two-year 
recruitment period was felt to be justified in order to recruit approximately 500 male 
participants and their female partners in total. 
2.5 Recruitment Criteria 
In order to minimise significant confounding factors that would be expected to 
impact on fetal growth independent of paternal metabolic profile, only fathers who 
met the following criteria were included in The Dad’s Health Study: 
• Aged 18 to 50 years 
• No significant medical problems 
• No drug, alcohol or substance abuse 
The following inclusion criteria were applied to the female partners (the mothers): 
• Aged 18 to 45 years 
• No significant medical problems 
• No drug, alcohol or substance abuse 
The following inclusion criteria were applied to the pregnancy: 
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• Singleton pregnancy 
• Natural conception 
Men whose female partners who were due to deliver a baby at UCLH were 
approached in the antenatal clinics or responded to a research poster. The majority 
of participants were recruited around the time of their female partners first 
ultrasound scan (10-14 weeks of gestation). 
Participating fathers were offered a ‘Well Man Health Check’, which I and Research 
Midwife Anna Greco performed, to measure phenotypic variables associated with 
metabolic health.   
2.5.1 Exclusion Criteria 
Offspring whose growth was likely to be affected by factors likely to confound any 
impact of paternal metabolic profile on offspring birth weight were excluded. Thus, 
the following exclusion criteria were applied: 
• Multiple pregnancy 
• Known maternal drug or excess alcohol intake 
• Pregnancies where the mother is affected by a significant medical condition, 
such as cardiac, endocrine, renal or haematological disease 
• Know fetal congenital infections such as CMV or toxoplasmosis 
• Known congenital chromosomal abnormalities 
• Known congenital structural malformations 
• Pregnancies conceived via artificial reproductive therapies (ART) 
• Maternal gestational diabetes 
2.5.2 Diagnosis of Fetal Growth Restriction 
Fetal Growth Restriction (FGR) is defined as failure of a fetus to meet its growth 
potential in the womb, and is associated with both long- and short term adverse 
health outcomes (175). A small for gestational age (SGA) infant is commonly defined 
as one whose weight at birth is less than the 10th centile for gestational age. It 
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remains a challenge to distinguish between infants who are constitutionally small and 
those affected by true growth restriction (175).  
In order to improve our identification of infants affected by FGR rather than being 
constitutionally small, as well as minimise the impact of maternal factors that could 
confound the effect of paternal metabolic profile on offspring birth weight, 
customised birth weight centiles were used instead of raw birth weights (176). 
Available from the Perinatal Institute, these customised centiles take into account 
maternal height, weight, ethnicity, offspring sex and gestational age, giving a more 
accurate representation of the ability of an infant to have met its intra-uterine growth 
potential (177). In the present study, infants were classified as SGA if their customised 
birth weight centile was <10, classified as AGA if their customised birth weight centile 
10-90 and classified as LGA if their customised birth weight centile was ≥ 90. 
In addition, mothers who developed gestational diabetes mellitus (GDM) during their 
pregnancy were excluded from the study, as this condition is associated with 
significant effects on fetal growth (section 1.3). Thus, in line with UCLH criteria for 
diagnosing GDM, participating mothers who had a 26-28 week glucose challenge test 
result that exceeded 7.8 mmol glucose per litre followed by a confirmatory glucose 
tolerance test (GTT) were excluded (178). 
2.6 Study Protocol 
The general outline of study procedures is illustrated in Figure 2-1. All phenotypic 
measurements of male participants (fathers) were performed in UCLH antenatal 
clinics using the same or identical equipment. The majority of men were studied 
around the time of their partner’s first ultrasound scan (10-14 weeks into gestation). 
As fasting measurements of blood glucose and insulin were required, male 
participants were asked to fast overnight or for at least 8 hours prior to the study. 
Each study visit took approximately 30 minutes to complete. All participants were 
given a Participant Information Sheet and provided written, informed consent prior 





Figure 2-1. Overview of recruitment, timing of study visits and phenotype data collected for The Dad's Health Study. 
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Male participants completed a questionnaire enquiring about past medical, family 
and treatment history (Appendix 1). Study participants’ own birth weight was 
recorded as remembered personally or from a parent. Height and weight were 
measured and recorded. Waist circumference was measured between the lower 
margin of the lowest palpable rib and the top of the iliac crest, using a stretch-
resistant tape according to WHO guidelines (179). After resting, two measurements 
of blood pressure (BP) were taken 15 minutes apart. 
Six vacutainers (20-25 mL blood in total) of whole blood were taken from 
participating males (fathers). Three (one purple top EDTA-coated, one gold top 
serum-separator tube (SST) and one grey top fluoride preservative) vacutainers were 
sent to the UCLH clinical biochemistry laboratory within one hour of venepuncture 
for fasting measurements of insulin, glucose, haemoglobin, c-reactive protein (CRP), 
haemoglobin A1c (HbA1c), lipid levels, liver function and kidney function. Insulin 
resistance was calculated using HOMA as detailed in section 2.7.  
Feedback to participants about results was available. Clinically significant results 
were conveyed to the participants as a priority along with relevant support literature 
and advice. Where appropriate and with the participant’s consent, general 
practitioners (GPs) were contacted on behalf of the participants. 
Two purple and one gold top vacutainers were ultracentrifuged for 15 minutes at 
1000g within one hour of venepuncture. Centrifugation of the purple top (EDTA-
coated) vacutainers produced three distinguishable layers; the uppermost, clear 
layer consisting of plasma, the intermediate layer consisting of buffy coat and the 
lowermost layer consisting of concentrated erythrocytes (Figure 2-2). Buffy coat is a 
leukocyte-enriched fraction of whole blood and was used for DNA extraction The 
Dad’s Health Study in preference to whole blood as this enhances DNA yield by 




Figure 2-2. Separation of components of whole blood following ultracentrifugation of EDTA-coated 
vacutainers. 
Whole blood separates into three distinct layers when ultracentrifuged for 15 minutes at 1000g; 
plasma, buffy coat and erythrocytes. Buffy coat was used for DNA extraction in The Dad’s Health 
Study. 
For each participant, two aliquots of plasma were obtained from the EDTA-coated 
vacutainers and stored in -80°C. Two aliquots of buffy coat were also obtained from 
the EDTA-coated vacutainers, one of which was used for DNA extraction (section 
2.8.1). The aliquots of buffy coat not used for DNA extraction as well as the extracted 
DNA were thenceforth also stored in -80°C. Two aliquots of serum were obtained 
from the gold top SST vacutainer following ultracentrifugation and also stored in 
-80°C. 
All female participants (mothers) were given a Participant Information Sheet and 
provided written, informed consent. The majority of female participants were invited 
for a study visit in conjunction with their 26 to 28 week GCT. Inviting participating 
females for a study visit around this time ensured that they were seen at a similar 
time in pregnancy, did not require an additional hospital appointment and were 
recruited well before their estimated delivery date (EDD), facilitating planning for 
later cord blood collection by placing a sticker and a leaflet in their antenatal notes. 
Some participating females instead opted to be seen around the same time as their 
male partners came to UCLH for the study visit (10-14 weeks into gestation), or in 
conjunction with another antenatal appointment. Female participants completed a 
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questionnaire enquiring about obstetric, medical, family and treatment history 
(Appendix 2). 
A total of three vacutainers (two purple and one gold top) were obtained from 
participating females. These were ultracentrifuged within one hour of venepuncture 
and samples of buffy coat, plasma and serum were obtained and stored as described 
for male participants. DNA was extracted from buffy coat as described in section 
2.8.1. Clinical biochemistry information required for participating females was 
obtained from electronic antenatal records, and included measurements of serum 
glucose at the initial antenatal visit (approximately 5-9 weeks of gestation), and 
results from the GCT or GTT. Information on ethnicity for both male and female 
participants as well as maternal height and weight, obstetric history and estimated 
date of delivery was obtained from electronic antenatal records. 
Cord blood samples were obtained shortly following the delivery of the placenta, 
either by myself or by the attending midwife. A 10 mL sample was obtained from the 
umbilical arteries or vein using a syringe. Samples were ultracentrifuged for 15 
minutes at 1000 g, aliquoted, processed and stored as described for parental 
samples. If any delay was expected between obtaining the cord blood sample and 
DNA extraction, samples were stored at 4° C. 
2.7 Insulin Resistance and Type 2 Diabetes Mellitus 
Insulin resistance (IR) is as a precursor to the development of Type 2 Diabetes 
Mellitus (T2DM), as well as forming part of the diagnostic criteria for the Metabolic 
Syndrome as discussed in section 1.1. 
2.7.1 Measuring Insulin Resistance 
The gold standard method for assessing insulin resistance is the hyperinsulinemic 
euglycemic glucose clamp. In brief, this involves intravenous administration of insulin 
at a constant, hyperinsulinemic rate and intravenous administration of glucose at 
variable rates to acquire and maintain a steady-state of euglycaemia. The rate of 
glucose infusion correlates to insulin sensitivity (181). Although a sensitive and 
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reproducible test for detecting IR, the hyperinsulinemic euglycemic glucose clamp is 
expensive and time- and labour intensive, and therefore inappropriate for routine 
clinical applications or larger-scale research studies (181). Thus, several indirect 
methods of assessing insulin resistance, which require only single measurements of 
fasting glucose and insulin, have been developed. Among these, the Homeostatic 
Model Assessment (HOMA) is among the most widely used and extensively validated 
(182). 
2.7.2 Homeostasis Model Assessment (HOMA) Measurements 
Homeostatic model assessment (HOMA) is a method for assessing insulin resistance 
(IR) and b cell function from basal (fasting) glucose and insulin concentrations. 
Originally described in 1985, HOMA values are derived from a mathematical 
assessment of the interaction between b cell function and IR in an idealised model 
that is then used to impute steady-state insulin and glucose concentrations. Using 
this calculated relationship between b cell function and IR, the model can then be 
used to estimate b cell function and IR from any given values of fasting insulin and 
glucose measurements (182). 
The original model (HOMA1) used a simple equation for estimating insulin resistance 
from fasting blood glucose and insulin concentrations: 
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The denominator 22.5 is a normalising factor derived from the product of a ‘normal’ 
fasting plasma glucose in a healthy individual (4.5 mmol/L) and a ‘normal’ fasting 
plasma insulin in a healthy individual (5 µU/L). The output is thus calibrated to give a 
normal IR of 1. 
It should be noted that neither fasting insulin levels nor HOMA-IR values are normally 
distributed. Thus, log(HOMA-IR) is frequently used to transform the skewed 
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distribution of values to yield a more linear correlation with glucose clamp estimates 
of insulin sensitivity (181). 
The model was updated from HOMA1 to HOMA2 in 1996 (182, 183). HOMA2 has 
nonlinear solutions and takes into account variations in hepatic and peripheral 
glucose resistance, increases in the insulin secretion curve for plasma glucose 
concentrations above 10 mmol/L and the contribution of circulation proinsulin, thus 
yielding a model closer aligned to physiological conditions (183, 184). Further, 
whereas the HOMA1 was calibrated based on an insulin assay used in the 1970’s, 
HOMA2 has been recalibrated in line with current insulin assays (182).  Therefore, 
whilst HOMA1 functions well to estimate relative change in IR when serial 
measurements are taken in the same individual, the corrected nonlinear model of 
HOMA2 is more accurate when assaying absolute insulin resistance or b cell function 
(183). HOMA2 values can be calculated using the calculator or excel plugin available 
from the Diabetes Trials Unit (184). Despite the update from HOMA1 to HOMA2, 
most recent large-scale trials have continued using the HOMA1 system for measuring 
insulin resistance, potentially due to the more straightforward calculation required 
and in order to make results more comparable to those in previous research. 
Therefore, both HOMA1 and HOMA2 values were calculated for participants included 
in the Dad’s Health Study. 
2.7.3 Validation of HOMA-IR 
HOMA measurements have been extensively employed and validated in large scale 
epidemiological analyses as appropriate measurements of insulin resistance when 
taking single fasting measurements of blood glucose and insulin (183). HOMA-IR 
values show a strong correlation with glucose clamp estimates of insulin sensitivity, 
especially when log transformed (181). In a recent meta-analysis of surrogate 
measures of insulin resistance compared to the hyperinsulinemic euglycemic glucose 
clamp, log(HOMA-IR) values were shown to be well correlated with measurements 
of insulin resistance obtained using the glucose clamp (r=−0.60 [−0.66, −0.53], n=22). 
The conclusion was that in studies using single, paired measurements of fasting blood 
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glucose and insulin as input data, log(HOMA-IR) would be an appropriate choice for 
estimating insulin resistance (185). 
2.8 Blood Sample Collection, Processing and Storage 
All researchers handling samples collected for The Dad’s Health Study were required 
to have completed the Good Clinical Practice eLearning (Secondary Care) course with 
a satisfactory score (186). Further, all individuals collecting samples for The Dad’s 
Health Study were required to have completed the Medical Research Council’s (MRC) 
Research and Human Tissue Legislation e-learning Package with a satisfactory score 
on the online module assessment (187). Tissue samples were handled in accordance 
with guidelines set out in the MRC ‘Use of human samples in medical research’ (188). 
Following these guidelines ensured that samples were handled in accordance with 
the 2004 Human Tissue Act. 
Blood samples (parental and cord blood samples) were ultracentrifuged in the same 
laboratory within the Fetal Medicine Unit (FMU) in UCLH. The samples were 
aliquoted as described in section 2.6 and the vials labelled with their unique 
participant identification number, date of sample provision and type of sample, 
before being transported over the UCL EGA Institute for Women’s Health Chenies 
Mews laboratory in plastic, airtight containers. DNA extraction was performed in the 
UCL EGA Institute for Women’s Health Chenies Mews laboratory using safety 
precautions detailed in the MRC ‘Use of human samples in medical research’ 
guidelines (187). Following DNA extraction, samples were stored in anonymised form 
in the designated -80°C freezer in the UCL Paul O’Gorman Building, which has 
restricted access. 
2.8.1 DNA Extraction from Blood Samples 
DNA was extracted from buffy coat in the same manner for parental and cord blood 
samples using 200 µL buffy coat according to instructions in the ‘DNA Purification 
from Blood or Body Fluids (Spin Protocol)’ handbook from the QIAamp® DNA Mini Kit 
(180). All centrifugation steps were carried out in room temperature. Prior to 
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commencing each DNA extraction, it was ensured that appropriate amounts of 96-
100% ethanol had been added to relevant Qiagen buffers. 
First, 20 µL of Qiagen Protease was pipetted into the bottom of a 1.5 mL 
microcentrifuge tube. Qiagen Protease is a serine protease that functions to digest a 
broad range of potentially contaminating proteins. It has an increased activity at 
higher temperatures. 200 µL buffy coat was then added to the microcentrifuge tube. 
As RNA-free DNA was not required for later experiments, the optional step of adding 
RNase A stock solution was omitted. 200 µL of Qiagen Buffer AL (lysis buffer) was 
then added to the microcentrifuge tube. While the exact composition of Qiagen 
Buffer AL remains proprietary, the lysis buffer contains guanidine hydrochloride, a 
chaotropic salt denaturant that functions to dissociate nucleoproteins and inhibit 
nucleases (189). The microcentrifuge tubes containing Qiagen Protease, the buffy 
coat sample and buffer AL was then pulse-vortexed for 15 seconds to ensure mixing, 
and then incubated in a 56° C water bath for 10 minutes. This temperature both 
works to increase the activity of Qiagen Protease as well as helps to denature DNases 
and RNases, ensuring that nucleic acids present in the tissue sample are left intact for 
later purification. 
Following incubation, the microcentrifuge tube was centrifuged at 13,000g for 15 
seconds to remove drops from inside the lid. 200 µL ethanol (>96%) was added, and 
the microcentrifuge contents were mixed by pulse vortexing for 15 seconds. In the 
presence of a buffer with a high concentration of chaotropic salt, such as Buffer AL, 
and a low (<7) pH, ethanol causes precipitation of DNA. The mixture was carefully 
pipetted onto a QIAamp Mini spin column in a 2 mL collection tube, making sure not 
the wet the rim, and centrifuged at 13,000g for one minute. During centrifugation, 
the DNA adsorbs specifically to the QIAamp silica-gel membrane while contaminants 
pass through. The collection tube containing the filtrate was discarded and the 
QIAamp Mini spin column was placed in a fresh 2 mL collection tube. 
The QIAamp Mini spin column was then opened and 500 µL of Qiagen Buffer AW1 
(wash buffer 1) was pipetted onto the column membrane. The cap was closed and 
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the column (in the 2 mL collection tube) was ultracentrifuged at 6,000g for 1 minute. 
While the exact composition of Qiagen Buffer AW1 remains proprietary, it contains 
a low concentration of chaotropic salts (e.g. guanidine hydrochloride) that help to 
remove residual protein from the QIAamp Mini spin column membrane. Following 
centrifugation, the collection tube containing the filtrate was discarded and the 
QIAamp Mini spin column was placed in a fresh 2 mL collection tube. The QIAamp 
Mini spin column was then opened and 500 µL of Qiagen Buffer AW2 (wash buffer 2) 
was pipetted onto the column membrane. The cap was closed and the column (in the 
2 mL collection tube) was ultracentrifuged at 13,000 g for 3 minutes. While the exact 
composition of Qiagen Buffer AW2 remains proprietary, it contains a tris-ethanol 
solution that helps to remove residual salts from the QIAamp Mini spin column 
membrane. Following centrifugation, the collection tube containing the filtrate was 
discarded and the QIAamp Mini spin column was placed in a fresh 1.5 mL 
microcentrifuge tube. 
The QIAamp Mini spin column was then opened and 200 µL of Qiagen Buffer AE 
(elution buffer) was added onto the spin column membrane. The mixture was 
incubated at room temperature for 5 minutes. During this elution step, the DNA on 
the spin column silica-gel membrane dissolves in the elution buffer, which contains 
10 mM Tris-Cl and 0.5 mM EDTA, and has a pH of 9.0 (190). The slightly basic pH of 
the buffer allows the DNA to dissolve more rapidly. Following incubation, the QIAamp 
Mini spin column, in the 1.5 mL microcentrifuge tube, were ultracentrifuged at 
4,000g for 1 minute. The spin column was discarded and the microcentrifuge tube 
containing the eluted DNA was labelled, quality controlled as described in section 
2.8.2 and stored as described in section 2.8.  
2.8.2 Quality Control of DNA Extracted from Blood Samples 
The quantity of DNA obtained from blood samples was measured using a Qubit 3.0 
Fluorometer (Life Technologies) and the Qubit dsDNA broad range assay kit according 
to manufacturer’s instructions. DNA yields were considered adequate if they were in 
the range of 25-50 µg, corresponding to the expected DNA yield detailed in the ‘DNA 
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Purification from Blood or Body Fluids (Spin Protocol)’ handbook from the QIAamp® 
DNA Mini Kit (180). 
2.9 Studies of DNA Methylation in Human Sperm: A Systematic Review 
A systematic review of studies investigating DNA methylation in human sperm was 
undertaken to summarise current knowledge, generate recommendations for 
research and inform the next stages of my project. The methods employed for the 
systematic review followed the Preferred Reporting Items for Systematic Reviews 
and Meta-Analyses (PRISMA) guidelines (191). 
2.9.1 Systematic Review Search Strategy 
An exhaustive literature search was performed using the PubMed electronic 
database on March 31st 2019. The following search criteria was applied: 
"semen" [Mesh] OR "sperm" [Mesh] AND "DNA methylation" [Mesh] OR 
"methylome" [Mesh] 
The same search criteria were thereafter applied to search the Web of Science and 
Cochrane databases in order to identify further relevant articles. Only publications 
that pertained to studies in humans and were written in English were included. 
Reference lists of identified articles and review articles were also searched for 
additional references. 
The primary search and filtering of search results was performed by myself. The 
search process was thereafter repeated by an independent researcher. Any 
differences in the selection of articles between myself and the independent 
researcher were resolved by discussion. 
2.9.2 Selection Criteria for Inclusion of Articles 




• Studies investigating DNA methylation in human spermatozoa 
• Any age group 
• Investigations of any type of analysis of DNA methylation 
• Publications in English only 
• Published from 2003 onwards 
Initially, publications relevant to the topic of interest were included irrespective of 
the year of their publication. However, upon later discussion regarding significant 
progress in DNA methylation analysis technologies that have occurred in particular in 
the last two decades, a cut-off of 2003 was decided. With the completion of the 
sequencing of the human genome in 2003, the use of Next Generation Sequencing 
technologies became more widespread, even though the first human second 
generation (short read) human genome was not introduced until 2008 (192, 193). 
Studies performed prior to 2003 typically analysed DNA methylation by restriction 
endonuclease digestion followed by Southern blotting. We deemed that these earlier 
studies, performed prior to 2003, employed methods of assaying DNA methylation 
that were too different from more recent methods to not make results comparable 
across studies. 
Articles identified through the search, but which did not meet the inclusion criteria 
detailed above were recorded, along with their reason for being excluded. 
2.9.3 Data Extraction and Evaluation of Quality of Evidence 
The following information was extracted from every identified study: 
• Author 
• Year of Publication  
• Rationale for study 
• Method of assaying DNA methylation 
• Area of research: 





- Diet/ lifestyle/ metabolic disease 
- Cancer 
- Neurological disease 
- Methodology 
- Tissue specificity 
- Other 
• Method of semen processing 
• Targeted, global or genome-wide analysis 
• Number of study participants 
• Age of study participants 
• Matching of cases and controls (where relevant) 
• Main results of study 
• Statistical analyses, e.g. correction for multiple comparison 
The GRADE criteria were used to objectively evaluate the quality of evidence in every 
study included in the systematic review (194). The criteria were adapted for 








Rating Reasons for 
down- or upgrading 
Quality of 
the evidence 














Very serious (-2) 
Age 
Smoking  
Somatic cell contamination  
Storage time/sample storage 
conditions  
Medication/supplement use 
Drug and alcohol use  
Abstinence  




Very serious (-2) 
Lack of replication cohort 









Very serious (-2) 
Small sample sizes 
Lack of appropriate controls 
Varying sperm processing 
Definition of subfertility 





Strongly suspected (-1) 




Large effect (+1 or +2) 
Dose response (+1 or +2) 
No plausible confounding 
(+1 or +2) 
 
Table 2-1. GRADE criteria as adapted for the systematic review of studies of DNA methylation in 
human sperm. 
RCT = Randomised Controlled Trial. Adapted from (194).
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Study design: The highest scoring studies would have been randomised controlled 
trials (RCTs). However, no such studies were identified in the search and therefore 
studies were mainly graded based on other factors. 
Risk of Bias: The grade for risk of bias was primarily based on whether appropriate 
confounders had been accounted for. In particular, I assessed whether age and 
smoking status  of participants had been taken into account, as these factors are 
known to significantly impact on DNA methylation (195, 196). Also, the potential 
degree of somatic cell contamination, i.e. whether samples had been adequately 
processed to remove cells such as leukocytes and epithelial cells, strongly influenced 
the scoring in terms of risk of bias. It is generally agreed that studies should be 
performed on the healthy, motile portions of the spermatozoa, which would be more 
representative of those leading to fertilisation and therefore of more relevance to 
offspring development. 
There are several methods of selecting for motile spermatozoa and cleaning the 
semen sample, referred to as ‘initial processing’ in the systematic review. The most 
common methods include a swim-up procedure and a discontinuous gradient 
ultracentrifugation procedure. In the former, the semen sample is layered under a 
sperm wash medium, allowed to incubate, and then the motile spermatozoa are 
harvested from the supernatant. In the latter, the semen sample is layered on top of 
two (or sometimes three) layers of different media, ultracentrifuged, and all but the 
pellet of motile spermatozoa is removed (Figure 2-4). Media used for the gradient 
centrifugation procedure include e.g. PureSperm, Percoll or Isolate media. Following 
selection of motile spermatozoa, the sample should be assessed for any remaining 







A score of -2 was given if a study had taken no or little account of confounders and 
somatic cell contamination, and a score of -1 was given if a study had taken some, 
but insufficient, account of confounders and somatic cell contamination. 
Inconsistency: Inconsistency was graded based on whether similar studies had shown 
contradicting results and whether the study had included a replication cohort. A 
score of -2 was given if a study had not included a replication cohort nor replicated 
results of a previous study, and a score of -1 was given if a study had either replicated 
previous findings or included a replication cohort. 
Indirectness: Indirectness was graded based on the generalisability of the findings, 
and whether studies were cross-sectional versus longitudinal. Factors that were 
particularly assessed was whether participants had been recruited from the general 
public or from reproductive medicine settings without taking this into account when 
discussing findings of the study. A score of -2 was given if a study was cross-sectional 
and the results had low generalisability, and a score of -1 was given if the study was 
either longitudinal or was more likely to be generalisable. 
Imprecision: Imprecision was graded based on sample size (or if a power calculation 
had been used to determine an appropriate sample size), presence or absence of an 
appropriate control population (where relevant) and whether descriptive statistics of 
Figure 2-3. Common methods of selecting motile spermatozoa 
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participants was provided. The method of initial sperm processing (for removal of 
somatic cells) was also taken into account- if no selection method had been 
employed, the risk of somatic cell contamination was deemed to be high and thus 
the findings less precisely relevant to spermatozoa. A score of -2 was given if the 
study satisfied none or few of these criteria, and a score of -1 was given if the study 
satisfied some of these criteria. 
Publication bias: Publication bias was particularly relevant for candidate gene 
analyses. As these studies are relatively cost-effective and often small-scale, it is 
possible that studies yielding negative results would have been less likely to be 
published than studies yielding positive findings. Therefore, candidate gene 
approaches were given -1 as a baseline for publication bias. 
Upgrading Factors: Upgrading factors, i.e. factors that would provide a higher score 
to studies, included if a dose-response effect was identified, that there was 
particularly large effect detected or if several confounders had been appropriately 
taken into account. 
After evaluating each study based on the above criteria, studies were given an overall 
rating: high/moderate/low/very low. 
2.9.4 Compiling Results from the Systematic Review 
Identified studies were divided into three categories based on their methodology 
(analyses of global DNA methylation, candidate gene approaches and genome-wide 
approaches). Conclusions from studies in the three categories were drawn based on 
the quality of evidence for the specific studies and used to summarise current 
understanding of DNA methylation in human spermatozoa. Conclusions from the 
grading of studies discussed in 2.9.3 were used to generate recommendations for 
future research. Also, conclusions from the systematic review were used to inform 
the next stages of my project, i.e. to perform an unbiased, genome-wide profiling of 
matched samples of sperm and blood from healthy, fertile males.  
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2.10 DNA methylation Covariation in Spermatozoa and Blood 
In order to investigate whether any observed association between paternal 
metabolic health and offspring birth weight could be mediated by spermatozoal DNA 
methylation changes passed from the father to his offspring, paternal semen was 
collected from consenting fathers taking part in the Dad’s Health Study. The initial 
analysis, processing, DNA extraction and DNA methylation analysis of these semen 
samples is described in sections 2.10 to 2.12.6. 
2.10.1 Semen Sample Collection 
Participants who provided informed consent to the provision of semen samples as 
part of The Dad’s Health Study were given the choice of producing the sample at 
home and bringing it to the UCLH Fertility and Reproductive Medicine Laboratory 
within one hour of sample production, or to produce the sample in the designated 
rooms in the Reproductive Medicine Unit. Most participants provided the semen 
sample within a month following their study visit, i.e. within the first half of their 
partner’s pregnancy. All semen samples were processed within one hour of sample 
production in line with standard guidelines followed by the UCLH Fertility and 
Reproductive Medicine Laboratory. Participants were not required to abstain prior to 
sample provision. 
As per ethical guidance obtained from the South East Coast - Surrey Research Ethics 
Committee prior to commencing study recruitment, no semen test results were 
discussed with participants due to the potential issue of non-paternity. 
2.10.2 Semen Sample Handling and Storage 
Semen samples collected as part of The Dad’s Health Study were handled in 
accordance with guidelines set out in the MRC ‘Use of human samples in medical 
research’ (187). Following these guidelines ensured that samples were handled in 
accordance with the 2004 Human Tissue Act. 
Researchers handling semen samples collected as part of The Dad’s Health Study 
(myself and Research Midwife Anna Greco) underwent training by senior clinical 
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andrologist Elizabeth Williamson to ensure that samples were handled and processed 
according to standard operating procedures employed in the UCLH Fertility and 
Reproductive Medicine Laboratory. 
Following the initial analysis and processing of semen samples described in sections 
2.10.3 and 2.10.4, samples were labelled with their unique participant identification 
number and date of sample provision before being transported over the UCL EGA 
Institute for Women’s Health Chenies Mews laboratory in plastic, airtight containers. 
DNA extraction, as detailed in section 2.10.5, was performed in the UCL EGA Institute 
for Women’s Health Chenies Mews laboratory using safety precautions detailed in 
the MRC ‘Use of human samples in medical research’ guidelines (187). Following DNA 
extraction, samples were stored in anonymised form in the designated -80°C freezer 
in the UCL Paul O’Gorman Building, which has restricted access. 
2.10.3 Initial Analysis of Semen Samples 
Within one hour of sample production, samples were placed on a warm plate (35-
37°C) for 20-30 minutes in order to liquefy prior to processing. Sample volume was 
measured and 5μL of the sample was pipetted onto a Leja disposable counting 
chamber and analysed using the Computer-Assisted Sperm Analysis 
(CASA)/Sperminator software (Pro-Creative Diagnostics, Staffordshire, UK). The 
semen sample parameters measured were sperm concentration (millions/mL), 
percentages of sperm in four categories of motility from most motile to least motile 
(A – D), and average motile speed (microns/second). 
2.10.4 Initial Processing of Semen Samples 
Following the initial analysis of semen samples as described in section 2.10.3, samples 
were processed to select for the more motile sperm and clean them from seminal 
fluid, cellular debris, epithelial cells and leukocytes. The process is illustrated in Figure 




Figure 2-4. Initial processing of semen samples. 
a) Semen samples were gently layered on top of a gradient consisting of 1 ml 45% PureSperm above 
1 ml 90% PureSperm in order to select for motile sperm (see text for details). b) Following 
ultracentrifugation, motile, viable sperm form a pellet at the bottom of the conical tube. 
Thus, a density gradient was set up in a Corning® 15mL centrifuge tube; 1 ml liquid 
consisting of 90% PureSperm (PureSperm 100®, Nidacon Laboratories) solution and 
10% sperm washing medium (Quinn’s™ Sperm Washing Medium, Origio 
Laboratories) was gently layered under 1 ml liquid consisting of 45% PureSperm and 
55% sperm washing medium, while ensuring that the interface between the layers 
was undisturbed. The liquefied semen sample was gently layered on top of the 45% 
PureSperm solution and then centrifuged at 300g for 20 minutes. Following this, the 
supernatant was removed, leaving only the pellet of motile sperm in the bottom of 
the conical tube. The pellet was then re-suspended in 1 ml sperm washing medium 
in a clean 15mL centrifuge tube and centrifuged at 300g for 10 minutes. Following 
this, the supernatant was again removed, and the pellet was re-suspended in 1 ml 
sperm washing medium in a clean 15mL centrifuge tube. 5μL of the washed sample 
was loaded onto a Leja disposable counting chamber and analysed using the 
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Computer-Assisted sperm analysis (CASA)/Sperminator software, assessing the 
sperm concentration, motility and average motile speed as described above. 
 
2.10.5 DNA Extraction from Semen Samples 
The protocol for DNA extraction from semen was obtained from Dr Michelle Holland, 
Queen Mary University London (QMUL), and had previously successfully been 
applied to DNA extraction from mouse semen. Its applicability to human semen 
samples collected as part of The Dad’s Health Study had was evaluated in the Pilot 
Study discussed in section 2.3.2. 
Samples were first pelleted in a microcentrifuge tube (Eppendorf, Germany) by 
ultracentrifugation for 10 minutes at 300g. 250 μL proteinase K buffer (10 mM Tris-
HCL, 100 mM NaCl, 25 mM EDTA and 1% SDS), 2.5 μL 1M dithiothreitol (DTT) and 5 
μL proteinase K was added to the pellet, and samples were incubated for 5-12 hours 
in a 55°C water bath (until completely lysed). 250 μL phenol was added to the samples 
and then shaken vigorously by hand for 5 minutes before centrifuging at 13,000g for 
Figure 2-5. Example of semen prior to and after selection of motile sperm. 
a) Prior to selection of motile spermatozoa 
b) Following selection of motile spermatozoa 
Images are taken at the same resolution using the Computer-Assisted sperm analysis 
(CASA)/Sperminator software. In a) there is visible debris and contaminating cells whereas in b) the 
samples has been cleaned of contaminating cells as well as dead/immotile semen 
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5 minutes. 225 μL of the top aqueous phase was placed in a fresh 2.0 mL 
microcentrifuge tube to which 225 μL phenol-chloroform was added. This was again 
shaken for 5 minutes and then centrifuged at 13,000g for 5 minutes. 210 μL of the 
top aqueous phase was placed in a fresh 2.0 mL microcentrifuge tube to which 210 
μL chloroform was added. This was again shaken for 5 minutes and then centrifuged 
at 13,000g for 5 minutes. 200 μL of the top aqueous phase was placed in a fresh 2.0 
mL microcentrifuge tube. 20 μL 3M sodium acetate and 500 μL 96-100% ethanol was 
added. Upon gentle inversion, the DNA precipitated. Samples were centrifuged for 
15 minutes at 13,000g; the supernatant was removed, and DNA pellets were re-
suspended in 500 μL 70% ethanol. Samples were again centrifuged for 15 minutes at 
13,000g; the supernatant was removed, and DNA pellets were finally suspended in 
50 μL Tris-EDTA buffer before being placed in -80°C until further processing and 
analysis. 
2.10.6 Quality Control of DNA Extracted from Semen Samples 
The quantity of DNA obtained from semen samples was measured using a Qubit 3.0 
Fluorometer (Life Technologies) and the Qubit dsDNA broad range assay kit according 
to manufacturer’s instructions. 
2.11 Bisulfite Conversion of Sperm- and Blood- derived DNA samples 
Bisulfite conversion of DNA from blood and semen samples was performed using the 
D5001 EZ DNA Methylation Kit (Zymo Research, Irvine, CA, USA) according to 
manufacturer’s instructions. This kit employs a three-step reaction procedure that is 
based on the fact that sodium bisulfite converts unmethylated cytosines (C) to uracil 
(U), while leaving methylated cytosines unchanged. 500 ng (+/-10%) of sample DNA 
quantified with a Qubit 3.0 Fluorometer (Life Technologies) was used as input DNA. 
First, the M-Wash buffer was prepared. Thus, 24 mL ethanol, (≥99.8% ethanol, VWR 
Chemicals, United Kingdom) was added to the M-Wash buffer concentrate (supplied 
in the kit) and the and the bottle was inverted several times to allow mixing. 
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Next, the CT Conversion agent, the powder form of which is supplied in the kit, was 
prepared. Thus, 750 μL water for molecular biology (Millipore, Germany) and 210 μL 
of M-dilution buffer (supplied in the kit) were added to the CT conversion reagent. 
The mixture was vortexed frequently during a period of 10 minutes in order to allow 
the CT conversion reagent to dissolve. The prepared CT conversion reagent was used 
immediately following preparation due to it being light sensitive and could thus 
otherwise have degraded. The CT Conversion reagent supplied in the kit contains 
sodium metabisulfite (Na2S2O5), which upon addition of water is converted to sodium 
bisulfite (NaHSO3). 
5 μL of M-Dilution buffer was then added to the DNA samples, and the total volume 
was adjusted to 50 μL with water for molecular biology (Millipore, Germany). The 
samples were then incubated for 15 minutes at 37 °C on a hot plate. The M-Dilution 
buffer contains sodium hydroxide and aims to denature the DNA in order to make it 
accessible to the sodium bisulfite for conversion of unmethylated cytosines to uracil. 
Following the incubation, 100 μL of the prepared CT Conversion Reagent was added 
to each sample, and the mixture was briefly vortexed. The samples were then 
incubated in a thermocycler under the following conditions:   
(95 °C for 30 seconds, 50 °C for 60 minutes) x 16 cycles, after which they were held 
at 4 °C.  
Following the incubation above, 400 μL of M-Binding buffer (supplied in the kit) was 
added to a Zymo-Spin IC Column (supplied in the kit) and the column was placed into 
a collection tube (supplied in the kit). The samples were loaded into the Zymo-Spin 
IC Columns containing the M-Binding buffer, the cap was closed and the column (with 
the collection tube) was inverted several times to allow mixing. The columns (with 
the collection tubes) were ultracentrifuged at 13,000g for 30 seconds after which the 
flow-through was discarded. 100 μL of the prepared M-Wash buffer was added to 
the column, and the columns (with the collection tubes) were ultracentrifuged at 
13,000g for 30 seconds. After this, 200 μL of M-Desulphonation buffer (supplied in 
the kit) was added to the column and the columns were left to incubate at room 
temperature (25°C) for 20 minutes. Following the incubation, the columns (with the 
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collection tubes) were ultracentrifuged at 13,000g for 30 seconds. The flow-through 
was discarded, and 200 μL of the prepared M-Wash buffer was added to the column. 
The columns (with the collection tubes) were then ultracentrifuged at 13,000g for 30 
seconds. This wash step was then repeated such that 200 μL of the prepared M-Wash 
buffer was again added to the column and then the columns (with the collection 
tubes) were ultracentrifuged at 13,000g for 30 seconds. The flow-through was 
discarded. 
Next, the columns were placed into 1.5 mL microcentrifuge tubes (Eppendorf, 
Germany). 10 μL of M-Elution buffer was added onto the column matrix and the 
columns (with the collection tubes) were ultracentrifuged at 13,000g for 30 seconds 
to elute the DNA. 
The bisulfite converted DNA (bsDNA) was stored at -20 °C for a limited time (2-3 days) 
before analysis using the Illumina MethylationEPIC Array as described below. 
2.12 DNA Methylation Analysis in Blood and Semen 
For an overview of techniques for DNA methylation profiling, please see section 1.7.1. 
Genome-wide CpG methylation for the study of DNA methylation in sperm and blood 
was measured using the Illumina MethylationEPIC Array. Introduced in 2015, this is 
the most recent array-based DNA methylation assay, and was specifically designed 
to interrogate potential enhancer regions as well as 90% or the CpG sites assayed by 
its precursor, the HM450 (197). The EPIC array assays over 850,000 CpG sites, 
350,000 of which are in enhancer regions of the genome. Overall, the EPIC array 
interrogates >95% of CpG sites in CpG islands, >90% of CpG sites in North and South 
shores and >80% of CpG sites in North and South shelves as well as gene bodies, 




Figure 2-6. Relative density distribution of CpG sites in genomic regions assayed by the EPIC array. 
The EPIC array interrogates >95% of CpG sites in CpG islands, >90% of CpG sites in North and South 
shores and >80% of CpG sites in North and South shelves, in addition to high coverage of potential 
enhancer regions, promoter regions and gene bodies. TSS 1500 and TSS 200 denote regions 1500 
and 200 base pairs (bp) upstream of the transcription start site respectively. TSS = Transcription Start 
Site, UTR = Untranslated Region, N = North, S = South. Modified from (198) with information from 
(197, 199). 
2.12.1 Illumina MethylationEPIC Array Workflow 
The overall Illumina EPIC workflow is summarised in Figure 2-7. First, genomic DNA is 
treated with sodium bisulfite, which converts unmethylated cytosine (C) to uracil (U) 
while leaving methylated cytosines unchanged (197). 
Next, the bisulfite converted DNA is subjected to whole-genome amplification 
(WGA), during which U is amplified as thymine (T). The DNA is then enzymatically 
fragmented and prepared for hybridisation to Illumina BeadChips. 12 samples are 
loaded onto each BeadChip, which have seals to separate the respective samples. Up 
to 8 BeadChips are incorporated into one kit, allowing analysis of up to 96 samples. 
The bisulfite converted, amplified and fragmented DNA samples are incubated 
overnight to allow hybridisation to the BeadChips (200). 
The BeadChips contain over 850,000 bead types, each of which contain a locus-
specific 50mer probe sequence with a CpG site at the 3’ end. The 50mer sequences 
are designed to be complementary to specific 50 base pair regions of the bisulfite 
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converted, fragmented DNA. Following hybridisation, single base extension 
incorporates either a fluorescently labelled biotin nucleotide or a fluorescently 
labelled dinitrophenyl (DNP) nucleotide; C and G nucleotides are biotin labelled 
whereas A and T are DNP labelled. The fluorescent signal is then measured (87). To 
analyse the methylation status of individual CpG sites across the genome, two 
different types of assay are employed; the Infinium Type I and Infinium Type II assays 
(see Figure 2-8).  
 
Figure 2-7. Overview of the Illumina MethylationEPIC Array Workflow. 
a) Sample DNA with one locus containing a methylated C and one locus containing an unmethylated 
C. b) The sample DNA is treated with sodium bisulfite, converting unmethylated C to U while leaving 
methylated C intact. c) The sample DNA undergoes whole genome amplification, during which U is 
amplified as T. d) The bisulfite-converted, amplified and fragmented DNA is hybridised to the 
Illumina BeadChips. e) The BeadChips are scanned by the Illumina ‘iScan’ array scanner. e) 
Methylation data output in the form of a heat map. Figure created using information from (200) C = 





Figure 2-8. The Infinium Type I and Type II assays used to determine CpG methylation status in the 
MethylationEPIC Array. 
a) The Infinium Type I Assay employs two bead types for each CpG sites; one for the methylated (C) 
and one for the unmethylated (T) state of the site. b) The Infinium Type I Assay employs only one 
bead type per CpG, and the methylation status is instead determined by the single base extension 





The Type I assay employs two bead types for each CpG site; the one for the 
methylated (C), and another for the unmethylated (T) state of the site. This assay 
relies on the assumption that all CpG sites within a 50 base-pair span share the same 
methylation status, which is supported be previous research (201). The 50mer probe 
sequence is thus designed to match either the methylated or the unmethylated 
version of the CpG site in the sample DNA, and hybridises accordingly. A sample DNA 
fragment with an unmethylated target locus will thus hybridise to the unmethylated 
bead type and allow subsequent single base extension of a fluorescently labelled 
nucleotide matching the nucleotide immediately upstream of the target CpG site. 
When a sample DNA fragment with an unmethylated target locus hybridises to a 
methylated probe sequence, however, base extension is inhibited. Vice versa occurs 
for methylated loci (87). 
The Type II assay employs only one type of bead per CpG, and the methylation status 
of the target CpG site is instead determined by single base extension following 
hybridisation (see Figure 2-8). For an unmethylated locus, the base complementary 
to the CpG site in the sample DNA will be adenine (A, complementary to T), whereas 
for a methylated locus the complementary base will be G (complementary to C) (201). 
The complementary bases are again fluorescently labelled. In contrast to the Type I 
assay, the Type II assay design makes no assumptions about the methylation status 
of neighbouring CpG sites; the other CpG sites within the 50mer sequence are 
replaced with degenerate R bases that hybridise both to T and C. Further, as one 
rather than two bead types are employed for each CpG locus, the Type II assay also 
take up less physical space on the BeadChips. For these reasons, the methylation 
status of the vast majority of CpG sites covered by the EPIC array (84%) are queried 
using the Type II probes (197).  
Following hybridisation and base extension that incorporates a labelled probe, the 
hybridised sample DNA is removed. The BeadChips are then imaged using the 
Illumina iScan System; a laser excites the fluorophore of the single base extension 
product on the beads and records high resolution images of the BeadChip to visualise 
the intensities of the methylated and unmethylated bead types (200). The BeadChips 
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are simultaneously scanned at two wavelengths, the red and the green channel, and 
an image file is created for each of these. A and T are assessed in the red channel 
whereas C and G are assessed in the green channel. 
2.12.2 Illumina Internal Quality Controls 
The Illumina EPIC array includes both sample-dependent and sample-independent 
controls in order to evaluate the quality of specific steps within the EPIC array process 
flow as well as performance across samples. There are controls that are assessed in 
each of the red and green colour channels, and those that are assessed in both (200). 
Sample-independent controls include staining controls, extension controls, 
hybridisation controls and target removal controls (see Figure 2-9). Staining controls 
assess the efficiency of the single base extension step where a fluorescently labelled 
nucleotide is incorporated into the probe sequence, and evaluate the efficiency of 
both the red and the green colour channel. The green channel shows a higher signal 
for biotin staining when compared to biotin background, whereas the red channel 
shows higher signal for DNP staining when compared to DNP background. A high level 
of background fluorescence reduces the ability to distinguish signal from noise and 
should lead to sample removal. 
Extension controls are beads that test the extension efficiency of A, T, C and G 
nucleotides respectively by using a hairpin probe. Both red (A, T) and green (C, G) are 
assessed, and a high intensity is expected from the extension control probes if the 
extension has worked correctly. Hybridisation controls employ synthetic targets that 
perfectly complement the probe sequences attached to the beads. These synthetic 
targets come in different levels of concentration (low, medium and high) which 
should correspond to observed intensities for these probes. 
The hybridisation controls should only be assessed in the green channel as biotin 
rather than DNP is incorporated at the base extension step. Target removal controls 
assess the efficiency of removing the sample DNA following hybridisation and base 
extension. The target removal controls are extended using the probe sequence as a 
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template, and should be efficiently removed to produce a low intensity compared to 
the hybridisation controls. The target removal controls should only be assessed in the 
green channel as it is the lack of incorporation of biotin that is assessed. 
 
Figure 2-9.Sample-independent controls included in the EPIC array. 
a) Staining controls have DNP or Biotin attached to the beads and evaluate the performance of the 
staining step. b) Extension controls test the efficiency of extension of A, T, C and G from a hairpin 
probe. c) Hybridisation controls use synthetic controls to test the overall performance of the assay. 
Synthetic targets are present in low, medium and high concentrations. Target by extension 
generates a signal, and the signal intensity increases as the target concentration increases. d) Target 
removal controls test the performance of the stripping step following the extension reaction using a 
non-extendable probe and a complementary extendable synthetic target. See text for further details.  




Sample-dependent controls include controls for the efficiency of bisulfite conversion, 
specificity of probe extension, levels of background intensity and overall 
performance of the assay (see Figure 2-10). 
Figure 2-10. Sample-dependent controls for the EPIC array. 
a) Bisulfite conversion controls test the efficiency of bisulfite conversion of genomic DNA. a)i. are 
bisulfite conversion controls that use the Infinium Type I design and a)ii. are bisulfite conversion 
controls that use the Infinium Type II design b) Specificity controls monitor potential non-specific 
primer extension for Type I ((b)i.) and Type II ((b)ii.) probes. c) Negative controls are randomly 
permutated sequences that should not hybridise to the DNA template. See text for further details. 
DNP = dinitrophenyl. C = Converted, U = Unconverted, PM = Perfectly Matched, MM = Mismatched, 
D = DNP, B = Biotin, NP = Non-Polymorphic. Modified from (200). 
The bisulfite conversion controls assess the efficiency of bisulfite conversion of 
genomic DNA. There are two types of bisulfite conversion controls; those that employ 
the Infinium Type I design (Bisulfite Conversion I probes) and those that employ the 
Infinium Type II design (Bisulfite Conversion II probes). The cytosines queried by the 
bisulfite conversion control probes are at non-CpG sites and chosen because they are 
the sole C base in a 50bp span. For Bisulfite Conversion I probes, the ‘C’ or converted 
probes will match the converted sequence if the bisulfite conversion was successful, 
whereas if the sample has unconverted DNA (meaning that the bisulfite conversion 
was incomplete), the ‘U’ or unconverted probes will be extended. Bisulfite controls 
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C1, C2 and C3 should be assessed in the green channel, whereas C4, C5 and C6 should 
be assessed in the red channel. Bisulfite Conversion II probes will use single base 
extension to incorporate an A if the bisulfite conversion was successful and a G if the 
conversion had been unsuccessful. The G would cause an elevated intensity in the 
green channel. 
Specificity controls assess the level of nonspecific probe extension for Infinium Type 
I (Specificity I) and Infinium Type II (Specificity II) probes, and are designed against 
nonpolymorphic T sites. If probe extension from Type I probes worked perfectly, then 
for a methylated CpG locus, the C in the sample DNA (or specificity control) should 
only anneal to G in the probe sequence.  For an unmethylated CpG locus, then the T 
in the sample DNA (or specificity control) should only anneal to A in the probe 
sequence. In other words, a G annealing to a T would be a mismatch. Specificity I 
probes assess the level of G/T mismatch (which prohibits further extension) and 
compares this to the level of perfect A/T matching (which would allow base extension 
and yield a high signal compared to a mismatch). Performance of G/T mismatch 
controls should be assessed in both red and green channels.   Specificity II probes   
should incorporate an A base to complement the nonpolymorphic T and have 
intensity in the red channel. If there is nonspecific incorporation of G instead, then 
the probe will have increased intensity in the green channel. 
Negative controls define the background intensity for the DNA methylation assay. 
They are constructed as randomly permutated sequences and thus should not bind 
specifically to any of the bead types. The mean signal intensity of 600 negative 
controls is used to establish detection limits for the methylation probes. Performance 
of negative controls should be monitored in both red and green channels. 
Nonpolymorphic controls test the overall performance of the assay, from 
amplification to detection, by querying a particular base in a nonpolymorphic region 
of the bisulfite genome. There are four nonpolymorphic controls, one for each of the 
4 nucleotides (A, T, C and G). These controls allow comparison of the performance of 
the assay across different samples. 
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2.12.3 EPIC Array Data Output 
Methylation data at each CpG site is expressed as a beta value (b), which describe 
the ratio of the methylated (C) to the unmethylated (T) signal, via the formula: 
β =
intensity	of	methylated	signal
(intensity	of	methylated	signal + intensity	of	unmethylated	signal + 100)
 
A b value of 0 represents a completely unmethylated CpG site and a b value of 1 
represents a fully methylated CpG site. For a single individual, the distribution of b 
values across all CpG sites is bi-modal, with the majority of CpGs being close to zero 
or one. However, for a single CpG site across individuals, the distribution of b values 
tends to be uni-modal (197) . In other words, most of the CpG sites in one individual 
are either fully methylated or completely unmethylated, and any given CpG site tends 
to be similarly methylated in one individual compared to another. 
The output data from the Illumina iScan System used for analysis of the 
MethylationEPIC Array is typically presented in the form of an intensity data (IDAT) 
file, where summary intensities for each probe-type on the array is detailed. IDAT 
files are binary files, one for each of the red and green channels, and comprises 
information on four fields; the ID of each bead-type on the array, the mean and 
standard deviation of their intensities, and the number of beads of each type (202). 
2.12.4 Quality Control of DNA Methylation Data from the Illumina 
MethylationEPIC Array 
Before data generated from an EPIC array can be analysed with regards to the 
outcome variable and its association to CpG methylation, the data needs to undergo 
a series of quality control and preprocessing steps. 
First, samples are checked for inconsistencies in the methylation data. Potential 
sample replicates that do not correlate are removed and if relevant, samples with a 
gender mismatch are also removed from further analysis. One way of uncovering 
sample mismatches is by visualising similarities between samples using a multi-
dimensional scaling (MDS) plot. In this, sample clustering can help to identify large 
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scale similarities between samples and interrogate further should samples deviate 
from the expected clustering. In studies with samples from both males and females, 
MDS plots are typically performed to look at methylation on the X chromosome. This 
should be relatively unmethylated for males and 50% methylated for females (due to 
X chromosome inactivation). Thus, when using MDS across the X chromosome you 
would expect samples to cluster according to whether they are from males or 
females. 
Following this, genotyping information can be used to identify potentially mislabelled 
samples. 59 of the control probes on the EPIC array are for direct interrogation of 
genotype. If there is separate genotype information for the individuals in a study, 
these genotype probes can be used cross-checked against existing genotype data. If 
the samples contain replicates or more than one sample from the same individual, 
these genotype probes can be used to check whether the genotypes at these 59 
probes are identical. If genotypes do not match, this most likely indicates that 
samples might be mislabelled or otherwise problematic. 
2.12.5 Data preprocessing for the Illumina MethylationEPIC Array 
Following quality control of the DNA methylation data, outcomes from the various 
types of internal quality checks and control probes described in section 2.12.2 should 
be taken into account and also give an indication of the overall reliability of the 
particular assay. One has to account for the presence of SNPs, cross-reactive probes 
and the different properties for the Type I and Type II probes described in section 
2.12.1. In general, Type II probes have lower reproducibility than Type I probes, and 
these differences should be normalised prior to analysis of methylation data. 
Potentially problematic probes are filtered out. These include the control probes and 
those probes where a significant proportion (the exact number varies between 
assays) fail to meet the detection p-value threshold. If a large number of probes for 
a given sample fail to reach the detection p-value, the entire sample should be 
removed from further analysis (203). 
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The presence of SNPs in close proximity to interrogated CpG sites can lead to false 
assumptions about the association of methylation of a particular CpG site and the 
outcome variable as SNPs in the probe sequence alter the binding affinity to the 
probe. For example, if one genotype of the SNP, e.g. A, always comes with a 
methylated CpG site, and the other genotype, e.g. T, always comes with an 
unmethylated CpG site and whereas the A genotype might bind the probe sequence 
100% of the time, the T may only bind 20% of the time, giving a skewed methylation 
readout. For this reason, data from e.g. the 1000 Genomes Project or other 
annotated lists of SNPs can be cross-matched with study results so that these signals 
can be analysed in more detail and false assumptions can be better avoided (197). 
Similarly, annotated lists of potentially cross-reactive probes that bind non-
specifically to the target regions of interest or that bind to repetitive regions of the 
genomes, can be used to flag or filter out these probes. 
In addition to using annotated lists of probes influenced by SNPs, there are other 
methods of identifying sites where the CpG methylation level is potentially influenced 
by the underlying genotype. One of these is “gap hunting”; a method that identifies 
clustered beta value distributions, such as those consistent with a bi- or trimodal 
distribution of beta values (204). 
The data should then be normalised in order to remove technical and systematic 
variability to make results comparable across samples. One key aspect of data 
normalisation for the EPIC array is to make measurements across the two different 
probe types comparable against one another. There are several ways to achieve this. 
One approach is to normalise the Type II probes to the Type I probes, so-called BMIQ 
normalisation, by transforming the distribution of Type II probes to be similar that of 
Type I probes (197). 
2.12.6 Interpreting DNA Methylation data from the MethylationEPIC Array 
Once DNA methylation data has been analysed and matched with appropriate study-
specific variables (e.g. phenotype profiles or case-control status), inferences can be 
drawn in terms of which biological processes may be involved. This can be achieved 
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by performing a gene ontology (GO) analysis, wherein significant CpG sites are 
annotated to biological networks (205). Pathway analyses can be performed to 
suggest particular molecular signatures that may be relevant in, for example, a 
disease process. Such pathways or individual genes can be taken forward for more 
conclusive investigations, e.g. expression profiling, and in extension may become 
targets for therapeutic intervention or the development of disease-specific 
biomarkers. 
Results from GO-analyses should, however, be interpreted with caution. For 
example, some genes represented on the HM450 and the MethylationEPIC bead 
chips have a considerably higher probe representation than others (206). This 
introduces a bias as genes with more probes are more likely to appear as differentially 
methylated. Recent bioinformatic approaches have been developed to overcome this 
bias. Such an approach includes the empirical Bayes Gene Set Enrichment Analysis 
(ebGSEA), which directly rank genes according to their overall level of differential 
methylation as assessed using all of the probes that map to a given gene and in a 
manner that avoids favouring genes containing more probes, before assessing for 
enrichment of biological terms using this ranked list of genes (206). Another method 
of overcoming this problems is to use functions such as the gometh function in the 
missMethyl R package used to analyse methylation data (207). In this, the selection 
bias is reduced by modelling the relationship between the number of genes per 
probes and the probability of the gene being selected (e.g. as hyper- or 
hypomethylated) (207). 
Inferences can also be drawn by analysing the genomic locations of identified CpG 
sites. In very general terms, increased CpG methylation of promoters is associated 
with transcriptional silencing. CpG methylation changes to enhancer or other 
regulatory regions can be investigated by cross-referencing these to information 
compiled by e.g. the ENCODE Project Consortium, which has systematically mapped 
regions of transcription, transcription factor association, chromatin structure and 
histone modification (208). The process of gene regulation of course involves a highly 
complex interaction between the nucleotide sequence, DNA methylation, small 
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interfering RNA molecules and histone modifications. Thus, integrating DNA 
methylation data with information on other genetic and epigenetic processes is vital 
for providing a more complete understanding of biological processes. For example, 
continued elucidation of methylation quantitative trait loci (mQTLs) will allow DNA 
methylation data to be integrated with SNP data to understand how genetic variation 
may have influenced results derived from genome-wide CpG analyses (209). 
2.12.7 DNA methylation analysis using the Gene Expression Omnibus 
A further way to interrogate CpG sites is to compare results from a DNA methylation 
array analysis to large, publicly available methylation data sets. This approach can 
significantly increase study power and thus increase the probability to detect 
biologically meaningful results. The MethylationEPIC data from sperm samples in my 
study was therefore added to data of previously performed DNA methylation (HM45) 
arrays available on the Gene Expression Omnibus (GEO) database and compared to 
a wide range of somatic tissues with methylation data available on GEO. The GEO 
database is a publicly available database that contains Illumina DNA methylation 
array data from tens of thousands of human tissue samples, as well as other array- 
and sequencing data (210). Indeed, as on July 2017, data from more than 60,000 
HM450 arrays had been deposited on this database (211). 
The recently developed bigmelon R package provides a memory efficient workflow 
to enable these complex, large scale analyses without the requirement for large 
random access memory (RAM) (211). This package was used to identify CpG sites that 
displayed hypo- and hypermethylation in sperm when compared to a several types 
of somatic tissues. Significant CpG sites were therefore investigated in terms of their 
annotation to biological networks by a GO analysis to identify biological pathways 
that significantly differed between sperm and somatic tissues. 
2.13 Obesity Associated DNA Methylation Profiling in Blood 
Validation of previously identified obesity associated CpG sites was performed using 
a multiplex bisulphite PCR sequencing microfluidics-based assay (Bis-PCR-Seq), which 
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constitutes a cost-effective, targeted alternative to Reduced Representation Bisulfite 
Sequencing (RRBS) in genome-wide analyses. 
 Blood samples collected from 96 lean (BMI 18-25 kg/m2) and 96 obese (BMI 
>30kg/m2) males were included in this validation. Most samples (78 from lean males 
and 78 from obese males) were collected as part of the Dad’s Health study as 
described in section 2.8. A proportion of blood samples (18 from lean males and 18 
from obese males) were collected at the Women’s Health Tissue Repository, 
University of Iowa Health Care, using the same methods. Blood-derived DNA was 
bisulfite converted as described in section 2.11. CpG sites were identified based on 
previous EWASs of obesity (section 2.14). Primers were designed to target the 
specific obesity associated CpG sites and were evaluated for performance (section 
2.14.1). Selected primers were then used to validate obesity associated CpG 
methylation in the blood-derived, bisulfite converted DNA samples. This validation 
was performed using the Fluidigm Access Array, a multiplex bisulphite PCR 
sequencing microfluidics-based assay (section 2.15). 
This study forms the first stage of a larger project that aims to generate a robust, 
reproducible obesity associated DNA methylation profile using peripheral blood from 
1000 lean and 1000 obese males (MRC reference code MR/P011799/1; title ‘Paternal 
obesity-associated DNA methylation: an investigation into its reproducibility, 
reversibility and association with fetal growth restriction’). 
2.14 Identification of obesity associated CpG sites 
Identification of obesity associated CpG sites for validation was performed through a 
PubMed search using the following search criteria: 
• Analysis of DNA methylation in association to human obesity or BMI 
• Minimum sample size of 1000 participants (discovery and replication cohorts 
combined) 




The search was performed on October 6th, 2017. Therefore, some of the most recent 
obesity EWASs discussed in section 1.8.1 were not included. In total, this led to the 












Discovery cohort 991 BMI CD4+ T cells 8 (Bonf.) European Americans GOLDN 
 (101) Replication cohort 1 2105 BMI Whole blood 2 (Bonf.) European Americans FHS 
  Replication cohort 2 1935 BMI Whole blood 4 (Bonf.) African Americans ARIC 




Discovery cohort 2097 BMI PBLs 76 (Bonf.) African Americans ARIC 
 (102) Replication cohort 3368 BMI Whole blood/ 
CD4+ T cells 
37 (Bonf.) European Americans FHS + GOLDN 
Al Muftah et 
al., 2016 
Discovery cohort 123 BMI Whole blood None Arab Quatari family study 
 (103) Replication cohort 810 BMI Whole blood None Caucasian TwinsUK 





Discovery cohort 3743 BMI Whole blood 135 (Bonf.) European Americans + 
Caucasian 
FHS + LBCs 
  Replication cohort 4055 BMI Whole 
blood/CD4+ T 
cells 
83 (Bonf.) African Americans + 
European Americans + 
Caucasian 
ARIC + GOLDN + PIVUS 
Sayols-
Baixeras et al., 
2017 
(105) 
Discovery cohort 641 BMI Whole blood 94** (Bonf.) European REGICOR 
 
Replication cohort 2515 WC Whole blood 49** (Bonf.) European Americans FOS 
Wahl et al., 
2017 
(106) 
Discovery cohort 5387 BMI Whole blood 278 (Bonf.) European + Indian-Asian EPICOR + KORA + LOLIPOP 
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  Replication cohort 4874 BMI Whole blood 187 (Bonf.) European + Indian-Asian ALSPAC + EGCUT + Leiden 
Longevity + LifeLines Deep 
+ LOLIPOP + RS-BIOS + RS-
III + TwinsUK 
Table 2-2. EWASs of obesity associated genome-wide CpG methylation included in the validation study. 
Note that some of these studies identified CpG sites associated with BMI-related traits, such as waist circumference and T2DM. However, these findings are not presented 
in the table. 
* This study replicated 1 out of 8 T2DM and 7 out of 39 BMI findings from previous EWASs in the Quatari discovery cohort. The meta-analysis was performed on these 8 
replicated loci 
* Results are from a meta-analysis of discovery and replication cohorts. 
WC = Waist Circumference, PBL = Peripheral Blood Leukocyte, FDR = False Discovery Rate, Bonf = Bonferroni, ARIC = Atherosclerosis Risk in Communities, GOLDN = Genetics 
of Lipid Lowering Drugs and Diet Network, FHS = Framingham Heart Study, REGICOR = Girona Heart Registry, FOS = Framingham Offspring Study, LOLIPOP = London Life 
Sciences Population Study, ALSPAC = Avon Longitudinal Study of Parents and Children, EGCUT = Estonian Genome Center of the University of Tartu, RS-BIOS = Rotterdam 
Study Bios Cohort, RS-III = Rotterdam Study-III
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One further study was included as it investigated the association between obesity 
associated SNPs and methylation of nearby CpG sites (212). This study interrogated 
methylation levels at CpG sites in proximity to 52 obesity associated SNPs, and 
identified 107 CpG sites in close proximity to 28 SNPs where methylation levels were 
associated with the genotype. One of these were removed as two CpG sites were 
associated with the same SNP. In addition, CpG sites where methylation levels have 
previously been shown to be influenced by epigenetic confounders such as smoking 
and inflammation (as measured by C-reactive protein, CRP) were included in order to 
be able to control for these variables. The smoking associated sites were identified 
from a meta-analysis of EWASs of smoking which included almost 16,000 participants 
in total (195). The CRP associated sites were identified from a meta-analysis of EWASs 
of serum C-reactive protein that included almost 13,000 participants in total (213). 
The blood cell composition control sites were identified from (214). A total of 546 
CpG sites were identified using the described criteria. 
Prior to primer generation, the CpG sites identified then underwent filtering based 
on the following criteria: 
• Consistency of discovery p value. The empirically derived threshold of p = 1.16 
x 10-7 was employed as all studies were performed using the Illumina HM450 
• Feasibility of generating a primer for the specific CpG site. This was 
determined mainly based on the surrounding genetic sequence 
• Ability of primers to align uniquely to the human genome 
• Ability of primers to capture the specific CpG site, i.e. that the CpG site was 
situated within 130bp of either primer end. This is to account for the drop off 
in read quality observed in 150 bp paired-end Illumina MiSeq System reads 
• No confounding genetic variation in the primer sequence 
Together with the technical requirement of processing samples in batches of 48, the 
above criteria lead to the removal of 162 CpG sites. Thus, 384 CpG sites were selected 
for primer generation. The process of identifying and selecting CpG sites for inclusion 




Figure 2-11. Pipeline for selecting obesity associated CpG sites for validation. 
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384 primer pairs (forward and reverse) were generated in silico using Primer3 with a 
customised script (215). Primers were designed to uniquely align to their target 
sequence and have an annealing temperature of 55°C. An additional sequence was 
added to the 5’ end of the forward and reverse primers for compatibility with 
downstream use of the Fluidigm Access Array microfluidics platform 2.15. 
 Forward primer tag: 5’ ACACTGACGACATGGTTCTACA 3’ 
 Reverse primer tag: 5’ TACGGTAGCAGAGACTTGGTCTA 3’ 
The primers were purchased from Sigma-Aldrich (Sigma-Aldrich, Gillingham, Dorset). 
2.14.1 Evaluation of primers 
The 384 primers were objectively evaluated using a classification system to 
qualitatively test their efficacy and specificity. This was to ensure optimal function of 
primers when used in the microfluidics based assay, and thus was designed to as 
closely as possible mimic the conditions used in the next steps of the experiment. The 
input genomic DNA for primer evaluation was extracted from blood or CD4+ T-
lymphocytes using the same protocol as described in section 2.8.1. The samples 
were, however, from different individuals to those included in the study of obesity 
associated CpG methylation. Bisulfite conversion was performed on 500ng genomic 
DNA as described in section 2.11. 
The evaluation of primers was performed by Dr Michelle Holland and Adrian Signell 
at Kings College London (KCL), and will only be discussed briefly below. Each of the 
primers were amplified using PCR in a reaction consisting of 2.5-5 ng bisulfite 
converted DNA (or the appropriate volume of ultrapure water for negative controls), 
Taq polymerase, dNTPs, MgCl2, appropriate buffer as well as the forward and reverse 
primers. The resulting amplicons were separated by size using agarose gel 
electrophoresis. Primers were evaluated using two sets of PCR agents from different 
manufacturers to determine which system would be used to generate sequencing 
libraries in subsequent experiments. Thus, the Roche FastStart High Fidelity PCR 
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System was compared to the Qiagen HotStarTaq DNA Polymerase (216, 217). 
Following gel electrophoresis, gels were imaged, and a scoring system was used to 
indicate the specificity and efficiency of each primer. 
Specificity of a primer was objectively measured by comparing the size of the 
observed amplicon to the expected size, whereas efficiency of a primer was 
objectively measured by comparing the relative brightness of the observed amplicon 
to a positive control, and took into consideration the contrast between the observed 
amplicon and background. The scoring system ranged from 1-5, where 1 indicated 
poor primer performance in terms of specificity and efficiency, and 5 indicated 
optimal primer performance. Further, the presence of primer dimers (usually ~100bp 
in size) was noted, but did not influence primer scoring. Primer dimers will be instead 
be removed through a size selection step, in which products under 150 bp will be 
removed prior to library preparation to eliminate primer contamination in the 
subsequent sequencing. Primers classified with a score of 3 or above were considered 
successful and compatible with the experimental protocol to be used with the 
Fluidigm Access Array microfluidics platform in the next phase of the study (section 
2.15). 
Overall, it was found that the Qiagen PCR System resulted in primers with higher 
efficiency and specificity using the given experimental conditions. Indeed, with the 
Qiagen system, 247 out of the 384 primers tested scored 3 or higher, whereas only 
207 out of 385 of the primers scored 3 or higher when using the Roche system. It was 
therefore decided that the Qiagen system would be used in future experiments (in 
the larger cohort of 1000 lean versus 1000 obese males). Primers selected for the Bis-
PCR-Seq were therefore selected among the 247 relatively highly scoring primers. 
As the next steps of the protocol run in multiples of 96, 192 out of the 247 relatively 
highly scoring primers were selected for validation in the cohort of 96 lean versus 96 
obese males. A small number of primers (n = 19) that scored were included despite 
scoring <3 but were of special interest as they had been replicated in at least two 
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EWASs of BMI. The complete list of the 192 primers and their scores in the evaluation 
assay can be found in Appendix 3. 
2.15 The Fluidigm Access Array 
The Fluidigm Access Array is a multiplex bisulphite PCR sequencing microfluidics-
based assay that allows analysis of 10s to 100s of targeted CpG sites simultaneously. 
This assay was used to validate the 192 selected obesity associated CpG sites in DNA 
from 96 lean and 96 obese males. Thus, following bisulfite conversion of the sample 
DNA, PCR reactions were performed using the Fluidigm Access Array, in which several 
target specific primers are amplified in parallel for each DNA sample. The products of 
the multiple PCR reactions were harvested from the Fluidigm Access Array Integrated 
Fluidic Circuit (IFC) for downstream sequencing (218, 219). The IFC process, library 
preparation and subsequent NGS was performed at the Genome Centre Facility at 




The Access Array System library preparation workflow is summarised in Figure 2-12. 
 
2.15.1 Preparation of primers 
192 primers were selected for validation as described in section 2.14. In order to 
comply with the 48.48 layout on the Fluidigm® C1 system (Fluidigm® USA), four 
primers (four forward and four reverse) were combined in each well. The primer 
concentration was 2.5 uM for each of the forward and reverse primers diluted in a 
total of 100 uL ultrapure water. The primers were pipetted into the IFC primer inlets 
(Figure 2-13). 
Figure 2-12. The Access Array System library preparation workflow. 
bp = base pair 
 
 130 
2.15.2 Preparation of DNA samples 
500ng of blood-derived DNA from the 192 samples (from 96 lean and 96 obese males) 
was bisulfite converted as described in section 2.11. Bisulfite converted DNA was 
diluted to a concentration of 11 ng/μL using a Qubit 3.0 Fluorometer (Life 
Technologies). 45 μL of DNA (i.e. approximately 500ng) was used from each 
participant. DNA samples were randomised onto two 96-well plates before being 
pipetted into the sample inlets on the Fluidigm C1 integrated fluidic circuit array chip 
(Figure 2-13). 
Figure 2-13. The Fluidigm C1 integrated fluidic circuit array chip 
Bisulfite converted DNA samples and barcode oligonucleotides were loaded into the sample inlets. 
The locus-specific primers were loaded into the primer inlets. Pneumatic pressure then drives the 
DNA samples, barcode oligonucleotides and primers into the chip's ultra-tiny microfluidic reaction 
chambers (represented as the middle grey area in the image above). 




2.15.3 Multiplex DNA methylation analysis of target regions 
An overview of the protocol for multiplex DNA methylation analysis of target regions 
is presented in Figure 2-14 (219). 
CS1 = Common Sequence tag 1, CS2 = Common Sequence tag 2, TS = Target-Specific primer 
Sequence, PE1 = paired end sequence 1, PE2 = Paired End sequence 2, BC = Barcode Sequence, IFC 
Integrated Fluidic Circuit. Adapted from (219). 
With refence to the steps in Figure 2-14, the process involves the following: 
1) Genomic DNA is bisulfite converted; unmethylated cytosines into uracils 
while leaving methylated cytosines unchanged 
2) During PCR amplification, uracil is amplified as thymine 
3) Multiplex PCR in the Fluidigm Access Array IFC. During this PCR process, the 
common sequence (CS) tags annealed to the target specific primer pairs are 
amplified along with the target specific primer sequences. The common 
sequence tag for the forward primer is 5’ ACACTGACGACATGGTTCTACA 3’ 
Figure 2-14. Overview of the protocol for multiplex DNA methylation analysis of target regions. 
 
 132 
and the common sequence tag for the reverse primer is 5’ 
TACGGTAGCAGAGACTTGGTCTA 3’. 
4) The tagged and amplified PCR products are transferred to a 96 well plate 
5) PCR products are ligated to sample-specific barcodes. This means that PCR 
products can be pooled for sequencing. Paired-end sequences are also 
ligated to comply with subsequent sequencing using the Illumina MiSeq 
sequencing system 
6) PCR products are pooled, harvested and transferred for sequencing 
2.15.4 Sequencing of PCR products 
Sequencing of the pooled amplicons was performed using the Illumina MiSeq 
sequencing system (Illumina, Sand Diego, California) (220). The V2 reagent kit was 
used. The MiSeq sequencing system employs NGS and is thus a high throughput 
sequencing technology based on the principle of running millions of amplified DNA 
sequences in parallel. It is particularly adapted for targeted resequencing. In addition 
to providing information on CpG methylation levels at the particular site selected in 
each primer, the method provides cis genetic information at single nucleotide 
resolution in the area surrounding the CpG site (220).  
The first step in sequencing of the pooled PCR products is cluster amplification. First, 
the library was loaded into a flow cell. The illumina patterned flow cell is an 8-channel 
sealed glass micro fabricated device on which surface are millions of nanowells 
covered with short oligonucleotide sequences (seeding primers) (221). After flow cell 
assembly, the PCR products are deposited into the nanowells. During cluster 
generation, only one single DNA template is able to hybridise and form a cluster 
within each nanowell. Each bound fragment is amplified as a clonal cluster through 
bridge amplification. Thus, a monoclonal cluster is formed in each nanowell 
consisting of approximately 1 million copies of the template DNA (221). 
The next step sequencing-by-synthesis. DNA polymerase is added together with all 
four nucleotides, each carrying a base-unique fluorescent label and with the 3’-OH 
group chemically blocked such that each incorporation becomes a unique event. 
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After incorporation, an imaging step occurs prior to the 3’ blocking group being 
removed to prepare the strand for the next incorporation. The emission wavelength 
and intensity are used to identify the base. Paired-end sequencing was used to 
increase the number of reads per sequence and improve accuracy when later aligning 
the fragments to a reference genome.  
Following sequencing-by-synthesis, the reads were demultiplexed by using the 
sample specific barcode sequences before being aligned to an in silico bisulfite 
converted reference genome. The final NGS data output was uploaded as binary files 
for each sample onto BaseSpace. 
Variant calling was used to identify the percentage of 5mC at each CpG site; 
unmethylated CpG sites in the target sequences would have T whereas methylated 





Chapter 3  
The Impact of Paternal 





Infants born with low birth weight are predisposed to developing diabetes and 
cardiovascular disease in later life (60). The most common cause of fetal growth 
restriction is poor placental development and invasion, but the reason for this 
deficiency is usually unclear. Other factors include maternal disease, maternal toxins 
such as cigarette smoke and, in less economically developed settings, suboptimal 
maternal nutrition (222). Most cases of fetal growth restriction remain idiopathic and 
it can be difficult to distinguish between infants affected by fetal growth restriction 
caused by a failure of a fetus to meet its growth potential and infants who are 
constitutionally small (222). It is therefore of considerable clinical importance to 
improve our ability to understand the risk factors, pathophysiology and prevention 
of fetal growth restriction. 
Animal studies suggest that paternal metabolic syndrome is associated with low 
offspring birth weight, as well as with an increased risk of metabolic disease in 
adulthood, when controlling for maternal factors (138, 223). 
In humans, whereas maternal obesity and insulin resistance predisposes her 
offspring to be large for gestational age (LGA), paternal obesity and  insulin resistance 
predispose his offspring to be small for gestational age (SGA) (68-70, 224-226). Rare 
genetic variants that cause monogenic diabetes in fathers are associated with both 
low birth weight of his offspring and an increased risk of offspring diabetes later in 
life (124). It is possible that less penetrant but more common genetic or epigenetic 
variants that are associated with insulin resistance in fathers, are also associated with 
reduced birth weight of his offspring.  
The association between paternal obesity and reduced offspring birth weight has not 
been replicated across studies (227). Further, studies in this area have mostly been 
retrospective, and sometimes relied on surveys that ask mothers to convey the 
weight/BMI of the father, potentially reducing the reliability of results. I therefore 
undertook a prospective cohort study, ‘The Dad’s Health Study’, in which I performed 
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detailed phenotypic measurements of fathers early in their partners’ pregnancies, 
focussing in particular on metabolic disease risk factors. In order to reduce 
confounding from maternal factors, I excluded mothers who smoked or who had 
chronic disease. I followed up pregnancies and noted pregnancy outcomes. I 
collected peripheral blood from the mothers and umbilical cord and childbirth. I used 
customised growth centiles rather than raw offspring birth weights in all analyses. 
This involved adjusting for maternal BMI, ethnicity, parity, length of gestation at 
delivery and neonatal sex. 
My aim was to identify paternal metabolic risk factors for poor intrauterine growth 
of his offspring. Identifying such factors would inform public health policies directed 
towards improving paternal health before conception and potentially improving the 
health of the next generation. 
3.1.1 Declarations 
Recruitment, sample collection, processing and DNA extraction for the Dad’s Health 
Study was performed by myself and a research midwife (Anna Greco). Statistical 
analyses were carried out by myself under guidance from a senior IT Trainer at UCL 
(Jim Tyson), and Professor Aviva Petrie at the UCL Eastman Dental Institute. 
3.2 Hypothesis 
Paternal obesity and/or insulin resistance increases the risk of fathering small for 
gestational age (SGA) offspring. 
3.3 Specific Objectives 
In a prospective cohort study: 
1. To identify whether paternal obesity, as measured by BMI, is associated with 
an increased risk of fathering SGA offspring. 
2. To identify whether paternal insulin resistance, as measured by HOMA-IR, is 




Methods for the prospective cohort study, hereafter referred to as ‘The Dad’s Health 
Study’, are described in detail in Chapter 2 section 2.3-2.8. 
The study was carried out at University College London Hospital between May 2016 
and June 2019. Favourable ethical approval for the study was granted from the South 
East Coast - Surrey Research Ethics Committee on 28 September 2015 (REC reference 
number 15/LO/1437, IRAS project ID 164459). The study was also registered with the 
UCLH Joint Research Office (Project ID 15/0548). All participants provided written, 
informed consent. 
3.4.1 Study Design and Population 
Recruitment for the Dad’s Health Study is described in detail in Chapter 2 section 2.6-
2.8. 
Briefly, the Dad’s Health Study aimed to investigate the association between paternal 
metabolic health and the risk of fathering a small for gestational age infant, here 
defined as an infant with a birth weight lower than the 10th customised birth weight 
centile (176). 
Paternal obesity was hypothesised to either be associated with an overall reduction 
in mean offspring birth weight, or with an increase in the proportion of offspring 
affected by FGR. Therefore, two different approaches to determining an adequate 
sample size were employed (discussed in detail in Chapter 2 section 2.3.4). In the first 
scenario, a sample size of 151 obese and 151 lean fathers was calculated to be 
required to achieve 90% power to detect a difference in offspring birth weight of 150 
grams (at 5% significance). In the second scenario, it was calculated that 219 lean and 
219 obese fathers would be required to detect a 5% difference in the risk of fathering 
FGR offspring with 80% power (at 5% significance). It was decided to recruit a total 
of 500 fathers and their partners to allow for participant drop-out. 
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Infants were classified as SGA if their customised birth weight centile was <10, 
classified as AGA if their customised birth weight centile 10-90 and classified as LGA 
if their customised birth weight centile was ≥ 90 using the Perinatal Institute’s 
customised birth weight centile charts (176, 228). 
3.4.2 Paternal Phenotype Measurements 
Paternal phenotype measurements are described in detail in Chapter 2 section 2.3-
2.8. 
Briefly, fathers were recruited antenatally, typically around the time of their female 
partner’s (the mothers) first ultrasound scan (10-14 weeks of gestation). The fathers 
were asked to be fasted for 8-10 hours prior to attending for a study visit at UCLH. 
Their phenotype was measured by a trained research doctor or midwife. This 
included measures of their height, weight, blood pressure and waist circumference. 
Peripheral blood was taken from the median cubital vein and sent for measures of 
insulin, glucose, haemoglobin, c-reactive protein (CRP), haemoglobin A1c (HbA1c), 
lipid levels, liver function and kidney function. Insulin resistance was calculated using 
HOMA as detailed in Chapter 2 section 2.7. Fathers were asked to fill in a 
questionnaire enquiring about past medical, family and treatment history (Appendix 
1). 
Two purple (EDTA-coated) and one gold top vacutainers were ultracentrifuged for 15 
minutes at 1000g within one hour of venepuncture. Buffy coat from the EDTA-coated 
vacutainer was used for DNA extraction as described in Chapter 2 section 2.8. 
As part of an additional study to investigate a potential genetic or epigenetic 
mechanism linking paternal metabolic health with offspring birth weight, 
participating fathers were also asked if they would provide a semen sample. 
Approximately one third (181/500) of participating fathers consented to providing a 
semen sample. Semen samples were analysed and processed as described in Chapter 
2 section 2.10. Results from DNA methylation analyses of semen samples are 
presented in Chapter 5. 
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3.4.3 Maternal Phenotype Measurements 
Female participants, the mothers, were typically seen by a member of the research 
team in conjunction with their 26 to 28-week Glucose Challenge Test (GCT). 
The mothers completed a questionnaire enquiring about obstetric, medical, family 
and treatment history (Appendix 2). Information regarding maternal ethnicity, 
height, weight, obstetric history and estimated date of delivery was obtained from 
electronic antenatal records. Clinical biochemistry information, including results from 
the glucose challenge test and, where relevant, the glucose tolerance test, were also 
obtained from electronic antenatal records. A peripheral blood sample was obtained 
from the median cubital vein. Two purple (EDTA-coated) and one gold top 
vacutainers were ultracentrifuged for 15 minutes at 1000g within one hour of 
venepuncture. Buffy coat from the EDTA-coated vacutainer was used for DNA 
extraction as described in Chapter 2 section 2.8. 
3.4.4 Offspring Sample Collection and Measurements 
At childbirth, umbilical cord blood samples were obtained shortly following the 
delivery of the placenta, either by myself or the attending midwife. A 10 mL sample 
was obtained from the umbilical arteries or vein. Samples were ultracentrifuged for 
15 minutes at 1000 g and DNA was extracted from buffy coat as described in Chapter 
2 section 2.8. 
Detailed information about the pregnancy and delivery was recorded, including any 
complication during the pregnancy, length of gestation, mode of delivery, any 
anaesthesia used, offspring Apgar scores at one and five minutes following birth as 
well as any neonatal complications. An Apgar score, named after the obstetric 
anaesthetist Dr Virginia Apgar, is a score developed to rapidly assess the physical 
condition of a newborn infant and the need for prompt intervention to establish 
breathing (229). The score comprises five components which also correspond to the 




3.4.5 Statistical Analyses 
Phenotype analyses were carried out using RStudio version 1.1.456. The cut-off value 
for significance was taken as 0.05 in all analyses unless otherwise stated. 
Measurements of BMI, waist circumference, systolic and diastolic blood pressure, 
total cholesterol as well as HDL and LDL cholesterol were found to be approximately 
normally distributed (Shapiro-Wilk test p>0.10) among study participants. For these 
measurements, results are summarised as mean values and standard deviations. The 
means of these measurements were compared between the discovery, replication 
and obesity cohorts using a one-way analysis of variance (ANOVA). This was followed 
by Tukey's Honest Significant Difference test if p < 0.05. The distribution of 
measurements of fasting glucose, C-reactive protein and triglyceride levels as well as 
calculated HOMA-IR values were found to be skewed (Shapiro-Wilk test p<0.10). 
These are therefore summarised as median values and interquartile ranges. In these 
cases, the Kruskal-Wallis test of ranks was used to compare median values between 
the cohorts. This was followed by Dunn's test of multiple comparisons using rank 
sums if p < 0.05. 
3.5 Results 
3.5.1 Recruitment Numbers to Study Groups 
As discussed in Chapter 2 section 2.3.4, the recruitment target was set to 500 
participating couples (mothers and fathers) in order to allow for participant dropout 
for reasons such as miscarriage, multiple pregnancy that was unknown at the time of 
recruitment and transfer of care to other hospitals. Recruitment was therefore 
capped after 500 couples had been recruited. A total of 110 participants were 
excluded from analyses of the paternal impact on fetal growth for reasons detailed 







Figure 3-1. Flow-chart of participants included in analyses of the paternal impact on fetal growth in 
the Dad’s Health Study, and reasons for participant exclusion. 
Participants were mainly excluded from final analyses on the basis of factors that are known to impact 
on fetal growth but were unknown at the time of recruitment the Dad’s Health study. These include 
maternal gestational diabetes, significant maternal disease and multiple pregnancy. Couples were also 
excluded if their antenatal care was transferred to another hospital such that pregnancy and delivery 
details could not be recorded, or in cases of miscarriage. Pregnancies resulting from ART were also 
excluded. 
*Adverse pregnancy outcomes refers to two cases of fetal death (>24 weeks of pregnancy) and one case 
of maternal disease in pregnancy that led to the delivery of her offspring at 24 weeks of gestation. 




Excluded Included p 
n 49 390  
Age (years). Mean (SD) 38.1 (5.3) 36.3 (5.2) 0.019 
BMI (kg/m2). Mean (SD) 26.8 (3.6) 26.3 (4.1) 0.426 
Waist circumference (cm).  
Mean (SD) 93.9 (9.8) 91.9 (12) 0.249 
SPB (mmHg), average of two 
measurements. Mean (SD) 119 (16) 123 (13) 0.065 
DPB (mmHg), average of two 
measurements. Mean (SD) 76 (11) 79 (9) 0.022 
Total cholesterol (mmol/L).  
Mean (SD) 4.9 (0.9) 5.0 (0.9) 0.523 
HDL cholesterol (mmol/L).  
Mean (SD) 1.4 (0.3) 1.5 (0.4) 0.182 
LDL cholesterol (mmol/L).  
Mean (SD) 3.0 (0.8) 3.0 (0.8) 0.667 
Fasting glucose (mmol/L).  
Median (IQR) 4.9 (0.5) 4.8 (0.5) 0.034 
Fasting insulin (mIU/L).  
Median (IQR) 8.0 (6.4) 6.6 (5.5) 0.060 
HOMA-IR. Median (IQR) 1.8 (1.4) 1.4 (1.2) 0.038 
HOMA2-IR. Median (IQR) 1.0 (0.8) 0.9 (0.7) 0.056 
CRP (mg/L). Median (IQR) 0.9 (0.7) 0.8 (0.8) 0.528 
Triglycerides (mmol/L).  
Median (IQR) 1.1 (0.4) 1.0 (0.7) 0.958 
Table 3-1. Phenotype comparisons between males who were excluded from the study after their 
study visit and males who were included in analyses of the paternal impact of fetal growth. 
There were small significant metabolic differences between males who initially partook in the Dad’s 
Health Study but were thereafter excluded for reasons such as transfer of antenatal care to another 
hospital or miscarriage. These differences were in diastolic blood pressure, fasting glucose and 
HOMA-IR. Fathers who were excluded were also significantly older.  
There were small but significant differences between excluded and included fathers 
in diastolic blood pressure, fasting glucose and HOMA-IR (Table 3-1). Fathers who 
were excluded were also significantly older. Most fathers were excluded because 
their partner developed gestational diabetes, or that the couple had conceived via 
ART. It is possible that men whose female partners developed diabetes were also 
more likely to be insulin resistant themselves (‘assortative mating’). It is also possible 
that couples who undergo ART are on average older than couples who conceive 
naturally. These would be potential explanations for the differences between 
excluded and included participating fathers. 
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3.5.2 Paternal Phenotype Profiles 
Phenotype characteristics of male participants (the fathers) are presented in Table 
3-2.  
There were clear, significant differences in metabolic characteristics between the 
three groups of male participants (lean, overweight and obese). Thus, measurements 
of BMI, waist circumference, systolic and diastolic blood pressure, HDL cholesterol, 
fasting glucose and insulin, HOMA-IR, HOMA2-IR, CRP and triglycerides were all 
significantly different at the p = < 0.05 level between the three groups (for details of 
significance see Table 3-2). In addition, there were significant differences in total and 
LDL cholesterol between the lean and overweight groups and between the lean and 
obese groups of male participants. The difference in BMI between the three groups 
of participating males is visualised in Figure 3-2. 
It should be noted that there was a slight but significant difference in age between 
the lean and obese groups of participating fathers (p = 0.025). This was included as a 
potential confounding factor in later analyses of the association between paternal 







In summary, three groups of metabolically distinct male participants and their female 
partners were recruited and followed up with regards to pregnancy outcome.    
 
Figure 3-2. Comparison of BMI (kg/m2) between participants in the groups of lean, overweight and 
obese participants respectively. 
The boxes indicate the middle 50% of values, with the strong black line representing the median 

















n 179 147 64     
Age (years). Mean (SD) 35.8 (4.8) 36.2 (4.6) 37.7 (6.6)  0.727 0.025 0.122 
BMI (kg/m2). Mean (SD) 23.1 (1.3) 27.1 (1.4) 33.5 (3.6) 18.5–24.9 <0.001 <0.001 <0.001 
Waist circumference (cm). Mean (SD) 83.4 (6) 94.5 (6) 110 (6) <94cm <0.001 <0.001 <0.001 
SPB (mmHg), average of two 
measurements. Mean (SD) 
118 (13) 123 (10) 134 (11) 90 - 120 <0.001 <0.001 <0.001 
DPB (mmHg), average of two 
measurements. Mean (SD) 
76 (8) 80 (8) 86 (9) 60 - 80 <0.001 <0.001 <0.001 
Total cholesterol (mmol/L). Mean (SD) 4.9 (0.9) 5.1 (0.9) 5.3 (0.9) < 5.0 0.029 <0.001 0.430 
HDL cholesterol (mmol/L). Mean (SD) 1.6 (0.3) 1.5 (0.4) 1.2 (0.3) 0.9-1.5 (males) <0.001 <0.001 <0.001 
LDL cholesterol (mmol/L). Mean (SD) 2.8 (0.8) 3.1 (0.8) 3.1 (0.7) < 3.5 0.009 0.036 0.970 
Fasting glucose (mmol/L). Median (IQR) 4.7 (0.5) 4.8 (0.6) 5.0 (0.5) 3.9-5.8 0.041 <0.001 0.017 
Fasting insulin (mIU/L). Median (IQR) 5.2 (3.2) 7.2 (5.1) 13 (11) 2.6-24.9 <0.001 <0.001 <0.001 
HOMA-IR. Median (IQR) 1.1 (0.7) 1.6 (1.3) 2.8 (2.6) Variable, often ≤ 2.0 <0.001 <0.001 <0.001 
HOMA2-IR. Median (IQR) 0.7 (0.4) 0.9 (0.7) 1.6 (1.5)  <0.001 <0.001 <0.001 
CRP (mg/L). Median (IQR) 0.6 (0.3) 0.9 (1.0) 1.5 (2.4) 0-5.0 <0.001 <0.001 <0.001 
Triglycerides (mmol/L). Median (IQR) 0.8 (0.4) 1.2 (0.7) 1.7 (1.4) <2.3 <0.001 <0.001 <0.001 
Table 3-2. Phenotypes of Male Participants in the Dad's Health Study 
Reference ranges are derived from the UCLH Clinical Biochemistry Test Information sheet available from (230). The reference range for HOMA-IR is derived from (231). The 
HOMA2-IR reference range is derived from (232). The reference range for waist circumference is derived from (179). The reference ranges for blood pressure are derived 
from (233). SD = Standard Deviation, IQR = interquartile range, BMI = Body Mass Index, SBP = Systolic Blood Pressure, DBP = Diastolic Blood Pressure, HOMA-IR = 
Homeostatic Model Assessment of Insulin Resistance, CRP = C-Reactive Protein, HDL = High Density Lipoprotein, LDL = Low Density Lipoprotein. 
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3.5.3 Maternal Phenotype Profiles 
Phenotype characteristics of female participants (the mothers) are presented in 
Table 3-3. 
There was a positive relationship between maternal and paternal BMI (R2 = 0.061, p 
= < 0.001, Figure 3-2), such that overweight and obese men were more likely to have 
overweight and obese partners (Table 3-3). 
Ideally, an investigation of the impact of paternal phenotype on fetal growth should 
control for maternal phenotype, as the direct ‘environmental effect’ of the mother 
during pregnancy is likely to overshadow a potential genetic or epigenetic 
contribution from the father. However, I adjusted for maternal BMI by using 
customised birth weight centiles (which take maternal height and weight into 
account) rather than raw birth weight (176). Thus, it was felt that despite there being 
a positive association between parental BMI measurements, birth weight centiles 
































n 179 147 64      
Age (years).  
Mean (SD) 34.2 (4.4) 34.6 (3.7) 34.2 (6.3) N/A 0.648 
   
BMI (kg/m2).  




4.4 (0.7) 4.4 (0.6) 4.4 (0.7) <6.1 0.970    
GCT result (mmol/L). 
Median (IQR) 6.0 (1.8) 6.1 (1.7) 6.2 (1.6) <7.8 0.542 
   
Parity.  
Median (IQR) 0 (0) 0 (0) 0 (1) N/A 0.062 
   
Table 3-3. Comparison of the metabolic phenotype of female partners of lean, overweight and obese males (fathers) respectively. 
The ‘booking glucose’ refers to a non-fasted blood glucose test that pregnant women are offered at their first antenatal appointment (typically 5-9 weeks of gestation) and 
provides an indication of whether further investigation of diabetes is warranted. The reference range for the GCT is taken from (178). BMI = Body Mass Index, GCT = 




3.5.4 Offspring Phenotype Profiles 















n 179 147 64   
Customised 
centile. Mean (SD) 44.5 (27.6) 43.3 (27.3) 46.7 (26.6) N/A 0.715 
Length of gestation 
(days).  
Mean (SD) 
280 (10) 280 (8.5) 280 (9.4) 259 – 294 0.928 
Apgar score at 1 
minute.  
Median (ICR) 
9 (0) 9 (1) 9 (0) >7 0.061 
Apgar score at 5 
minutes.  
Median (ICR) 
10 (0) 10 (0) 10 (0) >7 0.452 
Table 3-4. Comparison of offspring phenotypes between groups of lean, overweight and obese 
fathers 
The reference range for Apgar scores is derived from (15). Customised centiles are calculated using 
(9). SD = Standard Deviation. 
Figure 3-3. Comparison of BMI measurements for male and female participants 
There was a positive relationship between maternal and paternal BMI (R2 = 0.061, p = < 0.001). This 
graph shows the influence of assortative mating. 
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Contrary to my hypothesis, I found that lean, overweight and obese fathers had 
offspring with similar mean customised birth weight centiles. 
3.5.5 Offspring Birth Weight Centiles in Relation to Paternal Metabolic Health 
At the time of study completion, a total number of 48 SGA, 324 AGA and 18 LGA 
infants had been born to parents participating in the Dad’s Health Study. The mean 
customised birth weight centiles for these infants were 4.6 (SD 3.1), 47.6 (SD 22.4) 
and 95.6 (SD 3.5) respectively. The paternal metabolic profiles of SGA, AGA and LGA 





Fathers of SGA 
offspring 
Fathers of AGA 
offspring 








n 48 324 18   
Age (years). Mean (SD) 35.5 (4.5) 36.2 (5.2) 37.9 (3.9)  0.215 
BMI (kg/m2). Mean (SD) 26.5 (4.3) 26.1 (4) 27.4 (4) 18.5–24.9 0.411 
Waist circumference (cm). Mean (SD) 92.9 (12.2) 91.3 (11.2) 96.4 (12.9) <94cm 0.137 
SPB (mmHg). Mean (SD) 122 (14) 123 (12) 125 (12) 90 - 120 0.655 
DPB (mmHg). Mean (SD) 80 (9) 79 (9) 83 (12) 60 - 80 0.149 
Total cholesterol (mmol/L). Mean (SD) 5.0 (0.8) 5 (0.9) 5 (0.8) < 5.0 0.992 
HDL cholesterol (mmol/L). Mean (SD) 1.5 (0.4) 1.5 (0.4) 1.5 (0.3) 0.9-1.5 (males) 0.935 
LDL cholesterol (mmol/L). Mean (SD) 3.0 (0.7) 3 (0.8) 3 (0.7) < 3.5 0.982 
Fasting glucose (mmol/L). Median (IQR) 4.9 (0.6) 4.8 (0.5) 4.7 (0.2) 3.9-5.8 0.787 
Fasting insulin (mIU/L). Median (IQR) 7.3 (4) 6.4 (5.5) 6.5 (12) 2.6-24.9 0.444 
HOMA-IR. Median (IQR) 1.6 (1.0) 1.4 (1.2) 1.5 (2.6) Variable, often ≤ 2.0 0.395 
HOMA2-IR. Median (IQR) 0.9 (0.6) 0.8 (0.7) 0.9 (1.6) Variable, often ≤ 1.7 0.456 
CRP (mg/L). Median (IQR) 1.0 (1.5) 0.7 (0.7) 0.8 (1.1) 0-5.0 0.081 
Triglycerides (mmol/L). Median (IQR) 1.0 (0.7) 1.1 (0.7) 0.9 (0.9) <2.3 0.833 
Table 3-5. Phenotype characteristics of fathers of SGA, AGA and LGA offspring 
SGA = Small for Gestational Age, AGA = Appropriate for Gestational Age, LGA = Large for Gestational Age, BMI = Body Mass Index, SBP = Systolic Blood Pressure, DBP = 
Diastolic Blood Pressure, HOMA-IR Homeostatic Model Assessment of Insulin Resistance.
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As presented in Table 3-5, this study did not identify any paternal metabolic trait that 
was significantly associated with the risk of fathering SGA offspring. There was, 
however, a trend towards higher insulin resistance in fathers of SGA offspring when 
compared to AGA offspring. 
The relationship between offspring birth weight centile and paternal BMI is also 
presented in Figure 3-4. There was no significant association between paternal BMI 
and offspring customised birth weight centile (R2 = 0.002, p = 0.857). 
 
The relationship between paternal insulin resistance and offspring birth weight was 
further explored by regressing offspring customised birth weight centiles against 
paternal HOMA-IR (Figure 3-5). There was no significant association between 
paternal HOMA-IR category and offspring birth weight centile (p = 0.326). 
 
  





3.5.6 Remembered Parental Birth Weights 
There were 243 out of the 390 (62%) participating fathers and 258 out of the 390 
(66%) participating mothers who remembered their own birth weight or acquired 
this information from a parent. Because few of the parents confidently remembered 
the length of gestation at which they were born, these parental birth weights were 
analysed as raw values in grams rather than customised centiles. 
There was a trend towards paternal birth weight correlating with offspring birth 
weight, although this did not reach statistical significance (Table 3-6).  
 
Parents of SGA Parents of AGA Parents of LGA p 
n 48 324 18  
Paternal weight at birth.  
Mean (SD) 3393 (499) 3548 (592) 3700 (386) 0.231 
Fathers who remembered  
birth weight (%) 69 62 56 
 
Maternal weight at birth.  
Mean (SD) 3458 (757) 3268 (572) 3310 (534) 0.240 
Mothers who remembered  
birth weight (%) 69 66 56 
 
Table 3-6. Remembered parental birth weights according to offspring birth weight centile group 
Figure 3-5. Association between paternal HOMA-IR and offspring customised birth weight centile 
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The relationship between parental own weight at birth and offspring weight at birth 
was further explored by regressing parental birth weight against offspring 
customised birth weight centiles (Figure 3-6). 
 
Figure 3-6. Association between parental (own) birth weights and offspring customised 
birth weight centiles 
a) Association between paternal (own) remembered birth weight and offspring birth 
weight centile 




There was a statistically significant relationship between paternal (own) weight at 
birth and offspring customised birth weight centile (R2 = 0.046, p = <0.001). 
Interestingly, there was no significant association between maternal (own) weight at 
birth and offspring customised birth weight centile (R2 = 0.004, p = 0.984) (Figure 3-6). 
I thereafter investigated whether fathers that had been small at birth had a higher 
average BMI and HOMA-IR than fathers who had been born with a normal or high 
birth weight. Fathers who remembered their birth weights were therefore divided 
into three groups; those with a birth weight <2.5kg, those with a birth weight 2.5-
4.5kg, and those with a birth weight >4.5kg. As presented in Table 3-7, fathers who 
weighed <2.5kg at birth were heaviest as adults (BMI 27.5 kg/m2), but this was not 
significantly different from fathers born >4.5kg (BMI 26.2 kg/m2). There was no 












n 10 221 16  
Adult BMI.  
Mean (SD) 27.5 (4.4) 26.1 (4.1) 26.2 (2.4) 0.571 
Adult HOMA-IR. 
Mean (SD) 1.6 (0.7) 1.8 (1.6) 1.8 (1.6) 0.852 
Table 3-7. Association between paternal (own) weight at birth and adult BMI and insulin 
resistance. 
Low birth weight fathers refer to men born with a remembered birth weight <2.5kg. Normal birth 
weight fathers refer to men born with a birth weight of 2.5-4.5kg. High birth weight fathers refer to 





In this prospective cohort study of 390 mother-father-child trios I identified three 
groups of fathers according to their BMI (<25, 25-30 and >30 kg/m2) and followed up 
their partners’ pregnancies. I did not identify any paternal metabolic risk factors for 
fathering small for gestational age offspring. However, I did identify a significant 
association between paternal own birth weight and offspring customised birth 
weight centile. There was no such association between maternal own offspring birth 
weight centile. I also identified a trend towards higher insulin resistance in fathers of 
SGA infants, although this association was not significant. 
The finding of a significant association between paternal own birth weight and 
offspring birth weight should be interpreted with caution, as approximately one third 
of fathers did not remember their birth weight, and this was not a primary outcome 
of the study. However, the association between paternal own weight at birth and the 
birth weight of his offspring is in concordance with previous research in this area (67, 
68). It is interesting to hypothesise why offspring birthweight was associated with 
paternal but not maternal (own) birth weight. The observation suggests a paternal 
genetic influence on offspring birth weight, whilst the maternal influence on 
offspring’s birth weight is predominantly via her intrauterine environment, e.g. 
nutrient availability. This is in concordance with an extension of the parental conflict 
theory. The theory posits that paternal (epi)genetic variants are generally growth-
promoting, in order to increase the evolutionary fitness of his genes, whereas 
maternal (epi)genetic variants are generally growth-restricting, as she needs to 
balance the requirement for a large offspring with conserving resources for her own 
survival.  
Studies that have found an association between paternal metabolic traits and 
offspring growth may offer clues as to why my results did not support this association. 
For example, a nested cohort study by McCowan et al involving 2002 couples in the 
prospective Screening for Pregnancy Endpoints (SCOPE) cohort found that men who 
fathered SGA infants were 36% more likely to be obese compared to men who 
fathered normally grown infants (68). However, McCowan et al also found that 
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fathers of SGA infants were more likely to themselves have been small at birth. In 
that study, fathers of SGA infants were approximately 180 g lighter at birth compared 
to men who fathered non-SGA infants (p = < 0.01). As previously discussed, there is 
a well-established relationship between low weight at birth and an increased risk of 
adult metabolic disease (60). It is also well established that paternal birth weight is a 
significant and independent predictor of low birth weight in offspring (67). It is 
possible, therefore, that rather than paternal obesity being causal of low offspring 
birth weight through the inheritance of epigenetic changes acquired with obesity, 
paternal genetic variants that predispose to low birth weight may mediate a dual 
phenotype that also predisposes to metabolic disease in later life.  
In line with this, a case-control study by Hillman et al identified that males who had 
recently fathered growth restricted offspring were more likely to be sub-clinically 
insulin resistant (OR 7.68 of having a 1 unit higher log HOMA-IR value; 95% CI 2.63–
22.40; p = <0.001), and to themselves have been lighter at birth (69). 
From these two studies would follow that fathers who had themselves been light at 
birth would be more likely to have a higher BMI and higher HOMA-IR later in life. I 
did investigate whether there was an association between a low paternal own birth 
weight and obesity or insulin resistance later in life, however I found no association, 
potentially because the study was underpowered to detect such effects. 
Hillman et al also found that males who had fathered growth-restricted offspring 
were more likely to smoke cigarettes (OR 3.39; 95% CI 1.26–9.16; p = 0.016). A recent 
meta-analysis of the association between paternal smoking and offspring risk of SGA, 
comprising a total of 29,366 infants, concluded that paternal smoking was associated 
with a small but significant increase in the risk of fathering SGA offspring (pooled 
estimate = 1.21 (95% CI 1.03–1.44) (227). Smoking is itself associated with insulin 
resistance (234). It is also possible that males who are smokers are also more likely 
to lead a lifestyle that is otherwise also associated with metabolic disease.  Therefore, 
it is possible that rather than paternal insulin resistance being directly associated with 
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low offspring birth weight in this cohort, part of the association could be explained 
by paternal smoking that negatively impacts on fetal growth. 
Furthermore, from a statistical perspective, I found that measures of insulin, HOMA-
IR and HOMA2-IR in the Dad’s health Study were skewed, as opposed to normally 
distributed. Hillman et al treated the values as conforming to a normal distribution. 
Thus, the descriptive statistics and statistical analyses employed were slightly 
different. It is possible that these differences in study group and statistical analysis 
contributed to different results. 
In agreement with findings from the Dad’s Health Study, a recent systematic review 
of the paternal contribution towards perinatal outcomes did not find an association 
between paternal BMI and offspring birthweight (227). However, this systematic 
review did find an association between paternal height and offspring birthweight. In 
the Dad’s Health Study, I did not find a significant association between paternal 
height and offspring birth weight centile (p = 0.344), however the study was likely 
underpowered to detect modest effects. 
3.6.1 Strengths and Limitations 
The Dad’s Health Study is among the first prospective studies of the association 
between paternal obesity and insulin resistance and offspring birth weight. Previous 
comparable studies have either been retrospective case-control studies (69), or not 
included measures of insulin resistance but assessed more crude measures of 
metabolic health such as BMI alone (68). Therefore, strengths of the Dad’s Health 
Study include that the prospective study design helped to reduce potential selection 
bias and increase generalisability of results. The detailed phenotypic assessment of 
male participants also allowed me to obtain a more sensitive measure of, for 
example, paternal insulin resistance compared some previous studies that have used 
deaths associated with diabetes as a proxy for metabolic dysregulation (224). 
The findings of the Dad’s Health study suggest that the influence of paternal obesity 
and insulin resistance on offspring birth weight is limited. However, a limitation of 
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the Dad’s Health Study is that it was likely underpowered to detect modest effects of 
paternal metabolic health on fetal growth, in particular across the spectrum of 
normal birth weights. For example, it is possible that the trend of a higher insulin 
resistance in fathers of SGA offspring (mean HOMA1-IR = 1.6) compared to fathers of 
AGA offspring (mean HOMA-IR = 1.4) would have been significant had the sample 
size been larger. The power calculations performed prior to commencing study 
recruitment were based on recruiting lean and obese fathers only. However, the 
actual study also included a group of overweight fathers. This could have reduced my 
ability to identify significant effects. Further, the power calculations were based on 
previous retrospective studies in this field which might have included more severe 
phenotypes and therefore required smaller numbers of participants to demonstrate 
an effect (69). In particular, the Dad’s Health Study included a small number of SGA 
offspring (n = 48). Although this number is comparable to that in the study by Hillman 
et al (n = 42), it is likely that the SGA trios I studied included a heterogenous group of 
both growth-restricted and constitutionally small neonates. For comparison, the 
mean customised birthweight centile in the study by Hillman et al was 1.8 (SD = 2.2) 
and the mean customised birth weight centile among SGA infants in the Dad’s Health 
Study was 4.6 (SD = 3.1). Constitutionally small neonates are less likely to be affected 
by metabolic dysregulation than are those affected by growth restriction. 
It is also possible that despite controlling for maternal variables, e.g. by using 
customised birth weight centiles and excluding mothers who developed gestational 
diabetes, that could still be residual maternal confounding influencing the results. 
Another limitation of the study comes from the nature of recruitment to the Dad’s 
Health Study. The majority of male participants were recruited after responding to a 
study poster or a study leaflet placed in antenatal waiting areas at UCLH. The 
incentive for study participation was that metabolic health data such as blood 
pressure, insulin and glucose and blood lipid measurements would be shared with 
participants following their study visit. It is possible that men who were more 
interested in receiving such information were more likely to participate. This would 
reduce the generalisability of my findings. 
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A potential source of error in the Dad’s Health Study imprecision in how infants were 
classified as SGA, AGA and LGA respectively. There is considerable controversy in how 
such a classification should occur (228, 235, 236). For example, some large-scale 
population based studies of ‘optimal’ fetal growth (that is, fetal growth not obviously 
compromised by maternal factors such as illness or poor nutrition) across several 
geographical regions have led to the development of birth weight standards 
proposed to be used across various geographical settings and without taking 
individual maternal factors, such as maternal BMI, into account (235). Other have 
argued for the use of customised birth weight centiles, which control for factors such 
as maternal BMI, ethnicity and parity, as these may more accurately reflect the 
individual fetus’ ability to meet his growth potential (228). It has been argued that 
the widespread adoption of customised birth weight centiles across the UK has 
improved the detection of at-risk fetuses and reduced the rates of stillbirths due to 
this ability to individually assess the ability of each fetus to meet their growth 
potential (228). 
The Dad’s Health Study used customised birth weight centiles rather than birth 
weight standards that do not take individual maternal characteristics into account, 
such as Intergrowth-21, for several reasons (235). First, comparable retrospective 
studies had employed customised birth weight centiles, and using the same methods 
allowed study results to be compared more readily (69). Further, as customised birth 
weight centiles are now extensively employed across the majority of UK hospitals, it 
was felt that results from the Dad’s Health Study would be easier to interpret in a 
wider context of obstetric care by using the same definitions as used in clinical 
practice (228). 
One approach to reduce the influence of assortative mating and maternal BMI on 
study findings would have been to exclude all mothers with a BMI exceeding 25 
kg/m2. However, the feasibility of recruiting adequate numbers of study participants 
during the time period given would have been considerably compromised by such an 
approach. For example, in the present study, had we excluded all mothers with a pre-
pregnancy BMI of 25 kg/m2, we would have approximately halved the number of 
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obese male participants in the study (29 out of 64 would have been excluded). We 
therefore opted to instead control for the influence of maternal BMI via the use of 
customised birth weight centiles. As an aside, although numbers are too limited to 
draw definitive conclusions, I did assess whether there was an association between 
paternal BMI and offspring customised birth weight centiles when including lean 
mothers only (n = 278). However, regressing offspring customised birth weight 
centile onto paternal BMI did not yield a statistically significant finding (R2 = 0.005, p 
= 0.115). 
3.6.2 Future Directions 
As shown in a recent systematic review investigating the paternal role in offspring 
development, the association between paternal BMI and offspring health may not be 
evident when studying offspring birth weight alone, but rather when studying 
offspring weight in later childhood (227). Future studies should explore this 
possibility by longer term follow up of infant growth and metabolism born to parents 
with different metabolic phenotypes. This type of research is difficult in humans due 
to the strong effect of the shared, possibly ‘obesogenic’, environment of children and 
parents. It could nevertheless give clinically important insights into how targeted 
public health strategies could be directed towards families with an increased risk of 
developing obesity and T2DM. 
It would also be interesting to explore whether growth-restricted infants born to 
parents with metabolic disease are particularly vulnerable to metabolic 
consequences of rapid weight gain in their early years, comparable to the health 
consequences of ‘catch-up growth’ that is associated with metabolic dysregulation in 
infants born with low birth weight (66). 
It is possible that paternal metabolic dysregulation may affect fetal growth in a sex-
specific manner. For example, an observational study indicated that paternal BMI is 
associated with offspring birth weight in male but not in female infants (237). With 
only 23 female and 25 male infants born SGA, the Dad’s Health Study was not 
powered to detect sex-specific differences in the paternal impact on fetal growth. 
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Instead, this study used customised birth weight centiles that adjusted for the impact 
of sex on birth weight. However, future research should further investigate the 
potential sex-specific impact of the paternal metabolic health on offspring birth 
weight. 
3.7 Summary 
This prospective cohort study of 390 mother-father-offspring trios did not identify 
any paternal metabolic traits that were significantly associated with an increased risk 
of fathering SGA offspring. It is possible that despite adjusting for maternal BMI, 
assortative mating underpowered my ability to identify an association between 
paternal insulin resistance and fathering a growth restricted offspring. Longer term 
follow-up of the neonates may also reveal paternal influences on childhood growth 
and metabolism. However, in line with previous research, I identified a significant 
association between paternal (own) birth weight and offspring birth weight centile. 
This observation supports the notion that paternal genotype is more influential in 





Chapter 4  
DNA Methylation in 
Human Sperm: A 




Adequate epigenetic regulation of germ cells is imperative for embryogenesis and 
offspring health. Epidemiological studies in humans suggest that environmental and 
acquired paternal traits such as advanced age and smoking have the potential to 
negatively impact on the development and physiology of his offspring, presumably 
via alterations to his spermatozoa (227). The sperm methylome in non-human 
mammals can be altered by environmental and physiological changes, including 
dietary alterations, toxins, and even psychological stress (132, 134-137, 238). In 
addition, acquired traits in male mice induce epigenetic changes in his sperm which 
influence the physiology of his offspring (127, 140). It is possible that the same is true 
for men. 
There is limited, if any, evidence for such germline epigenetic inheritance in humans. 
Some researchers have suggested that similarities between epigenetic profiles of 
paternal and offspring blood can be seen as evidence for paternal germline 
transmission of epigenetic markers (153). However, such studies fail to account for 
the widespread epigenetic resetting of the genome that occurs shortly after 
fertilisation and during gonadal development in the human embryo (128). 
Human sperm is a less readily accessible tissue than peripheral blood and is only 
routinely analysed within reproductive medicine settings. This explains why our 
understanding of the human sperm epigenome is significantly less detailed compared 
with many somatic tissues. However, in the context of understanding how paternal 
environmental and acquired traits could influence offspring phenotypic outcomes, 
sperm represents the most relevant tissue to study. The growing interest in the field 
of inter- and transgenerational epigenetic inheritance partly underlies the increasing 
number of studies investigating the DNA methylation landscape of human 
spermatozoa. Another important reason for such research is the high prevalence of 
sub- and infertility. These conditions affect approximately one in seven UK couples 
and is attributed to male factor infertility in approximately 50% of cases (239, 240). 
Male factor infertility is associated with abnormal semen parameters, such as low 
sperm count, on routine semen analysis. However, the predictive power of semen 
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analysis tests is low (241). For example, a study that assessed semen parameters 
(sperm concentration, motility and morphology) in males in 765 subfertile couples 
and 696 fertile couples found that there was extensive overlap in sperm parameter 
measurements between the two groups (241). In other words, while a low sperm 
concentration was more frequently seen in the subfertile groups, none of the 
measurements was a powerful discriminator for fertility (241). Also, genetic variants 
linked to subfertility are only able to explain a small proportion of cases (242). Male 
factor infertility has, however, been epidemiologically linked to a range of lifestyle 
and environmental factors, including cigarette smoking, obesity and toxins such as 
organophosphates (239, 243). These associations make a plausible case for male 
infertility being at least in part caused by gene-environment, or epigenetic changes. 
With this background, the last couple of decades have seen a number of studies 
investigating the DNA methylation landscape of human spermatozoa. However, 
findings have rarely been replicated across studies. This is likely due to limited study 
sizes and results generated using different methodologies. Thus, it has been 
challenging to draw overall conclusions regarding the human sperm methylome and 
its potential to change in response to environmental or physiological alterations.  
In order to summarise current knowledge, generate recommendations for future 
research as well as inform the next stages of my project, I undertook a systematic 
review, following Preferred Reporting Items for Systematic Reviews and Meta-
Analyses (PRISMA) guidelines (191). 
4.2 Declarations 
The search for relevant papers, filtering of results and summarising of studies was 
first performed by myself and then repeated independently by Dr Amy Danson, 
Queen Mary University London (QMUL). Any differences in the selection of articles 
between myself and Dr Amy Danson were resolved by discussion. Dr Amy Danson 
also added to the grading of studies and together we discussed overall conclusions 
and recommendations for future research. Dr Sarah Marzi, QMUL, had an advisory 
role in the search process and evaluation of evidence. 
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4.3 Specific Objectives 
1. To conduct a comprehensive literature review of studies that investigated 
DNA methylation of human spermatozoa that were published between 
01/01/2003 and 31/03/2019, in accordance with PRISMA guidelines. 
2. To summarise studies included in the systematic review with regards to 
methodologies, limitations and main findings. 
3. To objectively evaluate evidence from studies included in the systematic 
review using the Grading of Recommendations Assessment, Development 
and Evaluation (GRADE) system (244). 
4. To generate recommendations for future research. 
4.4 Methods 
The search strategy, selection of articles and criteria for evaluation evidence are 
discussed in detail in Chapter 2 section 2.9. 
Briefly, publications relating to studies of DNA methylation in human sperm 
published between 01/01/2003 and 31/03/2019 were identified from the PubMed, 
Web of Science and Cochrane databases using the following search criteria: 
"semen" [Mesh] OR "sperm" [Mesh] AND "DNA methylation" [Mesh] OR 
"methylome" [Mesh] 
Articles identified through the search, but which did not meet the inclusion criteria, 
were recorded along with their reason for being excluded. 
The quality of evidence in articles selected for the systematic review was objectively 
rated according to the GRADE criteria as described in detail in Chapter 2 section 2.9.3. 








Rating Reasons for 
down- or upgrading 
Quality of 
the evidence 














Very serious (-2) 
Age 
Smoking  
Somatic cell contamination  
Storage time/sample storage 
conditions  
Medication/supplement use 
Drug and alcohol use  
Abstinence  




Very serious (-2) 
Lack of replication cohort 









Very serious (-2) 
Small sample sizes 
Lack of appropriate controls 
Varying sperm processing 
Definition of subfertility 





Strongly suspected (-1) 




Large effect (+1 or +2) 
Dose response (+1 or +2) 
No plausible confounding 
(+1 or +2) 
 
Table 4-1. GRADE criteria as adapted for the systematic review of studies of DNA methylation in 
human sperm 




4.5 Definitions of Sperm Analysis Parameters 
The most common reference guide for semen analysis is the ‘WHO laboratory manual 
for the examination and processing of human semen’ (245). Unless otherwise stated, 
‘abnormal semen parameters’ refers to samples that have parameters below the 5th 
centile as defined by this manual (see below). The current version of the manual was 
published in 2010. Therefore, some of the earlier studies discussed in this review 
employed an earlier version of the manual, which was one published in 1999. 
However, I have not regarded the differences in the definitions adopted by these two 
versions of the manual as significant enough to prohibit comparisons between 
studies. 
The semen parameters most commonly analysed during a routine semen analysis 
include sample volume, appearance, pH, viscosity, sperm motility, viability/vitality 
(i.e. the percentage of live sperm, which is particularly relevant if motility is low), 
concentration and morphology. The total sperm count is regarded as the most 
accurate indication of whether a semen sample is normal, and is calculated by 
multiplying the sample volume and concentration (245). Other tests, such as the 
mixed antiglobulin reaction (MAR) test, is included in a semen analysis when 
indicated. The MAR test assesses the presence of antibodies on sperm heads. A high 
level of these anti-sperm antibodies is associated with decreased fertility (245).  
Some specific definitions that appear in the systematic review are presented below. 
All definitions are derived from the ‘WHO laboratory manual for the examination and 
processing of human semen’ (245). 
Asthenozoospermia: reduced sperm motility. This is determined by the percentage 
of progressively motile spermatozoa, i.e. spermatozoa which move at a speed of 25 
µm per second or more. The 5th centile for progressive motility is 32% progressively 
motile spermatozoa. Below this level, the sample is considered asthenozoospermic. 
 
Azoospermia: no sperm in the ejaculate. 
 
Normozoospermia: a normal semen sample. Total number of spermatozoa, and 
percentages of progressively motile and morphologically normal spermatozoa, equal 
to or above the lower reference limits. This means: 
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- Volume ≥ 1.5 ml 
- Concentration ≥ 15 million sperm/ml 
- Total number of sperm ≥ 39 million 
- Progressive motility ≥ 32% 
- Vitality ≥ 58% 
- Morphology ≥ 4% of sperm with normal morphology 
 
Oligozoospermia: a low number of spermatozoa in the ejaculate. Defined as less than 
39 million sperm/ejaculate 
 
Teratozoospermia: sperm with abnormal morphology. A teratozoospermic sample 
has less than 4% morphologically normal sperm 
4.6 Results 
4.6.1 Articles selected for inclusion 
The selection process of articles for inclusion in the systematic review is presented in 
Figure 4-1. 
A total of 463 articles were identified by the search terms and through manual 
filtering of reference lists. Two of these were duplicate records and were thus 
removed. We excluded 120 records as they were reviews or did not describe original 
research. A further 217 articles were excluded because the study did not investigate 
humans (n = 51), investigated another tissue than sperm (n = 86), related to forensic 
identification of semen (n = 29) or was published before 2003 (n = 15). This resulted 
in 124 studies that met the predetermined inclusion criteria and were included in the 
systematic review. To my knowledge, these articles represent all published studies 
investigating DNA methylation in human sperm that were available up to March 
2019. 
Of the 124 articles included in the systematic review, 17 investigated global DNA 
methylation, 61 investigated candidate genes, and 46 were genome-wide analyses. 




Assembled according to PRISMA guidelines (191). 
  
Figure 4-1. Flow chart of selection of records for the systematic review 
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4.7 Studies of Global DNA Methylation in Human Sperm 
Studies of global sperm DNA methylation are presented in Table 4-2. 
Global DNA methylation refers to the total level of methylation across the entire 
genome. The gold standard for quantifying global levels of 5mC is liquid 
chromatography coupled with mass spectrometry (246). However, the cost and 
requirement for a mass spectrometer is often prohibitive. Therefore, 
immunohistochemical staining with antibodies against 5mC followed by a secondary 
antibody coupled to a reporter molecule such as fluorescein isothiocyanate for 
microscopic quantification of 5mC is a commonly used method (247, 248). 
Analyses of global DNA methylation have historically been most informative in 
oncology, where global hypomethylation has been found to be characteristic of 
several forms of cancer (246). However, the significance of global alterations of DNA 
methylation in spermatozoa is yet unclear. Indeed, several of the studies included in 
this review failed to provide a biological hypothesis justifying the analysis of global 
DNA methylation in association with particular phenotypes. 
Sample sizes varied widely but were often limited; the median number of total 
participants (cases and controls combined) was 60 (range 10-316) and the mean 99. 
Methodologically, most studies (10/17) employed some form of immunostaining for 
5mC as an assay for detecting global DNA methylation. However, this semi-
quantitative technique relies on visual image analysis and is thus prone to e.g. 
observer variability. Also, the technique is prone to underestimating levels of 5mC as 
the 5mC modified bases can be hidden within the double-stranded DNA helix (248). 
In 7 out of 17 studies, the method of cleaning the sample from somatic cells was 
either not detailed, or only involved washing the sample in phosphate buffered saline 




The quality of evidence for the majority of studies was graded as low or very low (11 
out of 17). The main reasons for downgrading the quality of evidence included a lack 
of correction for covariates, lack of correction for multiple testing, use of 
immunostaining as the sole method of assaying global DNA methylation, and lack of 
appropriate removal of somatic cells. In addition, the generalisability of findings to 
the general male population was found to be overall low, with approximately one 
third of studies (6/17) recruiting participants solely from reproductive medicine 
settings. The studies where the quality of evidence was graded as high generally 
included taking account of important epigenetic confounders such as age and 
smoking status, and validating global 5mC measurements by using more than one 
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5mC levels lower in 
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from Greenland, 
97 from Poland 
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N/A N/A Flow cytometry 
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between persistent 
organic pollutant (PCBs 
or DDT) exposure and 















1, 3, 5 and 7 
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N/A N/A No significant 
association between 
5mC levels and length 
of ejaculatory 
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levels of 5mC 
Samples 
washed in F10 
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associated with overall 
difference in 5mC 
levels 
Very low 
Table 4-2. Studies of global DNA methylation in human sperm. 
‘Gradient’ refers to a discontinuous gradient ultracentrifugation using the medium detailed in the table. ‘Initial processing’ refers to how the semen sample has been 
cleaned from seminal fluid, debris, somatic cells and immotile/dead spermatozoa. ND = Not Detailed, 5mC = 5-methylcytosine.
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4.7.1 Summary of findings from high quality studies of global DNA methylation 
Three studies of global sperm DNA methylation were assessed as being of high 
quality. One of these suggested that antioxidant supplementation could be linked to 
a fall in levels of reactive oxygen species (ROS) in semen and an a concomitant 
increase in global sperm DNA methylation (253). The authors suggest that ROS 
increases sperm DNA fragmentation, which leads to overall hypomethylation (253). 
Normal spermatozoal gene expression is characterised by overall transcriptional 
repression (265). In general, transcriptional repression is linked to high levels of 
methylation, especially of promoter regions (266). It is possible that ROS or other 
toxins damage DNA integrity with a resulting decrease in global DNA methylation. In 
line with this, another high quality study of global DNA methylation suggested that 
exposure to persistent organic pollutants could be associated with global 
hypomethylation (262). In contrast to this, however, a third high quality study by 
Barzideh et al found that DNA methylation levels were generally higher in the low 
quality proportion of spermatozoa (249). The authors suggested that an abnormally 
hypermethylated state was associated with the pre-apoptotic state (by using annexin 
V binding as a proxy for tendency towards apoptosis) (249). These results are not 
necessarily contradictory; it is possible that whilst normal spermatozoa display a 
relatively high level of DNA methylation that can be lowered by toxins such as ROS 
and persistent organic pollutants, this level of DNA methylation could be increased 
above the normal during the process of apoptosis. 
4.8 Candidate Gene Analyses of DNA Methylation in Human Sperm 
Candidate gene analyses of human sperm methylation are presented in Table 4-3. 
Early studies of the human sperm methylome followed epidemiological reports of a 
possible association between assisted reproductive technologies and an increased 
risk of imprinting disorders in the offspring (154). It was hypothesised that 
spermatozoa from males with abnormal semen parameters who underwent in vitro 
fertilisation or intracytoplasmic sperm injection could harbour a greater frequency of 
abnormally imprinted genes that would impact on the phenotype of the offspring. 
Genomic imprints are established on gametes, persist during embryonic 
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development and adulthood, and erased and re-established during gonadal 
development in germ cells (in the next generation) (267). It is therefore possible, at 
least in theory, that if these imprinted genes are inaccurately established on gametes, 
they could influence offspring development. 
With this background, several early candidate gene analyses were directed towards 
the imprinted gene cluster at 15q11-q13, which is implicated in the Prader-Willi and 
Angelman syndromes, as well as the H19/IGF2 locus, which is implicated in the 
Beckwith-Wiedemann and Silver-Russell syndromes (159, 268-271). Since then, 
candidate gene analyses have continued to, in particular, analyse DNA methylation 
profiles of imprinted genes, as well as genes implicated in processes such as germ cell 
function and embryonic development. 
4.8.1 General features of candidate gene analyses of human sperm 
For the majority of studies (32/61), the grade of evidence was deemed to be low or 
very low. The main reasons for downgrading studies was lack of adjusting for 
covariates, lack of description of phenotypic traits of participants (e.g. making it 
unclear whether cases and controls were appropriately matched), and lack of 
correction for multiple testing. Sample sizes varied widely; the median total number 
of participants (cases and controls combined) was 58 (range 10-350) and the mean 
was 85.  
Further, there were considerable methodological differences in the processing of 
semen samples prior to methylation analyses, making cross-study comparisons 
difficult. Thus, around one fifth of studies (12/61) used a swim-up method for 
selecting motile sperm, around one sixth (9/61) used a discontinuous gradient 
ultracentrifugation protocol and three studies used a combination of swim-up and a 
discontinuous gradient ultracentrifugation protocol. In around one quarter of the 
studies (16/61), no sperm selection method was detailed. In a further five studies the 
semen samples were centrifuged or washed in PBS, but no sperm selection method 
was applied. For such studies it is difficult to see that appropriate care had been taken 
not to analyse DNA methylation of somatic cells such as leukocytes and epithelial 
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cells. The remaining three studies used a somatic cell lysis buffer to remove somatic 
cells, or handpicked spermatozoa. In general, there was a lack of validation that the 
sperm selection methods had been successful (e.g. by microscopic examination of 
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Table 4-3. Candidate gene studies of DNA methylation in human sperm. 
‘Initial processing’ refers to how the semen sample has been cleaned from seminal fluid, debris, somatic cells and immotile/dead spermatozoa. ‘Gradient’ refers to a 
discontinuous gradient ultracentrifugation using the medium detailed in the table. ND = Not Detailed, ROS = Reactive Oxygen Species
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4.8.2 Genes studied in candidate gene analyses 
As presented in Figure 4-2, the most common reasons for investigating DNA 
methylation of specific candidate genes was their involvement in imprinting, germ 
cell development and function, and embryonic development. Indeed, as presented 
in Figure 4-3, a relatively small number of genes were analysed in multiple studies. 
 
  
Figure 4-2. Overview of the basis for selection of candidate genes in studies of spermatozoal DNA 
methylation. 
Most genes detailed in the figure have pleiotropic cellular functions. However, the biological 
processes described above are those used as a rationale for analysing their epigenetic regulation in 




4.8.3 Conclusions from studies of candidate genes in human sperm 
The relative cost-effectiveness of candidate gene studies has made them an 
attractive method of studying a small number of genes posited to be involved in a 
particular biological process. However, these hypothesis-driven approaches do suffer 
from several methodological limitations. 
First, our understanding of the biological pathway that the gene is part of is inevitably 
incomplete and may be wrong. Therefore, identifying an association between DNA 
methylation of a candidate gene and a particular phenotype does neither prove nor 
refute that the biological pathway that the gene is thought to be part of is disrupted. 
For example, low expression of a gene as a consequence of promoter DNA 
methylation may be compensated for by downstream effects of other pathway 
members.  
Second, candidate gene analyses are prone to publication bias, especially if they are 
relatively small-scale.  It is possible that several of the genes analysed in published 
studies of DNA methylation in sperm may have been investigated in similar studies 




previously, but that small studies with negative results were less likely to become 
published.  
Regarding generalisability of findings from candidate gene analyses, it is worth noting 
that at least two-thirds of studies (40 out of 61) recruited participants wholly or 
partially from a reproductive medicine setting. In a further five studies, it was unclear 
where participants had been recruited from. 
4.8.4 Summary of findings from high quality studies of candidate gene analyses 
of DNA methylation  
A couple of the high quality studies of candidate genes in human spermatozoa 
showed an association between abnormal semen parameters or poor outcomes of 
assisted reproductive technologies (ART) and abnormal DNA methylation in 
promoters of imprinted genes (278, 291). Similarly, a couple of studies showed an 
association between abnormal semen parameters or outcome of ART and levels of 
methylation at repetitive DNA elements (290, 307). In contrast, one high quality study 
showed that there was no association between rates of imprinting errors and the 
outcome of ART (158). Some high quality studies have shown an association between 
exposure to various toxins, such as organophosphates and mercury, and abnormal 
promoter methylation of imprinted genes or repetitive elements (317, 322, 324). One 
study showed that obesity could influence methylation of imprinted genes and genes 
associated with spermatogenesis (310). Given the methodological problems even 
with well-performed candidate gene analyses, such as potential publication bias and 
incomplete understanding of the biological pathways involved, it would be tentative 
to draw general conclusions from these sometimes conflicting results. Nevertheless, 
it is possible that relatively extreme situations of high toxin exposure, extreme 
obesity or severely abnormal sperm parameters are associated with abnormal sperm 
parameters and lower success rates of ART, but that these effects are negligible 
under more normal conditions. In the case of toxin exposure in particular, this would 
be in line with some of the high quality global analyses of spermatozoal DNA 
methylation discussed above. 
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Among the more replicated findings in high quality candidate gene analyses is 
hypermethylation of the methylenetetrahydrofolate reductase (MTHFR) promoter in 
association with subfertility, poor ART outcomes or toxin exposure (162, 281, 301). 
MTHFR catalyses a key step in folate metabolism, which is essential for the 
establishment of DNA methylation (326). Mutations in the MTHFR gene have reliably 
been linked to developmental perturbations related to folate metabolism, such as 
neural tube defects (326). It is possible, therefore, that hypermethylation of the 
MTHFR promoter, leading to its transcriptional repression, leads to inaccurate 
establishment of the sperm DNA methylome with downstream consequences such 
as poor outcome of ART.  
One high quality study analysed CpG methylation of HCG9 in sperm, post-mortem 
brain tissue and peripheral blood from individuals with schizophrenia and bipolar 
disorder (292). The study found that methylation at one CpG site was significantly 
different between cases and controls (292). To my knowledge, this finding has yet to 
be replicated and it should therefore be interpreted with caution. Nevertheless, it is 
interesting consider the now well-established association between paternal age and 
psychiatric disorders in his offspring, suggesting that there is an association between 
alterations to sperm during an individual’s lifetime and the health of his offspring 
(327). In this regard, it is also interesting to note that age-related methylation 
changes were observed in FOXK1 and KCNA7 in another high quality study by Atsem 
et al (315). 
The final high quality candidate gene study identified in this review showed that 
cryopreservation of sperm did not significantly alter the methylation status of 
selected genes (293). This is reassuring from a reproductive medicine point of view, 
as sperm is frequently cryopreserved for long periods of time in cases where, for 
example, individuals are due to undergo treatment that could negatively impact of 
their fertility and opt to preserve spermatozoa beforehand. 
4.9 Genome-Wide Analyses of DNA Methylation in Human Sperm 
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3 samples each 
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ND 12 21.8 (3.8); 
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with the aging process 
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ND 329 23-56; pooled 
data from 
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predicting age with an 
R2 of 0.89, a mean 
absolute error of 2.04 
years, and a mean 
absolute percent error 
of 6.28% 
Moderate  
Al Khaled et 
al., 2018 
(364) 
Toxins 450K array followed by 





92 25-50; fertile 
smokers. 14 for 
discovery 
cohort and 78 
for validation 
14 25-50; fertile 
non-smokers 
Smoking associated 
with DNAm in PGAM5, 










50 38.7 (6.9); 
subfertile males 




subfertility and DNAm 
of PRRC2A, ANXA2, 
MAPK8Ip3 and GAA 
Moderate  
Table 4-4. Genome-wide analyses of DNA methylation in human sperm 
‘Initial processing’ refers to how the semen sample has been cleaned from seminal fluid, debris, somatic cells and immotile/dead spermatozoa. ‘Gradient’ refers to a 
discontinuous gradient ultracentrifugation using the medium detailed in the table.  450K array = Illumina HM450 Methylation array, COBRA = Combined bisulfite restriction 
analysis, ART = Assisted Reproductive Technologies, ND = Not Detailed.
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4.9.1 General features of genome-wide analyses of human sperm 
For the majority of studies (27/48), the quality of evidence was rated as low or very 
low. Among common reasons for downgrading studies were lack of phenotypic 
information about participants, lack of information on sample processing, lack of 
accounting for confounders such as age and smoking, lack of correcting for multiple 
testing and small sample sizes. Indeed, the sample sizes were generally lower than 
those in global analyses of DNA methylation and in candidate gene studies; the 
median number of total participants (cases and controls combined) was 24 (range 
12-339), and the average was 48. The average was inflated by one study in particular 
that used pooled data from several previous studies to generate a total sample size 
of 339 (363). We decided to include both this large study and the smaller studies from 
which the data was pooled as they assessed different outcomes (e.g. the large study 
analysed age-related spermatozoal DNA methylation while the smaller studies 
investigated conditions such as subfertility and abnormal sperm parameters). 
Studies where the quality of evidence was rated as high typically used multivariate 
analyses to account for covariates, or validated results in independent cohorts, such 
as in two studies by Laqqan et al. (167, 360). 
The variability in sample sizes may help to explain why studies with similar 
methodologies have yielded contradictory results. For example, a case-control study 
Jenkins et al using the Illumina 450K methylation array (the HM450) that included 78 
smokers and 78 non-smokers identified 141 CpG sites that were significantly 
associated with smoking (355). Al Khaled et al, however, did not identify any CpG 
sites that were significantly associated with smoking when using a similar protocol, 
which may be explained by including only 19 smokers and 20 non-smokers (355, 364). 
Also, results could have differed because of differences in length and amount of 
smoking among smoking participants in the two studies.
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4.9.2 Summary of findings from high quality studies of genome-wide DNA 
methylation 
Possibly the most striking conclusion from high quality studies of genome wide DNA 
methylation in human sperm is the lack of overlap between these findings and 
findings from candidate gene analyses. For example, Camprubi et al used the HM450 
array to study genome-wide CpG methylation in subfertile cases and fertile controls, 
and also analysed results with regards to semen parameters and age (164). None of 
the intensively studied candidate genes were identified as differentially methylated 
between subfertile cases and fertile controls (164). Instead, significant associations 
were found between age and DNA methylation of RPS6KA2, between 
oligozoospermia and DNA methylation of APCS and between fecundity and DNA 
methylation of ANK2 (164). Similarly, Laqqan et al used the HM450 to analyse 
genome wide CpG methylation in subfertile cases and fertile controls, and did not 
identify any of the previously studied candidate genes as associated with subfertility 
(357). Instead, this study identified CpGs related to ALS2CR12, ALDH3B2, PRICKLE2, 
and PTGIR as significantly differentially methylated in subfertile cases (357). What is 
also evident from these two studies is that there is little overlap of results between 
them, even though the research methodology was similar. This is possibly due to the 
relatively small sample sizes compared to EWASs of more accessible somatic tissues. 
Other high quality studies include one that analysed genome wide CpG methylation 
in smokers versus non-smokers (360). The study identified DNA methylation at 
MAPK8IP and TKR as significantly associated with smoking (360). Given that paternal 
smoking has been consistently linked to birth defects and poor intrauterine growth 
of his offspring, further studies like these are warranted (227). Also, there is a well-
established relationship between paternal aging and the risk for psychiatric and other 
conditions in his offspring (227, 327). It is therefore interesting that a genome-wide 
analysis of sperm CpG methylation identified age-related methylation changes in a 
number of genes, including EED, CTNNA2, CALM1, CDH13 and STMN2 (328). Notably, 
none of the identified genes overlapped with those studied in candidate gene 
analyses of age related changes in DNA methylation (315).   
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4.10 Recommendations for Future Research 
4.10.1 Studies of global DNA methylation 
Studies investigating global DNA methylation in human sperm have yielded 
inconclusive results, and commonly suffered from methodological problems. 
Importantly, even a well-powered and methodologically adequate study of global 
DNA methylation would, by definition, not yield information on specific genes or 
biological pathways that may be epigenetically perturbed in particular phenotypes. 
Therefore, the value of global DNA methylation analyses to understand the influence 
of DNA methylation on conditions such as subfertility or the potential for the sperm 
methylome to respond to environmental change is limited. It would be advisable to 
focus efforts on genome-wide approaches with an improved potential for uncovering 
biologically relevant findings. 
4.10.2 Candidate gene studies 
Candidate gene analyses suffer from methodological drawbacks as discussed above. 
They also, by definition, only investigate known genes or known regulatory regions 
of the genome, and thus leave the vast majority of the genome unexplored. Results 
from candidate gene analyses thus far have been inconclusive, and few findings have 
been replicated in genome-wide analyses. It would be recommendable to shift the 
focus towards unbiased, genome-wide approaches in future investigations. 
4.10.3 Genome-wide studies 
Unbiased, genome-wide CpG methylation studies of biologically relevant tissues have 
yielded important insights in a range of common human conditions, including 
metabolic and psychiatric disease (106, 365). Using this unbiased approach to 
investigate the sperm methylome holds the most promise in terms of improving 
understanding of conditions such as subfertility and the impact of environmental 
conditions on germ cells. 
The majority of genome-wide investigations have employed the Illumina HM450 
array, which captures around 1.7% of the ~ 28 million CpG sites in the genome. 
  
 211 
Notably, the array only covers a small proportion of enhancers and other regulatory 
regions. Future investigations using the novel version of this array, the 
MethylationEPIC array, will generate an improved coverage of such regulatory 
regions with ~ 350, 000 additional CpG sites in enhancers (199). 
It is evident that for robust, reproducible findings to be achievable, sample sizes need 
to be increased. Performing a power calculation prior to study commencement is 
recommended, for example by using published guidance for the MethylationEPIC 
array (366). As sperm is not routinely collected outside a reproductive medicine 
setting, it is likely that multicentre collaborations will be required to meet the 
requirement for increased sample sizes. Such collaborations should harmonise 
protocols for phenotyping of participants, processing samples and perform 
methylation analyses in order to limit batch effects. Until whole genome bisulfite 
sequencing becomes a cost-effective possibility for large-scale investigations, 
microarray-based approaches will likely be the best option. In addition, results from 
these arrays can be compared across studies. For example, the MethylationEPIC 
covers >90% of CpG sites present of the HM450 array (199). Therefore, results 
obtained from analyses using the MethylationEPIC can be checked for consistency 
with results from studies using the HM450 provided that similar methodologies were 
used. 
Several genome-wide investigations thus far have been microarray-based analyses of 
subfertile cases and fertile controls (164-167, 343). Although these studies 
individually have identified a number of CpG sites that seem to be differentially 
methylated between cases and controls, there has been little overlap between study 
findings. It would be interesting to see if these identified sites are replicated in future, 
larger-scale investigations. It would also be advisable to combine DNA methylation 
analyses with functional studies to better characterise the biological pathways 
involved and their potential relevance to particular phenotypes. 
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4.10.4 Overall considerations 
Future research should present detailed phenotyping of participants, including 
information on matching of participants in case-control studies as well as exclusion 
criteria for study participation. Factors to consider include age, smoking status, 
medication use, BMI, abstinence, drug/alcohol use, diet and sample storage time and 
conditions. In future studies, multivariate regression analyses that take potentially 
confounding factors into account would generate more reliable results. 
The vast majority of studies performed to date have been cross-sectional. 
Longitudinal cohort studies with serial sampling would have a greater potential to 
improve our understanding of disease pathogenesis and identify biomarkers. 
Together with functional analyses, such studies would also begin to elucidate 
causality, i.e. whether particular sperm DNA methylation signatures are a cause or an 
effect of a particular phenotype. 
There is a range of protocols for selecting motile spermatozoa and cleaning semen 
samples from contaminating somatic cells. Of importance is that irrespective of 
which protocol is employed, samples should be checked post-processing to ensure 
that spermatozoa used for epigenetic analyses contain a pure sperm population. 
Bioinformatically assessing for somatic cell contamination would also be advisable. 
For studies of tissue specificity, e.g. comparing the DNA methylome of a somatic 
tissue to that of spermatozoa, samples should be matched. Several studies included 
in this review compared the DNA methylome of spermatozoa to that of somatic 
tissues of different individuals. Because genetic variation influences the DNA 
methylome, not using matched tissues increases confounding and should be avoided 
in future research. 
The generalisability of findings to the general male population from the majority of 
studies included in this review is debatable, as they recruited participants from 
reproductive medicine settings. This selection bias would be avoided by recruiting 
study participants that are more representative of the male population as a whole. It 
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is likely that multicentre collaborative efforts would be required to generate large 
enough sample sizes to meet this aim. 
The majority of studies have focused on differential DNA methylation related to 
subfertility or abnormal semen parameters. Widening the scope in future 
investigations to include more research on, for example, the influence of metabolic 
health, toxins and aging on sperm epigenetics would be recommended. Such 
research would also be more likely to help explain the epidemiological associations 
between paternal aging, smoking and BMI on offspring health (227). In this regard, 
however, other causes than changes to spermatozoa, whether genetic or epigenetic, 
need also to be taken into account. For example, there has long been an assumption 
that increased paternal age is associated with an increased risk of conditions such as 
autism and schizophrenia in his offspring due to age-related increases in the rate of 
de novo mutations in spermatozoal genomes (367). However, recent research 
suggests that a more influential part of the explanation for the association between 
paternal age and offspring psychiatric illness is that psychiatric illness is associated 
with an increased propensity for men to father his first child either at a relatively 
young or at a relatively old age (367). These two explanations for the association are 
of course not mutually exclusive, and it is possible that the increased rate of de novo 
mutations also play a part. Nevertheless, future research that explores the 
association between paternal age-related changes to his (epi)genome and the 
propensity for his offspring to develop psychiatric disease should take these 
behavioural or social factors into account. 
This systematic review has focused exclusively on DNA methylation as opposed to 
other epigenetic mechanisms, partly because DNA methylation has been the most 
widely studied epigenetic mechanism. However, other epigenetic mechanisms such 
as small RNA species and histone modifications may also influence the sperm 
epigenome and effects between generations and therefore require study (144, 145). 
Our understanding of crosstalk between the nucleotide sequence, the DNA 
methylome, histone modifications and non-coding RNA is also in its infancy. Future 
research that elucidates the integration of different epigenetic modifications would 
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significantly enhance our understanding of the dynamic nature of gene expression in 
spermatozoa. 
4.11 Strengths and Limitations of the Systematic Review 
The major strength of this systematic review is the comprehensive literature search 
identifying a large number of relevant publications. It is nevertheless possible that 
there are relevant publications which fit the scope of this review, but which were not 
identified by our search terms. 
We needed to modify the GRADE criteria to fit with the particular purpose of this 
review (244). It is possible that we should have included different rating criteria, for 
example modifying our assessment of studies depending on whether they were of a 
case-control EWAS type or whether they were studies of tissue specificity of DNA 
methylation. Also, the heterogeneity of studies included in this systematic review 
prevented us from adding meta-analyses where relevant. Meta-analyses might have 
given a better overview for the reader, and made summarising results more 
conclusive. 
Further, methods of epigenomic investigation have been developing rapidly since 
2003, i.e. the year from which studies were included in this review. This means that 
early studies may have been of relatively high quality at the time when they were 
performed, but rated as low quality in our review because they are compared to 
newer studies using improved methodologies. 
Another limitation is that it is difficult to assess the risk of, for example, publication 
bias. There can be a suspicion that small-scale, low-cost analyses with negative 
results are less likely to be published than small-scale, low-cost analyses with positive 
results. However, it is by definition impossible to know what the ratio between these 
outcomes are and how such biases may have impacted the understanding of a 
particular field. For example, if all candidate gene analyses of subfertility with 
negative results had been published in addition to those with positive results, would 
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there have been a general understanding that subfertility is associated with abnormal 
methylation of imprinted genes? 
4.12 Overall Conclusions 
Detailed characterisation of the human sperm methylome has the potential to 
improve our understanding of subfertility, embryogenesis and the ability for 
environmental and acquired phenotypes to influence the next generation. From 
human studies performed to date, however, there are few, if any, robust and 
replicable findings that have significantly improved this understanding. 
Importantly, in the context of intergenerational effects, there is yet no evidence of 
specific DNA methylation signatures in human spermatozoa that are able to influence 
offspring development. A large number of studies have investigated imprinted genes 
in sperm under the presumption that imprinting abnormalities identified in 
spermatozoa harbour the potential to influence the physiology of the next 
generation. However, such studies fail to take into account the widespread resetting 
of the epigenome that occurs between generations. It would be interesting to 
investigate whether there is overlap between CpG sites identified as differentially 
methylated in particular phenotypes and the so-called ‘escape variants’, i.e. sites that 
appear resistant to the demethylation processes that occur after fertilisation and 
during gonadal development (128). 
Lastly, it will be a long time before studies of DNA methylation in human spermatozoa 
reach a comparable magnitude to those that have been performed on peripheral 
blood. As an intermediate step, therefore, it would be interesting to characterise the 
epigenetic covariation between these tissues in a genome-wide, unbiased manner on 
matched sperm and blood samples. Such analyses would help to elucidate under 
which conditions, if any, peripheral blood could be used as a surrogate tissue for 
spermatozoa. It could also generate information on which specific CpG sites are 
highly correlated versus uncorrelated between the two tissues. The largest study to 
date that has performed this characterisation included a total of 8 participants, thus 
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Studies in humans and non-human mammals suggest that paternal metabolic health 
could influence the growth of his offspring (68, 69, 127). Animal studies suggest that 
the association between paternal metabolic disease and fetal growth could be 
mediated through epigenetic changes to spermatozoa that are passed from a father 
to his offspring and affect metabolism in the developing fetus (140, 141). Such studies 
are lacking in humans. 
Sperm represents the most relevant tissue to study in the context of whether 
acquired paternal traits could biologically impact on the next generation. However, 
human semen samples are not regularly collected and analysed outside of a 
reproductive medicine setting. They are also less readily obtainable than, for 
example, peripheral blood. Thus, the human sperm epigenome remains relatively 
poorly characterised compared to many somatic tissues.  
Some studies have used human blood as a proxy tissue for studying epigenetic 
profiles in germ cells (153). However, such studies are problematic. First, epigenetic 
signatures are highly tissue- and cell- type specific (77). Secondly, they fail to address 
the widespread two-stage process of DNA demethylation that occurs shortly after 
fertilisation and during gonadal formation (128). 
As discussed in detail in Chapter 4, previous analyses of DNA methylation in human 
sperm have focussed largely on studies of DNA methylation in subfertility, and there 
has been a lack of robust, reproducible results across studies. In addition, participants 
have generally been recruited from reproductive medicine settings, potentially 
making results and conclusions less applicable to the general population. 
It will be a long time before DNA methylation studies of human germ cells reach 
comparable magnitudes to those performed on peripheral blood. As an intermediate 
step, therefore, there is value in characterising the DNA methylation covariation 
between these tissues in order to better appreciate under which circumstances blood 
could be used as a surrogate tissue for sperm. Although absolute levels of DNA 
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methylation are likely to be highly tissue specific, sites where methylation levels co-
vary would be candidates for inferring spermatozoal DNA methylation from analyses 
of blood (368). 
To this end, I characterised the DNA methylomes of matched human sperm and blood 
samples from healthy males of proven fertility in an unbiased, genome-wide manner 
using the Illumina MethylationEPIC Array. The study aimed both to characterise the 
DNA methylome of the two tissues in detail, and to identify sites where methylation 
levels co-vary between the two tissues. In addition, a cohort of obese, fertile males 
were included to identify obesity specific co-variation between sperm and blood. 
Lastly, DNA methylation data from spermatozoa was compared to that of almost 
6,000 tissue samples from the Gene Expression Omnibus (GEO) database in order to 
identify CpG sites that are hyper- and hypomethylated in sperm relative to somatic 
tissues. 
5.1.1 Declarations 
The samples included in this study were collected by myself and a research midwife 
(Anna Greco). I performed DNA extraction of semen samples, as well as of blood 
samples in conjunction with Anna Greco. Bisulfite conversion of DNA from blood and 
sperm samples was performed by myself and Ama Brew, research technician at the 
Blizard Institute, QMUL. The Illumina MethylationEPIC arrays were processed by 
Yasmin Panchbhaya at UCL Genomics, Great Ormond Street Institute of Child Health. 
Methylation data preprocessing and analysis was performed by Dr Sarah Marzi at the 
Blizard Institute, QMUL. The GEO analysis was performed by Dr Tyler Gorrie-Stone at 
the University of Essex. 
5.2 Hypotheses 
1) A. The human sperm epigenome displays large-scale overall differences 
compared with matched somatic tissues such as blood 
B. At a select number of CpG sites, there is a high DNA methylation correlation 




2) Obesity influences the sperm DNA methylome 
5.3 Specific Objectives 
1) To characterise the DNA methylomes of matched human sperm and blood 
samples from a cohort of healthy, fertile males in an unbiased, genome-wide 
manner using the Illumina MethylationEPIC Array  
 
2) To identify CpG sites where DNA methylation levels co-vary between sperm 
and blood  
 
3) To identify whether CpG sites that covary between sperm and blood in 
obese or lean males exclusively 
 
4) To compare the DNA methylome of spermatozoa to that of methylation data 
from ~6,000 somatic tissues available on GEO 
5.4 Methods 
5.4.1 Study Outline 
Participants were recruited as part of the Dad’s Health Study at University College 
London Hospital (UCLH) between May 2016 and March 2019 as described in detail in 
Chapter 2 sections 2.3-2.8. All participants provided written, informed consent. 
Ethical approval was granted from the South East Coast - Surrey Research Ethics 
Committee on 28 September 2015 (REC reference number 15/LO/1437, IRAS project 
ID 164459). The study was also registered with the UCLH Joint Research Office 
(Project ID 15/0548). 
Participants were recruited into three cohorts; 1) a discovery cohort consisting of 48 
lean, fertile males (BMI 18-25 kg/m2) who provided one sample of blood and one 
sample of sperm each, 2) a replication cohort consisting of 24 lean, fertile males (BMI 
18-25 kg/m2) who provided one sample of blood and one sample of sperm each, and 
3) a cohort of overweight and obese, fertile males (BMI >25 kg/m2) who provided one 
  
 220 
sample of blood and one sample of sperm each. The cohort of overweight/obese 
males is hereafter referred to as the obesity cohort. 
Participants in the discovery, replication and obesity cohorts each completed a 
questionnaire enquiring about past medical, family and treatment history. 
Participants were phenotyped with regards to height, weight, waist circumference 
and blood pressure by a trained research doctor or research midwife.  
DNA was extracted from blood and sperm shortly after collection as described in 
section 5.4.6 below and in detail in Chapter 2 section 2.10.5. Extracted DNA 
underwent bisulfite conversion as described in Chapter 2 section 2.11. Bisulfite 
converted DNA samples were analysed for genome-wide CpG methylation levels 
using the Illumina MethylationEPIC Array at UCL Genomics, Great Ormond Street 
Institute of Child Health, as described in Chapter 2 sections 2.12. The output of the 
Illumina MethylationEPIC array analysis was provided as an intensity data (IDAT) file 
together with information on sample runs and chip positions. 
A series of quality control and preprocessing steps, as described in Chapter 2 section 
2.12 were applied to the DNA methylation data before analysis of CpG methylation 
with regards to the specific aims of the study was interrogated. An overview of the 






Figure 5-1. Overview of the analysis pipeline for analysing DNA methylation covariation in 
blood and sperm. 
IDAT = intensity data, SNP = single nucleotide polymorphism, DNAm = DNA methylation. 
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5.4.2 Study Population 
Participants included in the discovery and replication cohorts were recruited 
according to the following criteria: 
• Aged 18 to 50 years 
• No significant medical problems (as self-reported in study questionnaires) 
• No regular use of medications (as self-reported in study questionnaires) 
• No drug, alcohol or substance abuse 
• Proven fertility 
• BMI 18-25 kg/m2 
Participants included in the obesity cohort were recruited according to the following 
criteria: 
• Aged 18 to 50 years 
• No significant medical problems (as self-reported in study questionnaires) 
• No regular use of medications (as self-reported in study questionnaires) 
• No drug, alcohol or substance abuse 
• Proven fertility 
• BMI >25 kg/m2 
5.4.3 Statistical Analyses 
Phenotype analyses were carried out using RStudio version 1.1.456. Results were 
independently verified by Dr Aviva Petrie at the UCL Eastman Dental Institute 
Biostatistics Unit using STATA 15 (StataCorp LLC, Texas USA). 
Methylation data was processed and analysed using the wateRmelon package in R 
(203). The GEO analyses were performed using the bigmelon package in R (211). 
5.4.4 Sample Collection, Handling and Processing 
Detailed information regarding sample collection, handling of processing of samples 
collected as part of the Dad’s Health Study can be found in Chapter 2 section 2.8. 
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Brief descriptions of how blood and semen samples included in the study of DNA 
methylation covariation were processed prior to epigenetic analysis is provided 
below. 
5.4.5 Collection and Processing of Blood Samples 
Peripheral blood samples were taken from the median cubital vein and clinical 
biochemistry analyses were performed by the UCLH clinical biochemistry laboratory. 
Blood to be used for DNA extraction was centrifuged at 3000g for 15 minutes within 
one hour of venepuncture. Buffy coat was isolated and used for DNA extraction. DNA 
was extracted using the Qiagen QIAamp DNA Blood Mini Kit (Qiagen, Hilden, 
Germany) as described in Chapter 2 section 2.8.1 and stored in -80° prior to analysis. 
Bisulfite conversion of 500 (±10%) ng DNA derived from blood samples was 
performed using the D5001 EZ DNA Methylation Kit (Zymo Research, Irvine, CA, USA) 
according to manufacturer’s instructions as described in Chapter 2 section 2.11. 
Bisulfite converted samples of DNA were stored at -20° for a limited time (<3 days) 
prior to being randomised and transported to UCL Genomics at the Great Ormond 
Street Institute of Child Health for immediate analysis using the Illumina 
MethylationEPIC Array. 
5.4.6 Collection and Processing of Semen Samples 
Semen samples were produced in participants’ own homes or in designated rooms in 
the UCLH Reproductive Medicine Laboratory according to preference. Samples were 
obtained within one hour of sample production and initial processing of samples was 
performed in the UCLH Fertility and Reproductive Medicine Laboratory. First, 
samples were placed on a warm plate (35-37°C) for 20-30 minutes in order to liquefy. 
Sample volume was measured and 5μL of the sample was pipetted onto a Leja 
disposable counting chamber and analysed using the Computer-Assisted Sperm 
Analysis (CASA)/Sperminator software (Pro-Creative Diagnostics, Staffordshire, UK). 
Semen sample parameters measured were sperm concentration (millions/mL), 
percentages of sperm in four categories of motility from most motile to least motile 
(A – D), and average motile speed. Samples underwent gradient centrifugation (45 
and 90% PureSperm medium) to select for the most motile sperm and to clean the 
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samples from somatic cells, seminal fluid and debris. DNA was extracted from the 
motile proportion of the sperm as described in section 2.10.5. Semen DNA was then 
stored in -80° prior to further processing and analysis. Bisulfite conversion of 500 
(±10%) ng DNA derived from semen samples was performed using the D5001 EZ DNA 
Methylation Kit (Zymo Research, Irvine, CA, USA) according to manufacturer’s 
instructions as described in Chapter 2 section 2.11. Bisulfite converted samples of 
DNA were stored at -20° for a limited time (<3 days) prior to being randomised and 
transported to UCL Genomics at the Great Ormond Street Institute of Child Health 
for immediate analysis using the Illumina MethylationEPIC Array. 
5.4.7 Phenotype Characteristics of the Study Population 
Phenotype characteristics of participants in the discovery, replication and obesity 
cohorts are presented in Table 5-1. 
Measurements of BMI, waist circumference, systolic and diastolic blood pressure, 
total cholesterol as well as HDL and LDL cholesterol were found to be approximately 
normally distributed (Shapiro-Wilk test p>0.10) in all three cohorts, and are thus 
summarised as mean values and standard errors of the mean. The means of these 
measurements were compared between the discovery, replication and obesity 
cohorts using a one-way analysis of variance (ANOVA). This was followed by Tukey's 
Honest Significant Difference test if p < 0.05. The distribution of measurements of 
fasting glucose, C-reactive protein and triglyceride levels as well as calculated HOMA-
IR values were found to be skewed (Shapiro-Wilk test p<0.10), and are therefore 
summarised as median values and interquartile ranges. In these cases, the Kruskal-
Wallis test of ranks was used to compare median values between the cohorts. This 
was followed by Dunn's test of multiple comparisons using rank sums if p < 0.05. 
As presented in Table 5-1, phenotype characteristics between the discovery and 
replication cohorts did not differ significantly (at the 0.05 level) for any of the studied 
phenotypic traits apart from in fasting glucose levels, where there was a weak but 
significant difference such that the discovery cohort had, on average, slightly higher 
values of fasting glucose (p = 0.003). However, because insulin resistance as 
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measured by HOMA-IR did not differ significantly between the discovery and 
replication cohorts, it is unlikely that the small difference in fasting glucose 
measurements would indicate a substantial difference in metabolic health between 
the two cohorts. It was thus determined that the discovery and replication cohorts 
were sufficiently matched in terms of phenotypic characteristics.  
Chronological age is known to be associated with DNA methylation across several 
sites in the human genome (196). We therefore confirmed that there were no 
significant differences in age between the discovery, replication and obesity cohorts. 
There were, however, significant differences in BMI, waist circumference, fasting 
insulin levels, HOMA-IR and CRP between the discovery and obesity cohorts as well 
as between the replication and obesity cohorts (Table 5-1). The difference in BMI 
measurements is further detailed in Figure 5-2. In summary, there were substantial 
differences in metabolic profiles between the cohorts of lean, fertile males and the 




















Age (years). Mean (SD) 36.3 (5.2) 34.1 (4.6) 35.1 (4.1) 0.192    
BMI (kg/m2). Mean (SD) 23.4 (4.6) 22.3 (1.1) 29.1 (3.2) <0.001 0.060 <0.001 <0.001 
Waist circumference (cm). Mean (SD) 84.4 (4.8) 82.4 (6.4) 99.4 (8.7) <0.001 0.436 <0.001 <0.001 
SPB (mmHg), average of two 
measurements. Mean (SD) 
119 (11) 121 (10) 126 (9) 0.052    
DPB (mmHg), average of two 
measurements. Mean (SD) 
77 (8) 78 (6) 81 (8) 0.050    
Total cholesterol (mmol/L). Mean (SD) 4.7 (0.7) 4.9 (0.9) 4.9 (1) 0.614    
HDL cholesterol (mmol/L). Mean (SD) 1.6 (0.3) 1.5 (0.3) 1.4 (0.3) 0.060    
LDL cholesterol (mmol/L). Mean (SD) 2.7 (0.7) 2.9 (0.8) 2.9 (0.9) 0.330    
Fasting glucose (mmol/L). Median (IQR) 4.8 (0.5) 4.6 (0.4) 4.7 (0.6) 0.018 0.003 0.088 0.105 
Fasting insulin (mIU/L). Median (IQR) 5.3 (3.4) 5.1 (3.0) 8.9 (7.2) 0.002 0.309 <0.001 0.004 
HOMA-IR. Median (IQR) 1.2 (0.8) 1.1 (0.6) 1.9 (1.4) <0.001 0.285 <0.001 0.005 
HOMA2-IR. Median (IQR) 1.1 (0.5) 0.6 (0.4) 1.1 (0.9) 0.014 0.048 0.414 0.003 
CRP (mg/L). Median (IQR) 0.6 (0.3) 0.6 (0.1) 1 (1.8) <0.001 0.105 0.001 <0.001 
Triglycerides (mmol/L). Median (IQR) 0.9 (0.5) 0.9 (0.7) 1.2 (0.6) 0.282 0.335 0.056 0.157 




Table 5.1. Phenotype characteristics of participants included in the discovery, replication and 
obesity cohorts. Legend continued from previous page: 
Reference ranges are derived from the UCLH Clinical Biochemistry Test Information sheet available 
from (230). The reference range for HOMA-IR is derived from (231). SD = Standard Deviation, IQR = 
interquartile range, BMI = Body Mass Index, SBP = Systolic Blood Pressure, DBP = Diastolic Blood 
Pressure, HOMA-IR = Homeostatic Model Assessment of Insulin Resistance, CRP = C-Reactive 
Protein, HDL = High Density Lipoprotein, LDL = Low Density Lipoprotein. 
  
Figure 5-2. Comparison of BMI (kg/m2) between participants in the discovery, 
replication and obesity cohorts 
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5.4.8 Semen Sample Parameters of the Study Population 
Semen parameters, of participants in the discovery, replication and obesity cohorts 
are presented in Table 5-2. As shown, semen sample parameters did not differ 
significantly between participants in the three cohorts. 
 
Discovery Replication Obesity Reference Range p  
Volume (sperm, mL).  
Mean (SD) 2.9 (1.1) 2.9 (1.4) 2.6 (1.5) > 1.5 mL 0.538 
Concentration (sperm, 




Total count per 
ejaculate (millions). 
Mean (SD) 
161 (150.4) 149 (140.5) 157 (131.5) > 39 million 0.953 
Percentage A sperm. 
Mean (SD) 14.8 (10.6) 15.4 (10.6) 17.4 (10.3) N/A 0.610 
Percentage B sperm. 
Mean (SD) 23.9 (9.5) 22.1 (9.4) 20.4 (8.6) N/A 0.348 
Percentage C sperm. 
Mean (SD) 12.1 (3.7) 11.4 (3.7) 11.1 (4.3) N/A 0.589 
Percentage D sperm. 
Mean (SD) 49.3 (18.1) 50.5 (18.7) 51.1 (18.8) N/A 0.926 
Average motile speed. 
Mean (SD) 18.6 (2.6) 19.2 (4.4) 19.4 (2.3) N/A 0.603 
Table 5-2. Comparison of semen parameters between the discovery, replication and obesity 
cohorts 
Semen sample parameters were measured using the Computer-Assisted Sperm Analysis 
(CASA)/Sperminator software (Pro-Creative Diagnostics, Staffordshire, UK). V = volume, C = 
concentration, SD = Standard Deviation, WHO = World Health Organization. Percentage A-D sperm 
refer to the proportion of spermatozoa in different motility grades where A = most motile and D = 




5.4.9 Results from the Discovery Cohort Quality Control: Bisulfite Conversion 
Efficiency and Evaluation of Control Probes 
A quality control report from UCL Genomics, where the MethylationEPIC arrays were 
processed, reported high performance of the sample dependent and sample 
independent quality control probes discussed in Chapter 2 section 2.12. 
Sample dependent controls include bisulfite conversion control probes and probes 
that assess the specificity of probe extension, levels of background intensity and 
overall performance of the assay as discussed in Chapter 2 section 2.12. As visualised 




Figure 5-3. Bisulfite conversion efficiency for blood and sperm DNA 
samples included in the discovery cohort 
Conversion efficiences are based on data from the bisulfite conversion 
control probes included in the Illumina MethylationEPIC array. 
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5.4.10 Discovery Cohort Quality Control: Outlier Analysis 
An outlier analysis was performed using the outlyx() function in wateRmelon based 
on 1) the interquartile range of the first two principal components 2) the pcoout() 
algorithm detecting outliers in high dimensional datasets (369). Two blood samples 
in the discovery cohort showed substantial differences in DNA methylation when 
compared to the blood samples overall. Further investigation into the two particular 
samples, including analysis using the SNP genotyping probes described in section 
5.4.11, revealed that one had been mislabelled, and was reassigned as a sperm 
sample. Thus, only one participant (sperm and blood) from the original cohort of 48 
was removed from further downstream analyses. The outlier analysis following 
reassigning of the mislabelled sample is shown in Figure 5-4. 
 
Figure 5-4. Outlier analysis of blood and sperm samples in the discovery cohort. 
The sample that appeared as an outlier in two dimensions (as indicated by falling into the area with 
red, diagonal lines) was removed from further downstream analyses, along with the sperm sample 





5.4.11 Discovery Cohort Quality Control: SNP based clustering 
59 of the control probes included in the Illumina MethylationEPIC array are for direct 
interrogation of genotype. In this study, which included two matched samples from 
each individual, information from the genotype probes was used to confirm that the 
genotypes at these 59 probes are identical for the matched samples. As visualised in 
Figure 5-5, the clustering dendrogram clustered the samples into pairs and it was 
confirmed that the two samples from each individual were always clustered into the 
same pair. 
Figure 5-5. Heatmap showing correct clustering of matched samples according to the SNP 
genotyping control probes. 
Matched samples of sperm and blood collected from the same participant show identical genotypes 




5.4.12 Discovery Cohort Quality Control: Principal Component Analysis 
Principal component analysis identified that the main determinant of differences in 
DNA methylation in the samples included in the discovery cohort was their tissue of 
origin. This was expected due to the highly tissue-specific nature of DNA methylation 
signatures. As visualised in Figure 5-6, blood and semen samples formed two distinct 
clusters indicating large scale overall differences in DNA methylation. 
 
  
Figure 5-6. PCA plot of samples included in the discovery cohort 
As visualised, the tissue of origin accounts for the main variability in the data, which was 
expected due to the tissue-specific nature of DNA methylation signatures. PCA= Principal 
Component Analysis, PC1 = Principal Component 1, PC2 = Principal Component 2. 
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5.4.13 Discovery Cohort Data Preprocessing: Probe Filtering 
General considerations behind probe filtering is discussed in Chapter 2 section 2.12. 
Prior to probe filtering, a total number of 866,577 probes were included in the 
MethylationEPIC array analysis. In the case of the discovery cohort, 9779 probes were 
removed because more than 5% samples displayed a detection p value (probability 
that the total intensity for a given probe falls within the background signal intensity) 
higher than 0.05. 3337 probes were removed because of having a bead count of less 
than three. There were no samples for which more than 5% of CpG sites displayed a 
detection p value higher than 0.05. Following removal of the probes described above, 
a total of 853,461 probes were included in further analyses. 
The presence of single nucleotide polymorphisms (SNPs) in close proximity to 
interrogated CpG sites can lead to false assumptions about the association of 
methylation of a particular CpG site and the outcome variable. In addition, potentially 
cross-hybridising probes that bind non-specifically to the target regions of interest or 
that bind to repetitive regions of the genome should be filtered out. Stringent 
filtering of probes in close proximity (within 10 base pairs) of SNPs as well as 
potentially cross-reactive probes were filtered using three sets of annotated lists (87, 
370, 371). This led to the removal of a total of 149,105 CpG sites. Thus, following 
probe filtering based on p-values, SNPs in the probe sequences and cross-
hybridisation, a total of 704,356 CpG sites were included in further analyses. 
5.4.14 Discovery Cohort Data Preprocessing: Data Normalisation 
In order to remove technical and systematic variability and to make results 
comparable across samples, the DNA methylation data was normalised using the 
dasen method (see Chapter 2 section 2.12 for details). Dasen is a quantile 
normalisation algorithm which normalises type I and type II backgrounds separately 
in a first step and then quantile normalises methylated and unmethylated signal 
intensities. This normalisation also accounts for the different types of assay, the Type 
I and Type II assays (described in section 2.12) employed in the Illumina 
MethylationEPIC Array. An example of the density distribution of the red and green 
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colour channels before and after normalisation using the dasen method is provided 
in Figure 5-7. 
 
5.4.15 Discovery Cohort Data Preprocessing: Methylation Age Prediction 
The DNA Methylation Age prediction tool developed by Horvath et al uses DNA 
methylation data from analyses of close to 8,000 tissue samples to predict the age of 
study participants based on DNA methylation markers in their tissue samples (196). 
As visualised in Figure 5-8, the DNA Methylation Age tool accurately predicted the 
age of study participants when examining their blood samples (R = 0.74, p = <0.001), 
but failed to do so in the case of sperm samples (R = 0.26, p = 0.07). 
It should be said that Horvath specifically mentions that the tool inaccurately predicts 
age in the case of sperm, which is consistent with our findings (196). Therefore, in 
Figure 5-7. Example of pre- and post- dasen normalisation profiles of unmethylated probes from 
sperm and blood sample methylation data in the discovery cohort. 
The red and the green represent the two channels of differing wavelength used to scan the Illumina 
MethylationEPIC array BeadChips. The x axis depicts Log2 transformed b values of unmethylated 




subsequent age related analyses of sperm samples (section 5.9), the more recently 
developed DNA methylation clock developed by Jenkins et al and which was 




5.4.16 Summary of Quality Control and Data Preprocessing for the Discovery 
Cohort 
Quality control of DNA methylation data demonstrated a high bisulfite conversion 
efficiency and that the major explanation for variance between samples was their 
tissue of origin. One matched set of blood and sperm was removed from further 
analysis as it was an outlier. Stringent p value filtering and filtering for cross-reactive 
and SNP probes was applied to minimise misinterpretation of DNA methylation data 
Figure 5-8. Quality control of sperm and blood samples included in the discovery 
cohort using the DNA Methylation Age prediction tool. 
The x axis depicts the age of the participants included in the cohort and the y axis 
describes their predicted age based on the DNA Methylation Age prediction tool. 
There was a significant correlation between actual and predicted age of 
participants when analysing the blood samples (R = 0.74, p = <0.001), however this 




in downstream analyses. Use of the DNA Methylation Age prediction tool accurately 
predicted the age of participants in the case of blood samples, but not in the case of 
sperm samples. 
5.5 Data Preprocessing and Quality Control for the Replication and Obesity 
Cohorts 
Quality control and data preprocessing for the replication and obesity cohorts was 
performed in the same way as described in for the discovery cohort. The replication 
and obesity cohorts were analysed on the same DNA MethylationEPIC array such that 
the array contained 24 matched sets of blood and sperm from overweight/obese 
males and 24 matched sets of blood and sperm from lean males. They were therefore 
also analytically processed together. The samples were randomised on the array to 
minimise any potential effect of sample location on array processing and results. 
5.5.1 Replication and Obesity Cohorts Quality Control: Bisulfite Conversion 
Efficiency and Evaluation of Control Probes 
An initial quality control report from UCL Genomics, where the MethylationEPIC 
arrays were processed, reported high performance of the sample dependent and 
sample independent quality control probes (data not shown).  
The sample dependent controls (bisulfite conversion control probes and probes that 
assess the specificity of probe extension, levels of background intensity and overall 
performance of the assay also demonstrated good performance. Bisulfite conversion 
rates were high (≥85%). 
5.5.2 Replication and Obesity Cohorts Quality Control: Outlier Analysis 
An outlier analysis of samples included in the replication and obesity cohorts 





Figure 5-9.  Outlier analysis of blood and sperm samples included in the replication and obesity 
cohorts. 
 
5.5.3 Replication and Obesity Cohorts Quality Control: SNP based clustering 
SNP based clustering based on the 59 SNP probes included in the DNA Methylation 
EPIC array identified five problematic samples, three of which were samples where 
blood DNA matched semen of another study participant, and two of which were 
samples that did not match any other samples in the study. This suggested mix-ups 
in the collection or laboratory handling procedures and these samples were therefore 
removed from downstream analyses. The problematic samples were from two 
participants in the replication cohort and three participants in the obesity cohort. 
Thus, the replication and obesity cohort study populations were reduced to 21 and 
22 participants respectively. 
5.5.4 Replication and Obesity Cohorts Data Preprocessing: Probe Filtering 
In the case of the array on which the replication and obesity cohorts were processed, 
11,366 CpG sites were removed from downstream analysis due to having a bead 
count of less than three. 9,443 CpG sites were removed due to having a detection p-
value > 0.05. A further 148,400 CpG sites were removed due to being in close 
proximity (within 10 base pairs) of SNPs, or for being potentially cross-hybridising 
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probes (87, 370, 371). This left a total number of 697,442 CpG sites that were 
included in downstream analyses. 
5.5.5 Replication and Obesity Cohorts Data Preprocessing: Data Normalisation 
As for the discovery cohort, data was normalised using the dasen method. 
5.5.6 Replication and Obesity Cohorts Data Preprocessing: Methylation Age 
Prediction 
As was the case for the discovery cohort (section 5.4.15), the DNA Methylation Age 
prediction tool accurately predicted the chronological age of participants in the case 
of blood samples (R = 0.82 and p = 2.355 x 10-11), but not in the case of sperm samples 
(R = - 0.01 and p = 0.967) in both the replication and obesity cohorts (196). 
5.5.7 Summary of Quality Control and Data Preprocessing for the Replication 
and Obesity Cohorts 
Quality control of DNA methylation data generated by DNA MethylationEPIC array 
analysis of 24 matched samples of blood and sperm from lean males and 24 matched 
samples of blood and sperm from overweight/obese males demonstrated a high 
bisulfite conversion efficiency and that the major explanation for variance between 
samples was their tissue of origin. Five matched samples of blood and sperm were 
removed from further downstream analysis due to incorrect SNP-based clustering. 
Stringent p value filtering and filtering for cross-reactive and SNP probes was applied 
to minimise misinterpretation of DNA methylation data in downstream analyses. Use 
of the DNA Methylation Age prediction tool accurately predicted the age of 
participants in the case of blood samples, but not in the case of sperm samples. 
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5.6 DNA Methylation Analysis Results 
5.6.1 Accounting for cell type composition in blood samples 
Buffy coat derived from whole blood represents a heterogenous tissue containing 
numerous different types of leukocytes. This mixed cell type composition can induce 
confounding in epigenetic analyses if not accounted for. Thus, blood cell type 
coefficients of monocytes, granulocytes, NK-cells, B cells, CD8+-T-cells, and CD4+-T-
cells were estimated from the methylation data using the method described by 
Houseman et al (214) (Figure 5-10) 
Figure 5-10. Blood cell DNA methylation coefficients for blood samples included in the discovery 
cohort 
The black dots represent the average DNA methylation level at cell-type discriminating probes in 
the discovery cohort samples. The coloured dots represent the average DNA methylation levels in 
the reference sorted cells that were used to determine the prediction model 
CD4T = CD4 T-cell, CD8T = CD8 T-cell, Neu = Neutrophils, NK = Natural Killer cells. 
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5.6.2 General characterisation of sperm and blood methylomes 
Comparison of the array-wide distribution of CpG methylation in sperm versus blood 
revealed that sperm exhibits a highly polarised methylation profile towards the two 
extremes of DNA methylation levels (Figure 5-11). Thus, both low (<20%) and high 
(>80%) levels of methylation were more commonly seen in sperm than in blood, 
which displayed a tendency towards more intermediate levels of methylation (20-
80%). Overall, the sperm methylome was found to be slightly hypermethylated 
compared to blood (independent sample t-test on median DNA methylation values 
in blood and sperm, P = 0.016, mean difference in DNA methylation = 0.14%). Overall 
levels of methylation showed substantial differences between sperm and blood. 
603,519 probes were significantly differentially methylated between the two tissues 
(paired t-test, FDR < 0.05). At 349,951 (58%) of these significant sites, 
hypermethylation of sperm compared to blood was observed, while 252,242 (42%) 
showed lower methylation in sperm compared to blood. 
  
Figure 5-11. Genome-wide comparison of CpG methylation in sperm and blood for the discovery 
dataset 
Comparison of genome-wide CpG methylation between blood and sperm revealed that the sperm 
methylome is highly polarised, such that both low (<20%) and high (>80%) methylation levels are 
more common in sperm when compared to blood. 
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5.6.3 Proportion of DNA methylation variance explained 
The extent to which blood can be used as a proxy tissue for sperm DNA methylation 
was then addressed by assessing the proportion of DNA methylation variance in 
sperm that can be explained by the DNA methylation variance in blood. This 
relationship is presented in Figure 5-12. As shown, for the majority of CpG sites, 
interindividual methylation variation in blood explains only a small amount of the 
variation seen in spermatozoa.  
 
  
Figure 5-12. Variation in DNA methylation in blood as a predictor of DNA methylation 
variation in sperm 
Shown is the proportion of sites (y-axis) for which variation in blood explains a certain of 
percentage of DNA methylation variance (x-axis) in sperm 
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A linear regression model was used to calculate the proportion of variance in DNA 
methylation explained by tissue (sperm versus blood), individual and age. As shown 
in Figure 5-13, tissue was able to explain the largest proportion of variance in DNA 
methylation compared to age and individual. 
 
  
Figure 5-13. Proportion of DNA methylation variance in whole blood and sperm 




5.6.4 Characterisation of sperm and blood methylomes according to genomic 
regions 
A more detailed characterisation of the relative levels of CpG methylation across 
different genomic regions was then performed. In this, DNA methylation levels were 
assessed in CpG islands (500-1500 base pair long sequences with a an observed-to-
expected CpG ratio greater than 0.6), CpG island shores (regions with lower CpG 
density that lie within 2 kb up- and downstream of a CpG island), CpG shelves (regions 
located 2 kb outside of a CpG island shore) and CpG sites in open seas (CpGs not 
associated with an CpG island) (373). To compare DNA methylation levels between 
sperm and blood in these genomic regions, the mean methylation at each CpG site 
was calculated and a two sample t-test was used to compare the means between the 
tissues. In other words, the mean of the mean methylation level at all CpG sites 
assigned to CpG islands in sperm was compared to the mean of the mean methylation 
level at all CpG sites assigned to CpG islands in blood and so forth. 
As shown in Figure 5-14, there were clear differences in CpG methylation levels 
between blood and sperm in CpG islands, CpG island shores, CpG island shelves and 
CpG sites in open sea in blood and sperm (p < 2.2 * 10 -16 for all of these). In CpG 
islands, CpG methylation levels in blood were ~7% higher than in sperm (132,883 
probes assessed). In CpG island shores, CpG methylation levels in blood were ~16% 
higher than in sperm (128,079 probes assessed). In CpG island shelves, CpG 
methylation levels in blood were ~6% lower than in sperm (48,301 probes assessed). 
At CpG sites in open seas, CpG methylation levels in blood were ~7% lower than in 






A comparison of CpG methylation levels between blood and sperm in regions 200 
base pairs from transcription start sites (TSS200), regions 1500 base pairs from 
transcription start sites (TSS1500), 5’ untranslated regions (5’ UTR), gene bodies, 3’ 
untranslated regions (3’ UTR) and CpG sites that are not annotated to genomic 
regions is presented in Figure 5-15. In TSS200 and TSS1500 regions, the methylation 
levels in blood were significantly higher than those in sperm (p < 2.2 * 10 -16 for both). 
CpG methylation in TSS200 regions was ~2% higher in blood (54,041 probes assessed) 
and CpG methylation in TSS1500 regions was ~11% higher in blood (88,587 probes 
assessed). CpG methylation in 5’ UTRs was lower in blood by ~2% (p < 5.3 * 10-14; 
61,449 probes assessed). CpG methylation in gene bodies was also lower in blood by 
~2% (p < 2.2 * 10 -16; 290,256 probes assessed). CpG methylation in 3’ UTRs was not 
significantly different between blood and sperm (p = 0.830; 17,923 probes assessed). 
In CpG sites not annotated to genomic regions, CpG methylation was lower in blood 
by ~2% (p < 2.2 * 10 -16; 192,100 probes assessed).
Figure 5-14. Comparison of DNA methylation levels in CpG islands, CpG island shores, CpG 






Figure 5-15. Comparison of DNA methylation levels in blood and sperm in regions 200 base pairs 
from transcription start sites (TSS200), regions 1500 base pairs from transcription start sites 
(TSS1500), 5’ untranslated regions (5’ UTR), gene bodies, 3’ untranslated regions (3’ UTR) and CpG 
sites that are not annotated to genomic regions 
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5.7 Detailed Analysis of the Correlation of DNA Methylation between Blood 
and Sperm 
The correlation of DNA methylation between blood and sperm was first explored by 
comparing the observed distribution of correlation coefficients against a simulated 
null distribution. In this, samples were randomly permuted and correlations between 
DNA methylation in whole blood and sperm were recalculated. Had there been no 
methylation correlation between the two tissues, the observed distribution of 
correlation coefficients would align to the null distribution. As presented in Figure 
5-16, the observed distribution of correlation coefficients closely matched that of the 
null distribution. However, the histogram was shifted slightly to the right, i.e. there 
was a slightly higher correlation between the tissues than what would have been 
expected if the tissues were entirely uncorrelated. 
Interestingly, there was also a small number of specific CpG sites that appeared to 
display a high correlation of DNA methylation levels between the two tissues (circled 
in green in Figure 5-16). The number of CpG sites where the DNA methylation level 
was significantly correlated between sperm and blood was calculated using the 
empirically derived significance threshold for MethylationEPIC array analyses of 9 * 
10−8 (366). Using this threshold, a total of 5,307 CpG sites (i.e. approximately 0.8% of 
the 704,356 informative sites in the discovery cohort) were found to have 
significantly correlated methylation levels between the tissues. This number was 
similar to if a Bonferroni adjusted significance had been used (5,272 sites) but slightly 
lower than if an FDR adjusted significance threshold had been used (7,856 sites). 
Of these 5,307 significantly correlated CpG sites, 5,271 were also represented in the 
replication/obesity quality controlled dataset. The 5,307 sites were taken forward for 
further characterisation, partly because these could potentially be sites were using 




Figure 5-16. Histogram showing the distribution of correlation coefficients between 
DNA methylation in whole blood and sperm (discovery dataset only) 
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5.7.1 Characterisation of CpG sites with apparently high methylation correlation 
between sperm and blood 
The 5,307 CpG sites that appeared to display a high level of methylation correlation 
between the two tissues were characterised first by visually inspecting the 
distribution of DNA methylation levels. From doing so, it appeared that although 
stringent SNP filtering criteria had been applied (section 5.4.13), methylation levels 
in a large proportion of these CpG sites appeared to be genetically driven. This was 
suggested from the way the majority of these CpG sites displayed bimodal and 
trimodal patterns of methylation, as exemplified in Figure 5-17. 
 
 
The presence of SNPs in the CpG site and probe sequence is a recognised 
complication in interpreting DNA methylation data. To further explore this issue in 
the analysis of the 5,307 sites that appeared to display a high methylation correlation 
between blood and sperm, two approaches were applied. First, an algorithm was 
devised such that CpG sites where methylation levels formed two or three distinct 
clusters (bimodal/ trimodal distribution patterns) were identified. In this, a two 
Figure 5-17. Examples of bimodal and trimodal DNA methylation distributions when comparing 
blood and sperm 
a) cg24596064, which displayed a bimodal pattern of methylation level distributions 
b) cg14499602, which displayed a trimodal pattern of methylation level distributions 
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dimensional outlier test was used by adapting the rosnerTest() function in R to 
exclude unimodal distributions. Next, k means clustering was applied for 2 and 3 
clusters as implemented in the function pamk() of the R package cluster. This function 
determines the best fitting number of clusters (two or three – corresponding to bi- 
and tri-modal methylation distributions). The clustering algorithm identified 5052 
with a bimodal pattern of methylation, and 255 sites that displayed a trimodal 
pattern of methylation distribution, i.e. there were no CpG sites with a unimodal 
methylation distribution. Second, the CpG sites that correlated between tissues were 
cross-checked for SNPs in the CpG site using the dbSNP Human Build 151 database 
(374). Only 11 out of the 5,307 significantly correlated sites were found to have no 
known SNPs anywhere in the probe sequence. Of these, 10 were represented among 
the quality controlled probes in the obesity/replication cohorts.  
The CpG sites where two clusters were identified by the clustering algorithm were 
explored further by assessing the number of individuals in the smallest cluster. In 
3078 out of the 5052 sites (~61%) with two clusters, the smallest cluster consisted of 
only one individual outlier. This was also the case when examining CpG sites that 
displayed a trimodal distribution of DNA methylation levels. Such findings are 
consistent with these individual outliers having a rare or low frequency genetic 





It was then investigated whether the same or only a small number of individuals were 
overrepresented in the clusters that consisted of only one or a couple of individuals. 
This analysis also included data on the self-reported ethnicity of participants, as a 
probable cause for genetic variation would be different ethnic background. However, 
as shown in Figure 5-18, although a couple of individuals had either no instances of 
being the sole outlier in a bi- or trimodal pattern of methylation distribution and a 
couple of individuals were very frequently outliers, it was more commonly the case 
that different individuals were outliers at different CpG sites. Further, there was no 
correlation between the frequency of private clusters and the individual’s reported 
ethnicity (data not shown). 
 
  
Figure 5-18. Analysis of whether some individuals were overrepresented in private clusters 
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In summary, it seemed that for the vast majority of CpG sites that originally appeared 
to exhibit DNA methylation co-variation between sperm and blood, the correlation 
was likely driven by the underlying genotype. Examples of methylation data for the 
10 CpG sites where no known SNP in the CpG site was able to explain the high DNA 
methylation correlation between the tissues (in the discovery and replication/obesity 
cohorts) are presented in Figure 5-19. For some of these sites, such as cg21625068 in 
Figure 5-19 a), there did indeed appear to be a true correlation between sperm and 
blood DNA methylation levels in a non-genetic manner. For other sites, however, 
such as cg23350716 in Figure 5-19 b), the methylation levels seemed to still cluster 
in a pattern consistent with underlying genetic effects. It is possible that this effect 
could have been caused by SNPs in the probe sequence not present on the 
comprehensive dbSNP Human Build 151 database, or represent a true strong 
biological effect of a SNP not in the probe sequence at the CpG site of interest (374). 
Figure 5-19. Examples of CpG sites where the methylation correlation between sperm and blood 
could not be explained by known SNPs in the CpG site. 
These scatter plots depict all samples included in the study, i.e. from the discovery, replication and 
obesity cohorts. ‘Batch’ refers to whether the samples were from the discovery cohort (‘Batch 1’) or 
the replication and obesity cohorts (‘Batch 2’). Whether the participant was lean or obese is 





5.7.2 Sites characterised by a negative DNA methylation correlation between 
sperm and blood 
A subset of CpG sites among the 5,307 that were significantly correlated in the 
discovery cohort (n = 44 at the empirically derived threshold for MethylationEPIC 
arrays of 9 * 10-8, 42 of which were included in the quality controlled 
replication/obesity dataset) displayed negative correlation between sperm and 
blood. In other words, for these sites, the higher the DNA methylation levels were in 
blood, the lower the methylation levels were in sperm. Shown in Figure 5-20 are two 
examples of such negative DNA methylation correlation; cg05480191 (Figure 5-20 a) 
and cg01812571 (Figure 5-20 b).  





5.7.3 Correlated sites characterised by highly discordant methylation between 
sperm and blood 
A high proportion of CpG sites among the 5,307 in the discovery cohort that were 
significantly correlated showed both significant correlation and significant 
differences between blood and sperm DNA methylation (n = 3,348). This was 
calculated using a paired t-test for mean methylation at the 5,307 probes. Two 
examples of such sites are provided in Figure 5-21.  
In the case of cg07533224 (Figure 5-21 a)), the DNA methylation level  in sperm is 
consistently low (<15%) for all participants, whereas the methylation level in blood 
appears to follow a trimodal distribution pattern with methylation levels ranging 
from approximately 5% to approximately 85%. It is possible that tissue specific 
transcription factors (TFs) are responsible for repressing particular genomic regions 
via DNA methylation according to tissue specific gene expression requirements. 
Indeed, it is well established that TFs can influence the establishment and 
maintenance of DNA methylation at particular genomic regions (375). 
Figure 5-21. Examples of correlated CpG sites that displayed highly discordant DNA methylation 
between sperm and blood 
a) cg07533224, where the methylation level in sperm is consistently low, but the methylation level in 
blood appears to follow a trimodal distribution pattern 
b) cg00456343, where the methylation level in sperm is consistently low, but the methylation level in 
blood appears to follow a bimodal distribution pattern 
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5.8 Comparison of results with the obesity cohort 
To make use of the full collection of samples and explore the relationship between 
obesity, genetics and DNA methylation we analysed two further models. These were 
run on 692,265 probes that remained after filtering in both datasets (discovery and 
replication/obesity). 
First, a mixed effects model was run regressing DNA methylation onto tissue (blood 
versus sperm), age, batch and obesity status, while controlling for interindividual 
variation with a random effect: 
fit <- lmer(Meth ~ Tissue + Age + Batch + Obesity +(1|ID), data=pheno, REML=F) 
As in the discovery cohort, at a large proportion of sites, DNA methylation was 
associated with tissue type.  Using the empirically derived threshold of 9 * 10-8, 
444,785 out of the 692,265 probes (64%) showed significant DNA methylation 
differences between the blood and sperm. In 274,854 (62%) of these, DNA 
methylation in sperm was higher than that in blood. 
This model identified that methylation at one CpG site, cg19357369, was significantly 
associated with obesity status in sperm and blood (p = 8.95 * 10-8) (Figure 5-22). The 
effect size was 1.4%, i.e. the average DNA methylation difference between lean and 





Secondly, an interaction model was used to determine whether obesity altered the 
nature of blood and sperm DNA methylation covariation.  This model regressed DNA 
methylation in blood onto DNA methylation in sperm, obesity and their interaction 
effect, while covarying for experimental batch and age: 
fit <- lm(MethBlood ~ Methsperm * Obesity + Age + Batch) 
This statistical model identified 691 CpG sites where obesity was significantly 
associated with blood DNA methylation and 7668 CpG sites where sperm DNA 
methylation had a significant effect of blood DNA methylation (p < 9 * 10-8). Further, 
there was a significant interaction effect at 686 CpG sites where obesity impacted on 
the correlation between sperm and blood DNA methylation. 
However, there was considerable overlap between the CpG sites identified in this 
model and those previously identified as significantly correlated between sperm and 
blood in previous analyses in either the discovery or replication/obesity dataset. 
Thus, 600 out of 691 CpG sites (87%) where obesity was significantly associated with 
blood DNA methylation were the same as those previously identified as significantly 
Figure 5-22. Boxplot showing methylation levels in control participants (discovery 
and replication cohorts combined) compared to obese participants at cg19357369 
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correlated between sperm and blood (section 5.7). 6,675 out of the 7,668 CpG sites 
(87%) where sperm DNA methylation had a significant effect of blood DNA 
methylation were the same as previously identified as correlated. In the case of the 
686 CpG sites where obesity significantly impacted on the correlation between sperm 
and blood DNA methylation, 596 (87%) were the same as those already identified as 
correlated. As the clustering algorithm together with the dbSNP data strongly 
suggested that these correlation effects were mostly driven by genetic variation, this 
also suggests that the results from the interaction model also are driven by genetic 
variation. 
There was also considerable overlap of sites between the categories of sites 
identified in the interaction model. Indeed, after removing sites that had previously 
been identified as significantly correlated between the tissues and those represented 
in the other categories, there were only 6 sites where obesity significantly impacted 
on the correlation between sperm and blood DNA methylation. In all of these cases, 
the effect again seemed to be caused by one or a small number of outliers in a 
manner suggestive of a genetic effect (exemplified in Figure 5-23). 
Figure 5-23. Examples of CpG sites where obesity significantly impacted on the correlation 
between sperm and blood, and which had not been previously identified as correlated between 





Similar methylation distributions were observed for the vast majority of CpG sites 
identified as by the interaction model, i.e. that results were highly suggestive of 
genetic effects. In conclusion, therefore, there was no convincing evidence that 
obesity influenced the correlation between sperm and blood.  
5.9 Comparison of the sperm methylome to tissues in the Gene Expression 
Omnibus (GEO) database 
The GEO database (Chapter 2 section 2.12.7) was used to identify CpG sites that 
significantly differ between sperm and a range of human somatic tissues (210). The 
DNA methylation data was processed using the bigmelon R package and statistical 
tests were performed using limma (211, 376). 
The following criteria were used to select tissue samples on GEO: 
• HM450K data available (or Illumina MethylationEPIC data, in which case only 
the CpG sites represented on the HM450 were included in the model) 
• Samples from males only 
HM450K methylation data from 281 sperm samples (from five different accessions) 
was available on GEO. Together with data from the 90 MethylationEPIC samples that 
passed quality control in the discovery, replication and obesity cohorts, this 
generated a total sample size of 371 sperm samples. The age of participants was only 
detailed for six out of the 281 sperm samples available on GEO. Therefore, as the 
more widely used model by Horvath et al did not provide accurate age estimates for 
sperm samples (section 5.4.15), a recently developed model by Jenkins et al was used 
to impute the age of participants from the other 275 samples (196, 372). This model 
was specifically designed to predict chronological age from genome-wide sperm DNA 
methylation data. For the sperm samples where age data was actually available (6 
from GEO and 90 from the MethylationEPIC dataset), the model accurately reflected 





DNA methylation data from 5,917 somatic tissue samples which met the above 
criteria on GEO and were included in the analysis. These are detailed in Table 5-3. 
Type of tissue N Type of Tissue N 
Adipose 42 Mesenchymal stem cells 9 
Amniotic membrane 3 Mesenchymal stromal cells 8 
Blood 2,317 Mucosa 95 
Brain 978 Muscle 17 
Buccal 214 Neuroendocrine tumour 3 
Cardiac tissue 11 Neuron 71 
Cartilage 60 Neutrophils 69 
Chorion 3 Pancreas 112 
Chorionic Villi 68 Pituitary adenoma 21 
Colon 170 Rectum 13 
Cornea 8 Saliva 146 
Epithelial 183 Skin 38 
Fibroblast 54 Squamous cell carcinoma 7 
Glioblastoma 36 T Cells 306 
Intestines 1 Thymoma 11 
Kidney 45 Thymus 1 
Liver 90 Umbilical cord 6 
Lung 103 Unsorted Cell Line 9 
Lung adenocarcinoma 12 Unsorted Tissues 379 
Lymph node 24 Unsorted Tumours 174 
Table 5-3. Types of somatic tissue samples included in the GEO analysis 
Figure 5-24. Comparison between the DNA methylation age predicted 
by the sperm-specific DNA methylation age tool developed by Jenkins 
et al compared to the age of participants where this data was available 
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5.9.1 Identification of significant CpG sites 
A linear regression model was used to identify sperm-specific DNA methylation 
signals on the 6,288 samples (371 of which were sperm). The linear models were 
performed on 452,626 CpGs using the lmFit function from the limma R package and 
included age and array type as covariates. The data was not normalised because 
global large-scale differences between somatic tissues and sperm were expected, 
and because of the high number of different types of samples included. 
With Bonferroni correction, a total of 156,654 genome-wide significant CpG sites 
were identified as differentially methylated between sperm and somatic tissues 
(Figure 5-25).
Figure 5-25. Manhattan plot of CpG sites that are differentially methylated between sperm and 
somatic tissues on GEO 
The red line represents a Bonferroni adjusted significance level and the blue line represents an FDR 




5.9.2 Gene Ontology pathway analysis 
The 156,654 genome-wide significant CpG sites were annotated using the Gene 
Ontology (GO) database and enrichments for specific biological pathways were 
calculated (205). Enriched gene ontology terms from the Bonferroni significant CpGs 
were identified separately for both hypermethylated and hypomethylated CpGs 
using the gometh function from the missMethyl R package (207). No GO terms were 
found to be significantly enriched for hypomethylated CpG sites. However, six GO 
terms were identified as significantly enriched amongst hypermethylated CpG sites. 
These six terms are detailed in Table 5-4.  
GO ID GO TERM N DE P.DE 
GO:0000981 DNA-binding transcription factor activity, RNA 
polymerase II-specific 
1537 835.2 3.72E-14 
GO:0045944 Positive regulation of transcription by RNA 
polymerase II 
975 559 1.88E-11 
GO:0001228 DNA-binding transcription activator activity, RNA 
polymerase II-specific 
390 247.3 1.38E-09 
GO:0000978 RNA polymerase II proximal promoter sequence-
specific DNA binding 
379 233 1.82E-07 
GO:0003700 DNA-binding transcription factor activity 480 278.8 4.30E-06 
GO:0008134 Transcription factor binding 264 164.5 1.38E-05 
Table 5-4. Gene ontology terms that were significantly enriched for hypermethylated CpG sites 
when comparing sperm to somatic tissues 
GO = Gene Ontology, N = number of genes in the GO term, DE = number of genes that were 
differentially methylated, P.DE = p-value for over-representation of the GO term 
As seen in Table 5-4, the GO terms that were significantly enriched for 
hypermethylated CpG sites all related to transcriptional regulation, either through TF 
binding or RNA polymerase activity. In very general terms, DNA hypermethylation, 
especially of gene promoters, is associated with transcriptional repression (266). 
Spermatozoa represent highly specialised cells with the main function of delivering 
genetic material to the oocyte. They have previously been shown to contain a low 
number of RNA transcripts compared to somatic cells (265). The significant 
hypermethylation enriched GO terms supports this observation; that spermatozoal 





To my knowledge, this study constitutes the largest genome-wide investigation of 
CpG methylation in matched sperm and blood samples performed to date. It also 
constitutes one of the largest genome-wide investigations of sperm from healthy, 
fertile males. 
The main conclusion is that the DNA methylation profiles of sperm and blood are 
clearly distinct, with highly significant mean differences of methylation levels at 
multiple sites across the genome. Indeed, factors such as age and interindividual 
variation make a much smaller contribution to overall variation in DNA methylation 
than do differences between the two blood and sperm. 
A small subset of CpG sites that displayed a high DNA methylation co-variation 
between the two tissues. However, closer analysis showed that methylation at these 
sites was most likely influenced by underlying genetic variation. Most of the 
identified genetic variants were directly in the CpG site itself, confounding the DNA 
methylation measurements. Beyond that, even genetic variants in the probe 
sequence are known to affect binding properties and therefore induce technical 
artefacts in DNA methylation quantification. The small number of sites (10 out of 
~700,000) where no obvious genetic driver of methylation variability was identified 
are likely too few to be of value in studies where blood is needed as a surrogate tissue 
for sperm. These findings demonstrate that the use of blood DNA methylation as a 
proxy for sperm DNA methylation is inappropriate. 
The results of this study are in line with similar studies of epigenetic co-variation. For 
example, whole blood has been found to be an inappropriate proxy tissue for 
understanding DNA methylation in several brain regions (368). It should be said, 
however, that the results of this study do not preclude the use of blood for, for 
example, identifying CpG biomarkers for conditions such as subfertility or other 
reproductive conditions. For example, if a robust and reproducible blood DNA 
methylation profile of subfertility is identified in blood, this could be a helpful test in 
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fertility evaluations without it necessarily reflecting the epigenetic profile of 
spermatozoa. 
This study identified one CpG site, cg19357369, as differentially methylated in sperm 
and blood from obese versus lean males. This finding should be interpreted with 
caution as it requires replication. Interestingly, however, this CpG site has, to my 
knowledge, not been identified in EWASs of obesity/BMI when only blood samples 
have been analysed. Therefore, it could point towards the possibility of an obesity 
associated signature of spermatozoa. Of note, cg19357369 has previously been 
identified as differentially methylated in hepatic tissue from obese compared to lean 
males (377). Another study found that methylation at cg19357369 is significantly 
altered during human fetal brain development (378). This study analysed genome-
wide CpG methylation in fetal brain samples from day 23 to 184 post-conception, and 
found that methylation at cg19357369 peaked in fetal brains around day 70 post-
conception (378). cg19357369 is found in the north shore of the gene for a large 
intergenic non-coding RNA (lincRNA) called RP11-503N18 (377). To my knowledge, 
this lincRNA has yet to be characterised in terms of biological function. 
The wider coverage of the MethylationEPIC array compared to its predecessor, the 
HM450, allowed the present study to refute some earlier general characterisations 
of the sperm epigenome. For example, previous analyses have suggested that the 
sperm epigenome is overall hypomethylated compared to somatic tissues (168, 343). 
My results show that the sperm epigenome is overall slightly hypermethylated 
compared to peripheral blood. Previous findings regarding overall hypomethylation 
in sperm may have arisen from the bias towards assessing promoter methylation in 
the HM450. In line with this, the present study showed that CpG islands in 
spermatozoa are significantly hypomethylated compared to CpG islands in blood. 
Among previous analyses of the human sperm methylome, not only studies using the 
HM450 have suggested that the human sperm methylome is relatively 
hypomethylated compared to somatic tissues such as components of blood (330). 
For example, Rakyan et al employed a combination of methylated DNA 
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immunoprecipitation (MeDIP) and a custom high-density microarray to profile 13 
normal somatic tissues as well and sperm and placenta, finding that sperm was 
characterised by overall hypomethylation relative to somatic tissues (including B-
cells, CD4+ T cells, CD8+ T cells, colon, liver and uterine tissue) (330). Again, the 
results study are likely to reflect the methodology used; the custom oligonucleotide 
array was heavily biased towards interrogating CpG sites in CpG islands, and, 
consistent with our findings, such regions are characterised by relative 
hypomethylation in spermatozoa (330).  
Further, in the context of genomic regions characterised by hypomethylation in 
spermatozoa relative to somatic tissues, we identified that CpG island shores were 
hypomethylated in spermatozoa compared to the equivalent regions in components 
of blood. This finding is in line with a previous study that used whole genome shotgun 
bisulfite sequencing and identified that spermatozoa exhibits relative 
hypomethylation in regions adjacent to CpG islands compared to, for example, 
human embryonic stem cells (379). 
It should be said, however, that despite the relatively wider coverage of the 
MethylationEPIC array compared to its predecessor, the MethylationEPIC array is still 
biased towards certain parts of the genome (most notably enhancer regions, RefSeq 
genes and CpG islands) and does not give an complete picture of genome-wide CpG 
methylation (199). It will only be with analysis whole genome methylation that 
conclusive statements can be made regarding whether one tissue exhibits overall 
hyper- or hypomethylation in relation to another.  
The comparative analysis between DNA methylation in sperm and DNA methylation 
of >6,000 somatic tissue samples on the Gene Expression Omnibus (GEO) database 
supported previous studies showing that spermatozoal gene expression is 
characterised by overall transcriptional repression (265). This is to be expected in a 




In the publication of the widely used DNA methylation age tool developed by Steve 
Horvath, the author specifically mentions that the tool does not provide an accurate 
estimated chronological age for sperm, which was consistent with our findings (196). 
This can most likely be explained by the fact that the tool was constructed using data 
from only 45 samples of semen in a total of 7,844 samples (0.6%) of different tissue 
types, whereas it used data from 4,180 blood-derived samples (53%) (Additional file 
1 from (196)). The model specifically developed by Jenkins et al to predict 
chronological age from genome-wide sperm DNA methylation data more accurately 
reflected the chronological age of participants where age data was available (372).  
DNA methylation age tools, such as the one developed by Horvath, have been shown 
to not only be able to accurately predict chronological age from CpG methylation of 
DNA samples from various tissues, but also (to an extent) predict the biological age 
of the tissue (196, 380, 381). In this context, the ‘biological age’ refers to changes 
associated with the functional decline of a tissue that naturally occurs with aging, but 
which can occur more rapidly in, for example, disease states. The biological age is 
thus different from the chronological age, which is wholly determined by the time 
elapsed since an individual’s birth. In future studies, it would be interesting to see 
whether there are reliable associations between phenotypic traits, such as disease 
states, and accelerated rate of biological aging in spermatozoa.  
5.10.1 Strengths and Limitations 
Strengths of this study include the matching of sperm and blood samples, the use of 
the most comprehensive DNA methylation array available to date, and the inclusion 
of healthy, fertile males rather than individuals recruited in a reproductive medicine 
setting. The latter allowed me to comprehensively characterise the human sperm 
methylome in a manner that is likely to be generalisable to a large proportion of the 
male population. In terms of the GEO analysis, strengths included using the bigmelon 
analysis pipeline that allowed the inclusion of a large number (>6,000) of somatic 
tissue samples and thus greatly added power. Also, whilst the main part of this study 
focussed on comparing the DNA methylomes of sperm and blood specifically, those 
results could reflect leukocyte specific gene expression requirements, i.e. be less 
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valuable when trying to elucidate sperm-specific gene expression requirements. 
Thus, the addition of the GEO analysis improved the ability to identify sperm specific 
biological processes. 
This study also has a number of limitations. Whilst having a large sample size 
compared to previous analyses of gamete epigenomes, the sample size is limited 
compared to EWASs of, for example, peripheral blood (106). In particular, the obesity 
cohort (n = 24) was likely too small to detect modest differences in sperm-blood 
methylation covariation between lean and obese males. The obesity cohort also 
included some participants that were overweight (BMI 25-30 kg/m2) rather than 
obese (BMI >30 kg/m2). This potentially contributed to the lack of significant findings. 
We were able to speculate as to the effects of genetic variants in CpG sites influencing 
our results, given trimodal methylation patterns and the presence of known SNPs in 
the CpG site. However, we did not have the actual genetic sequence of our subjects 
to verify this directly. It is likely however, that for the majority of CpG sites exhibiting 
significant correlation between blood and sperm methylation, genetic variation is the 
driver. In this regard, it is surprising that several thousand variants seem to have 
escaped previously compiled lists of genetic variants in probe sequences of 450K or 
EPIC arrays (87, 370, 371). While genetic variation in DNA methylation probes 
represents a known challenge in the interpretation of methylation array data, it 
nevertheless added a layer of difficulty in the identification of sites with a high 
methylation co-variation. In the case of the GEO analysis, limitations include the lack 
of normalisation of the datasets included in the analysis and that cross-hybridising 
and probes with high detection p-values were not filtered out. 
5.10.2 Future Directions 
In line with previous research, the present study demonstrated that the human 
sperm methylome is highly polarised towards high and low levels of methylation 
compared to blood (168). In future research, it would be interesting to functionally 
explore genomic regions that display high versus low levels of methylation in sperm 
compared to somatic tissues, e.g. by expression profiling. 
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This study also identified CpG sites where DNA methylation levels were significantly 
correlated, but at the same time displayed highly discordant DNA methylation levels 
between the two tissues. These included sites where, for example, the DNA 
methylation level in sperm was low and similar across individuals, but displayed a 
trimodal distribution pattern in blood. It is possible that tissue specific transcription 
factors underlie such differences. In this regard, it is interesting to consider that all of 
the GO terms that were significantly enriched for hypermethylated CpG sites in 
sperm compared to somatic tissues related to transcriptional regulation, mostly via 
TF binding. Better characterisation of sperm-specific transcriptional regulation and 
CpG sites that show highly discordant methylation levels between sperm and somatic 
tissues would yield insights into which biological processes are important for germ 
cell development and function. This, in turn, could aid the understanding of fertility, 
embryogenesis and the potential for germ cells to respond to environmental and 
physiological change. 
Future investigations should avoid using blood as a proxy tissue for analyses of sperm 
DNA methylation. They should also better characterise the methylation ‘escape 
variants’, i.e. CpG sites that appear to escape the global DNA demethylation that 
occur shortly following fertilisation and during gamete development (128). Such 
research would be more likely to yield informative insights into the potential for 
acquired traits to influence the next generation than would additional studies of 
surrogate tissues such as blood. 
In the context of escape variants, these appear to be particularly enriched for in 
repeat elements of the genomes, including retrotransposons (128). Further, there 
appears to be a correlation between how evolutionarily young a particular 
retrotransposon is, and its propensity for resisting demethylation (128). For example, 
a considerable fraction of loci within SINE-variable number of tandem repeats-Alu 
elements (SVAs), which are relatively evolutionarily young and active, appear to resist 
the demethylation process that other retrotransposons undergo in during, typically, 
weeks 5.5-9 of human primordial germ cell development (128). The authors suggest 
that, together with other methods of regulation of gene expression, e.g. by 
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transcription factor binding, this resistance to demethylation in evolutionarily young 
retrotransposons may limit potentially hazardous retrotranspositions of SVAs in the 
germline (128). 
This study identified a number of specific CpG sites that would be interesting to take 
forward for further investigation. For example, 42 CpG sites were identified where 
there was a significant negative correlation between DNA methylation in blood and 
DNA methylation in sperm (section 5.7.2). Such sites have previously been 
characterised when comparing genome wide CpG methylation in blood with that of 
different brain regions (368). To our knowledge, however, this is the first study to 
identify such sites when examining blood and sperm, and it is fascinating to 
hypothesise about the potential underlying mechanism. For example, could there be 
an environmental or physiological trait that influences both sperm and blood DNA 
methylation but in opposite directions? 
5.11 Summary 
In this study I investigated genome-wide CpG methylation in 92 matched sperm and 
blood samples using the Illumina MethylationEPIC array. DNA methylation profiles of 
the two tissues were found to be highly discordant, with few CpG sites confidently 
demonstrating a methylation correlation between the tissues. Results from this study 
confirm the importance of using disease relevant tissues in epigenomic investigations 
and question the validity of previous analyses where blood has been used as a proxy 
tissue for sperm DNA methylation. 
This study also identified a number of particular CpG sites that would be interesting 
to take forward in future investigations. These include CpG sites that display 
negatively correlated DNA methylation between sperm and blood, and CpG sites 
that, despite being significantly correlated, show near complete methylation in one 
of the tissues but are near complete lack of methylation in the other. The study 
identified one CpG site, cg19357369, as differentially methylated sperm and blood 
from obese versus lean males. This CpG site has not previously been identified in 
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EWASs of obesity performed on blood only, and would be interesting to further 
characterise. 
A comparison of DNA methylation in sperm to that of a wide range of somatic tissues 
suggested that there is an overall tendency towards transcriptional repression in 
spermatozoa. 
Characterisation of the human sperm epigenome has important implications for 
understanding fertility, embryogenesis and the potential for germ cells to respond to 
environmental and physiological change. The findings presented in this study 





Chapter 6  
Obesity Associated DNA 





Obesity and its related metabolic syndrome constitute major public health problems 
globally (13). In 2016, 39% of all adults globally, more than 1.9 billion people, were 
overweight (BMI >25 kg/m2), of whom one-third were obese (BMI >30 kg/m2) (2). 
Once obesity is acquired, the probability of achieving and maintaining a normal body 
weight is low (17). Despite decades of rising awareness of the morbidity, mortality 
and financial implications of the obesity epidemic, no country has successfully 
sustained a reversal of current trends (16). 
Obesity and overweight most commonly arise as a result of excessive calorie intake 
and a sedentary lifestyle (2). However, obesity is a multifactorial condition that 
involves a complex interplay of genetic, gene-environment, environmental and 
behavioural factors. Although some genetic variants are robustly associated with the 
development of obesity, these can only explain a minority of cases (29). Further, the 
rising prevalence of obesity has been too rapid to be explained by genetic factors 
alone (382). Therefore, a major research focus has been to conduct increasingly large 
epigenome wide association studies (EWASs) of obesity (discussed in detail in section 
1.8.1). However, despite relatively large sample sizes, few of the CpG sites identified 
in these EWASs have been replicated across studies. There is therefore value in 
validating the previously identified CpG sites to assess whether they are replicable 
across cohorts. 
The identification of a robust, reproducible DNA methylation profile associated with 
obesity would improve our understanding of the pathogenesis of the metabolic 
syndrome, identify biomarkers for disease progression, and therapeutic targets.  
In the present study I validated a set of 192 previously identified obesity associated 
CpG sites in a novel cohort of 96 obese men (BMI > 30 kg/m2) compared with 96 lean 
men (BMI 18-25 kg/m2). This study forms the first stage of a larger project that aims 
to generate a robust, reproducible obesity-associated DNA methylation profile using 
peripheral blood from a total of 1000 lean and 1000 obese males (MRC reference 
code MR/P011799/1; title ‘Paternal obesity-associated DNA methylation: an 
  
 271 
investigation into its reproducibility, reversibility and association with fetal growth 
restriction’). 
6.1.1 Declarations 
Peripheral blood samples were collected as part of the Dad’s Health Study by myself 
and Anna Greco, research midwife, at UCLH. Peripheral blood samples from the Iowa 
cohort were collected by Dr Donna Santillan at the Women’s Health Tissue 
Repository, University of Iowa Health Care. DNA extraction from the Dad’s Health and 
Iowa cohort blood samples was performed by myself and Anna Greco. CpG sites from 
previous obesity EWASs were identified by Dr Sarah Marzi at Queen Mary University 
London (QMUL), who also designed the primers for the multiplex bisulfite PCR 
sequencing microfluidics-based assay. Primers were tested for efficacy by Adrian 
Signell and Dr Michelle Holland at Kings College London. Bisulfite conversion of blood 
samples was performed by Theodoros Xenakis at QMUL. The multiplex bisulfite-PCR-
sequencing microfluidics-based assay, library preparation and subsequent Next 
Generation Sequencing (NGS) was performed at the Genome Centre Facility at 
QMUL. DNA methylation data preprocessing and analysis was performed by Dr Sarah 
Marzi at the Blizard Institute, QMUL. 
6.2 Hypothesis 
Differential DNA methylation of CpG sites associated with obesity from previous 
EWASs can be replicated in a new cohort of obese men. 
6.3 Specific Objectives 
1. To identify which CpG sites previously identified as associated with obesity in 
EWASs are significantly associated with obesity in a novel cohort of 96 lean 




6.4.1 Study design and population 
Ethical approval was granted from the South East Coast - Surrey Research Ethics 
Committee on 28 September 2015 (REC reference number 15/LO/1437, IRAS project 
ID 164459). The study was also registered with the UCLH Joint Research Office 
(Project ID 15/0548). All participants provided written, informed consent. Ethical 
permission for the transfer of peripheral blood samples collected in Iowa was 
provided via a materials transfer agreement (MTA-17-252). 
CpG sites were identified from six EWASs of BMI and used to generate specific 
primers as described in Chapter 2 section 2.14-2.15 (101-106). CpG sites were also 
included from a study investigating the association between obesity associated SNPs 
and methylation of nearby CpG sites (212). Smoking and inflammation are important 
covariates in studies of obesity, as they are known to influence DNA methylation and 
can confound results. Therefore, CpG sites where methylation levels have been 
shown to be influenced by smoking and inflammation (as measured by C-reactive 
protein, CRP) were included as controls for these covariates. The smoking associated 
sites were identified from a meta-analysis of EWASs of smoking (195). The CRP 
associated sites were identified from a meta-analysis of EWASs of serum C-reactive 
protein (213). Blood represents a heterogenous tissue containing numerous different 
types of leukocytes, which can lead to confounding in EWASs using blood (382). In 
the present study, this was accounted for by using highly cell type specific 
methylation signatures as proxies for cell type composition. The blood cell 
composition control sites were identified from (214). 
Primers were evaluated for specificity and efficacy as described in Chapter 2 section 
2.14.1. 192 of the primers that performed well in the evaluation assay were selected 
to be included in this study. The 192 selected primers consisted of 140 that targeted 
CpG sites identified from obesity EWASs, 14 that targeted CpG sites associated with 
smoking or CRP, 27 that targeted CpG sites associated with blood cell composition, 
and 11 that targeted CpG sites associated with SNPs of obesity. 
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Peripheral blood samples were collected as part of the Dad’s Health Study at 
University College London Hospital (UCLH) between May 2016 and March 2019 as 
described in detail in Chapter 2 sections 2.3-2.6. DNA was extracted as described in 
Chapter 2 section 2.8 and bisulfite converted as described in Chapter 2 section 2.11.  
Quantification of CpG methylation in the 192 regions of interest in bisulfite converted 
genomic DNA from 96 lean and 96 obese males was performed using a multiplex 
bisulfite-PCR-sequencing microfluidics-based assay, hereafter referred to as the ‘Bis-
PCR-Seq assay’. This is described in detail in Chapter 2 section 2.15. Briefly, regions 
of interest in bisulfite converted genomic DNA were amplified using the 48.48 layout 
on the Fluidigm® C1 system (Fluidigm®, USA) (218, 383). Next Generation Sequencing 
(NGS) libraries were generated from the amplicons using the same kit, including 4 µl 
of Access Array Barcode Library Primer and 1 µl of PCR product diluted 1:100. 
Libraries were sequenced on an Illumina MiSeq sequencer (150 bp, paired-end). The 
output data was provided as FastQ files, which are text files containing the target 
sequence together with a quality score (384). 
6.4.2 Statistical analyses 
Phenotype analyses were carried out using RStudio version 1.1.456. Sequencing 
reads were aligned to a bisulfite converted reference genome, the GRCh38.p13, using 
Bismark (385, 386). The 5mC level at each CpG site was calculated using a customised 
python script, calculating the methylation value β as the ratio of methylated reads 
over the total number of reads at each covered CpG site (387). 
Measurements of BMI, waist circumference, systolic and diastolic blood pressure, 
total cholesterol as well as HDL and LDL cholesterol were found to be approximately 
normally distributed (Shapiro-Wilk test p>0.10), and are therefore summarised as 
mean values and standard deviations of the mean. The means of these 
measurements were compared between the lean and obese cohorts using a Welch 
t-test. The distribution of measurements of fasting glucose, C-reactive protein and 
triglyceride levels as well as calculated HOMA-IR values was found to be skewed 
(Shapiro-Wilk test p<0.10), and are therefore summarised as median values and 
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interquartile ranges. In these cases, a Wilcoxon rank sum test was used to compare 
median values between the cohorts. 
6.5 Results 
6.5.1 Phenotype profiles of study participants 
Phenotype characteristics of lean (BMI 18-25 kg/m2) and obese (BMI >30 kg/m2) 
participants are presented in Table 6-1. 
There were clear, significant differences in metabolic characteristics between lean 
and obese participants (Table 6-1). Measurements of BMI, waist circumference, 
systolic and diastolic blood pressure, total- HDL- and LDL-cholesterol, fasting glucose 
and insulin, HOMA-IR, HOMA2-IR, CRP and triglycerides were all significantly 
different between the two groups (p < 0.001 for all but fasting glucose where p = 





Lean Obese Reference Range p 
n 96 96   
Age, years. Mean (SD) 35.8 37.0 N/A 0.232 
BMI, kg/m2. Mean (SD) 23.2 (1.2) 33 (3.3) 18.5–24.9 <0.001 
Waist circumference, cm.  
Mean (SD) 82.3 (10.5) 110 (9.6) < 94 cm <0.001 
SPB, mmHg. Mean (SD) 119 (13) 131 (16) 90 - 120 <0.001 
DPB, mmHg. Mean (SD) 76 (9) 84 (12) 60 - 80 <0.001 
Total cholesterol, mmol/L.  
Mean (SD) 4.8 (1) 5.3 (0.9) < 5.0 <0.001 
HDL cholesterol, mmol/L.  




LDL cholesterol, mmol/L.  
Mean (SD) 2.8 (0.9) 3.2 (0.8) < 3.5 <0.001 
Fasting glucose mmol/L.  
Median (IQR) 4.7 (0.5) 4.9 (0.5) 3.9-5.8 0.001 
Fasting insulin, mIU/L.  
Median (IQR) 5.8 (2.9) 13.0 (10.5) 2.6-24.9 <0.001 
HOMA-IR. Median (IQR) 1.2 (0.6) 2.7 (2.7) Usually ≤ 2.0 <0.001 
HOMA2-IR. Median (IQR) 0.8 (0.4) 1.7 (1.4) Usually ≤ 1.8 <0.001 
CRP, mg/L. Median (IQR) 0.6 (0.4) 1.6 (2.3) 0-5.0 <0.001 
Triglycerides, mmol/L.  
Median (IQR) 0.9 (0.5) 1.6 (1.3) <2.3 <0.001 
Table 6-1. Phenotype characteristics of study participants. 
Reference ranges are derived from the UCLH Clinical Biochemistry Test Information sheet available 
from (230). The reference range for HOMA-IR is derived from (231). The reference range for HOMA2-
IR is derived from (232). The reference range for waist circumference is derived from (179). The 
reference ranges for blood pressure are derived from (233). SD = Standard Deviation, IQR = 
interquartile range, BMI = Body Mass Index, SBP = Systolic Blood Pressure, DBP = Diastolic Blood 
Pressure, HOMA-IR = Homeostatic Model Assessment of Insulin Resistance, CRP = C-Reactive 




6.5.2 Quality Control of Sequencing Data 
Illumina MiSeq sequencing data was provided as FastQ files. FastQC quality control 
profiles were generated for all FastQ files and no large abnormalities or low quality 
data was detected for any files (an example of FastQC files of the Illumina MiSeq 
sequencing data is provided in Appendix 5) (384, 388). 
6.5.3 Aligning of amplicons to a reference genome 
Reads were aligned to an in silico bisulfite converted reference genome 
(GRCh38.p13) using Bismark (385, 386). In the bisulfite converted reference genome, 
non-CpG cytosines are replaced with thymines (T), whereas CpG cytosines remain as 
cytosines (C) (383). A phred score of 10, equivalent to a base call accuracy of 90%, 
was set as a minimum quality score for amplicons to align to the reference genome 
(389). CpG methylation was quantified by observing the base calls at the CpG sites in 
the mapped reads; unmethylated CpG sites in the target sequences would have T 
whereas methylated CpG sites in the target sequences would have C in the mapped 
reads. Methylation levels were expressed as percentages, ranging from 0 (completely 
unmethylated) to 100 (fully methylated). For each CpG site, the methylation level in 
the original sample, expressed as a percentage, was determined as follows: 
Methylation	level	(β) = C2 + 4 	5	100 
A relatively low mapping efficiency was observed when aligning the reads to the 
reference genome (mean 19.4%, median 20%, range 8.4-24.9%). In other words, 
most of the reads mapped non-specifically and could not be analysed adequately. No 
participants were excluded due to low mapping efficiency. An average read coverage 
of 20 was used as a minimum cut-off for each CpG site. This meant filtering of 113 
amplicons, leaving 79 amplicons containing CpG sites of interest for further analyses. 
Of these 79, 64 were from obesity EWASs, 3 were control probes for smoking or CRP, 
6 were control probes for blood cell type composition and 6 were for CpG sites 






Several of the amplicons contained multiple CpG sites in addition to the specific one 
of interest. This meant that a total of 441 CpG sites were included in downstream 
analyses. 
  
Figure 6-1. Amplicons excluded based on low read coverage 
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6.5.4 Principal component analysis 
Principal component analysis (PCA) of the 192 samples revealed no overall difference 
between samples according to the cohort they had been collected from, i.e. UCLH or 
Iowa (Figure 6-2). It did identify three samples (two from the Iowa cohort and one 
from the UCLH cohort) as outliers. These were removed from further downstream 
analyses. Thus, 189 samples remained. 
 
6.6 Association between CpG methylation and Obesity Status 
Different approaches were used to test for an association between CpG methylation 
at the 70 sites of interest (64 from obesity EWASs and 6 associated with obesity SNPs) 
and BMI. 
The main analysis model was a linear regression with methylation as the outcome 
regressed onto BMI, age, blood cell composition (B cells, CD4+ T cells and 
monocytes), smoking and CRP. In this model, one CpG site was picked randomly as a 
proxy for each of the covariates for which multiple associated CpG sites were 
Figure 6-2. Principal component analysis of the 192 samples included in the study of validating 
obesity associated CpG sites 
The three samples indicated by the arrows were identified as outliers and were removed from 
downstream analyses. PC = Principal Component 
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available (i.e. smoking, monocytes and CD4+ T cells). These were the only covariates 
which had CpG sites with sufficient read coverage. With FDR correction for multiple 
testing, no CpG sites were identified as significantly associated with BMI in this 
model. This model most closely reflects the methods used in the EWASs from which 
CpG sites were selected, and is therefore the focus of the results from this study 
(hereafter referred to as the ‘main’ linear model). Results for the 70 informative 
probes (64 from obesity EWASs and 6 that are associated with obesity CpGs) are 
presented in Table 6-2, where they are ranked according to the p value for their 
association with BMI. 
Probe p (linear model) p (main linear model, FDR corrected) 
cg07037944 0.001225299 0.06758115 
cg26651978 0.00193089 0.06758115 
cg07960624 0.028959025 0.53335775 
cg00431050 0.030477586 0.53335775 
cg00108715 0.043737376 0.61232326 
cg03078551 0.092536946 0.67541442 
cg14264316 0.152834633 0.67541442 
cg15442888 0.15059464 0.67541442 
cg03957124 0.154380438 0.67541442 
cg15357118 0.096551232 0.67541442 
cg09363892 0.075239381 0.67541442 
cg20507228 0.127862974 0.67541442 
cg25570328 0.117257923 0.67541442 
cg08877257 0.15074389 0.67541442 
cg13840239 0.14040811 0.67541442 
cg03433986 0.152859854 0.67541442 
cg12917475 0.210549984 0.71687174 
cg07504977 0.235146089 0.71687174 
cg00916899 0.217534508 0.71687174 
cg25217710 0.235206539 0.71687174 
cg25096107 0.236494038 0.71687174 
cg16395997 0.234860561 0.71687174 
cg19750657 0.245784598 0.71687174 
cg01101459 0.243367995 0.71687174 
cg08857797 0.385964057 0.76683972 
cg10508317 0.354063565 0.76683972 
cg05628049 0.274293957 0.76683972 
cg10717869 0.336288407 0.76683972 
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cg01677628 0.312000927 0.76683972 
cg01798813 0.288047918 0.76683972 
cg26257082 0.305562691 0.76683972 
cg00994936 0.370362156 0.76683972 
cg00834536 0.368435589 0.76683972 
cg10734665 0.378845657 0.76683972 
cg15497724 0.363650291 0.76683972 
cg22143698 0.394374716 0.76683972 
cg09349128 0.482897241 0.84507017 
cg13997435 0.473347066 0.84507017 
cg04924511 0.455350281 0.84507017 
cg02008402 0.478693773 0.84507017 
cg26357885 0.500347584 0.85425197 
cg07728579 0.531564474 0.88594079 
cg00634542 0.627067371 0.89581053 
cg03327570 0.618423436 0.89581053 
cg01881899 0.620896593 0.89581053 
cg11152384 0.607840439 0.89581053 
cg27269962 0.596640489 0.89581053 
cg23172671 0.619094684 0.89581053 
cg00489954 0.591012002 0.89581053 
cg09109383 0.685979872 0.95301219 
cg09222732 0.702631133 0.95301219 
cg24145109 0.707951914 0.95301219 
cg11376147 0.787153269 0.96115174 
cg13084458 0.775574576 0.96115174 
cg16611584 0.815517269 0.96115174 
cg16721489 0.771621426 0.96115174 
cg24824917 0.764482708 0.96115174 
cg05149343 0.837575085 0.96115174 
cg13010621 0.735506089 0.96115174 
cg22950899 0.826453951 0.96115174 
cg04816311 0.799271833 0.96115174 
cg04557677 0.853213285 0.96330532 
cg17560136 0.911985835 0.98213859 
cg11660018 0.892933475 0.98213859 
cg23576855 0.903057926 0.98213859 
cg18217136 0.930732814 0.98714086 
cg06876354 0.973260779 0.99181011 
cg23417875 0.971493686 0.99181011 
cg09956615 0.977641392 0.99181011 
cg14020176 0.992235325 0.99223532 
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Table 6-2. (Previous page) Results from the main linear regression model of DNA methylation 
regressed onto BMI, age, blood cell composition, smoking and CRP 
Of the 70 probes in the table, 64 were identified from obesity EWASs and 6 from a study of CpG sites 
associated with obesity SNPs. The CpG sites are ranked from lowest to highest FDR-adjusted p value. 
As shown, no CpG site reached assay-wide significance after multiple testing 
correction. There were, however, two sites which were suggestive of an association 
with BMI. These were cg07037944 (p = 0.068) and cg2665197 (p = 0.068) (Figure 6-3). 
It is possible that a larger study cohort would have identified these as significantly 
associated with BMI. All other sites had FDR corrected p values for an association 
with BMI >0.5. 
 
Figure 6-3. Scatter plots for methylation levels in the two CpG sites with the lowest p value for an 
association with BMI in the main linear regression model 
a. cg07037944 (p = 0.068) 
b. cg26651978 (p = 0.068) 
Another linear model that included all the CpG markers for the covariates, i.e. one 
for B cells, two for CD4+ T cells, three for monocytes, one for CRP and two for smoking 
was performed. It was first confirmed that the CpG sites selected were independently 
associated with the covariates, for example that the two CpG sites associated with 
smoking did not correlate with each other. This model did not identify any CpG sites 
as significantly associated with BMI after multiple testing correction. 
Finally, a t-test for methylation level differences between the lean and obese 
participants was performed. With FDR correction for multiple testing, no CpG site 
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was identified as significantly associated with obesity. The p values for the two CpG 
sites identified as suggestive of an being associated with BMI in the main linear 
regression model were p = 0.201 for cg07037944 and p = 0.352 for cg26651978. For 
all the other 68 CpG sites of interest, FDR corrected p values for an association with 
BMI exceeded 0.5 (Appendix 4). 
6.7 Comparison of results from the Bis-PCR-Seq assay with results from the 
original EWASs of BMI 
 
Given the non-replication of previously reported results, a dependent sample sign 
test was used to investigate whether the direction of methylation change (i.e. higher 
or lower in relation to BMI) in the Bis-PCR-Seq assay was correlated to that observed 
in the original obesity EWASs. This analysis did not find that the direction of 
methylation change was significantly correlated (p = 0.10, data not shown). 
Next, it was investigated whether the change in methylation per unit of BMI observed 
in obesity EWASs was correlated with the change in methylation per unit of BMI 
observed in the Bis-PCR-Seq assay. To this end, the raw methylation change per unit 
change of BMI was extracted from the obesity EWASs for the 70 informative probes 
(64 from obesity EWASs and 6 associated with obesity SNPs) or transformed when 
necessary. This data was available in all but one study, where methylation levels were 
reported as M values, i.e. the log2 ratios of the intensities of methylated probe versus 
unmethylated probe in the Illumina methylation arrays, rather than beta values (105, 
390). The mean of these raw beta value changes was calculated for each of the 50 
probes for which changes in beta value of methylation were available. This mean 
value was then assessed for correlation with the methylation change beta value 
observed in the Bis-PCR-Seq assay (Figure 6-4). Using Pearson’s product-moment 
correlation, effect sizes were found to be significantly correlated (R2 = 0.14, p = 
0.006). In brief, this means that the change in methylation per unit of BMI observed 
in obesity EWASs was correlated with the change in methylation per unit of BMI 




6.8 Comparison of results of the Bis-PCR-Seq assay to the MethylationEPIC 
array 
Given the very limited replication of previous results observed in this study, we next 
investigated the characteristics and quality of the Bis-PCR-Seq data against a 
comparable sample of whole blood DNA methylation profiles from lean and 
overweight/obese men profiled on the Illumina EPIC array. Thus, it was investigated 
whether results obtained using the MethylationEPIC array (Chapter 5) correlated 
with those obtained using the Bis-PCR-Seq assay. DNA MethylationEPIC data from 21 
lean (BMI 18-25 kg/m2) and 22 overweight/obese (BMI> 25 kg/m2) participants was 
included in this analysis. Measurements of BMI, waist circumference, fasting glucose, 
insulin resistance (HOMA-IR and HOMA2-IR) and CRP were significantly different 
between the cohorts of lean and overweight/obese participants (p < 0.05). 
All the obesity EWASs from which CpG sites were selected were performed using the 
HM450. The MethylationEPIC array includes >90 % of the CpGs from the HM450 (87).  
Figure 6-4. Comparison of mean effects in obesity EWASs to the effect 
observed in the Bis-PCR-Seq assay (‘Fluidigm’) 
The black markers represent the 70 informative sites. The x axis shows 
the mean methylation effect observed in obesity EWASs and the y axis 
shows the effect observed in the Bis-PCR-Seq assay (“Fluidigm”). 
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60 out of the 70 informative sites from the Bis-PCR-Seq assay were represented on 
the MethylationEPIC array. 
The correlation of DNA methylation values obtained using these two methods is 
presented in Figure 6-5. As shown, there was a high and significant correlation 
between the median methylation levels obtained using the Bis-PCR-Seq assay and 
the MethylationEPIC array (R2 = 0.90, p = 2.2 x 10-16). 
 
It was clear that the results from the Bis-PCR-Seq assay overall reflected those 
obtained using the MethylationEPIC array. It was then assessed whether the 
methylation levels at the 60 probes individually showed the same direction of 
association with BMI when comparing results from the Bis-PCR-Seq assay to those 
obtained using the MethylationEPIC array. This yielded mixed results, with 30 of the 
60 sites showing the same direction of association with BMI on the Bis-PCR-Seq assay 
and the MethylationEPIC array. Bis-PCR-Seq assay and MethylationEPIC data for the 
Figure 6-5. Comparison of results from the Bis-PCR-Seq assay (‘Fluidigm’) and the 
MethylationEPIC array 
The black markers represent the CpG sites that were included in the Bis-PCR-Seq assay as well 
as being present on the MethylationEPIC array (n = 60). The two CpG sites with the highest 
difference in median methylation levels are circled. They correspend to cg04924511, which has 
a median methylation difference of 32% between the Bis-PCR-Seq assay and the 
MethylationEPIC array, and cg00489954, with a 29% median methylation difference. 
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two CpG sites which had the lowest p values in the main linear regression model of 
methylation regressed onto BMI, age, blood cell composition, smoking and CRP 
(Table 6-2) are visualised in Figure 6-6. 
 
As exemplified in Figure 6-6, the variability of methylation results at individual CpG 
sites was considerably higher in the Bis-PCR-Seq assay compared to those measured 
using the MethylationEPIC array. For example, at probe cg07037944, the methylation 
levels vary between ~0-47% when measured using the Bis-PCR-Seq assay, but vary 
between ~15-26% when measured using the MethylationEPIC array. The higher 
methylation variability in the Bis-PCR-Seq assay was observed for all of the 60 CpG 
sites that were analysed in the Bis-PCR-Seq assay and represented on the 
MethylationEPIC array. This effect could, in part, be related to the level of read 
coverage of the individual CpG sites. Indeed, there was a significant correlation 
between the average coverage of each CpG site and the variability of methylation 
levels, measured as standard deviations (R2 = 0.14, p = 8.4 x 10-4) (Figure 6-7). Other 
potential explanations for the higher variability in the Bis-PCR-Seq assay include PCR-
related artefacts. 







Figure 6-7. Correlation between average coverage of CpG sites and 
variability (expressed as standard deviation, SD) in the Bis-PCR-Seq 
assay 
The black markers represent the 79 informative CpG sites that passed 




This study formed the first part of a large scale analysis aimed to identify a robust, 
replicable DNA methylation signature of obesity. Whereas the present study included 
~200 participants, the larger analysis will include ~2,000 participants. Therefore, the 
results should not be seen as conclusive. The present study was nevertheless an 
important step in identifying suggestive CpG sites, evaluating the methodology and 
informing the next stages of the large scale project. 
In the present study, despite comparing well-characterised obese and lean men, 
none of the previously identified CpG sites were replicated as significantly associated 
with obesity/BMI. Two CpG sites, cg07037944 and cg26651978 were suggestive of an 
association with BMI in a linear regression model that controlled for age, blood cell 
type composition, smoking and inflammation (FDR corrected p = 0.068 for both sites). 
The CpG site cg07037944 is annotated to the gene Death Associated Protein Kinase 
2 (DAPK2) (104). The CpG site is, however, not in the 5’ promoter of the gene, where 
it would have been expected to have the highest likelihood of influencing expression 
of DAPK2, but is intragenic. The role of cg07037944 in the regulation of DAPK2 should 
therefore be interpreted with caution. In either case, cg07037944 was identified as 
associated with BMI in two large scale EWASs of BMI, one of which was the reason 
for its inclusion in this analysis and the second published after the time of identifying 
CpG sites for the present project (104, 106). In addition, cg07037944 was associated 
with BMI change (when comparing BMI at age 18-21 and BMI in middle age) in a twin 
family study (391). DAPK2 is a member of a family of kinases with cellular functions 
related to apoptosis, autophagy and immune system functioning (392, 393). 
Inhibition of DAPK2 has been shown to reduce the inflammatory response to 
infection in a murine model (393). Obesity is a condition characterised by chronic, 
low-grade inflammation, which contributes to related conditions such as insulin 
resistance (394). Alterations in the function of DAPK2 may therefore play a role in the 
pathogenesis of obesity. 
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The CpG site cg26651978 is annotated to the gene Lectin Galactoside-Binding Soluble 
3-binding Protein (LGALS3BP) (104). An important caveat to mention here, however, 
is that cg26651978 is 3’ of LGALS3BP and therefore, although LGALS3BP is the gene 
nearest to the CpG site, it may not actually be involved in its regulation. Several 
EWASs have, however, identified CpG sites annotated to LGALS3BP, as associated to 
BMI and related traits such as waist circumference (102, 106, 107). In one of these 
studies, CpG sites annotated to LGALS3BP were also found to be associated with BMI 
in adipose tissue (106). LGALS3BP has pleiotropic cellular functions, including roles in 
cellular migration, angiogenesis and immune system functioning (395). The gene has 
been implicated in the development of several forms of cancer (395). The gene 
product, LGALS3B, has recently been shown to be differentially expressed in non-
alcoholic fatty liver disease (NAFLD), which is commonly associated with high BMI 
(396). Therefore, it is possible that LGALS3BP is associated with BMI because of its 
role in inflammation/immune system regulation, or because of its role in NAFLD. 
6.9.1 Strengths and Limitations 
The multiplex bisulfite-PCR-sequencing assay used in this study provided a high-
throughput, cost-effective method of quantifying targeted CpG methylation at a 
single base resolution (383). However, it also presented methodological limitations.  
Most evidently, there was a relatively low rate (79/192) of primer regions with 
adequate coverage for downstream analyses and a relatively low mapping efficiency 
of approximately 20%. The multiplexing of four primer pairs in each well of the 
Fluidigm Access Array likely contributed to these inefficiencies by increasing the rate 
of primer dimer formation. Other causes include different annealing temperatures of 
the primers, and sequence-dependent differences in PCR efficiency, i.e. that genetic 
variation in the primer sequence could have resulted in differences in the efficiency 
of PCR products (397). Mapping efficiency is generally decreased when mapping 
bisulfite treated sequences to a reference genome due to the reduced sequence 
complexity (386). Previous research has, however, suggested that a mapping 
efficiency of approximately 50-70% would have been expected from this type of 
experiment (398, 399). Not multiplexing the primers would have made the method 
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less cost-effective. However, in future experiments the balancing of cost versus a 
potentially improved rate of regions with enough coverage should be carefully 
considered. It is also striking that while no single previously identified obesity-
associated CpG site replicated in this study, effect sizes in the Bis-PCR-Seq assay were 
significantly correlated to effect sizes of the original obesity EWASs. 
6.9.2 Future Directions 
The results of this study will be taken into account when refining the methodology of 
the large scale study of 1000 lean and 1000 obese males, such as in deciding whether 
or not to multiplex primers. 
It would also be of value to identify sites associated with obesity in more disease 
relevant tissues, such as adipose or hepatic tissue. Further, coupling the study with 
functional gene output, such as transcriptome, analyses would yield insights into the 
interactions between epigenetic signatures of obesity and their physiological 
consequence. 
The mortality associated with obesity does not come from having a high BMI, but 
from associated conditions such as cardiovascular events, some forms of cancer and 
chronic kidney disease (13). Therefore, it is of particular value to identify epigenetic 
biomarkers that are associated with an increased risk of developing such 
complications before they occur. This way, individuals could be offered targeted 
intervention or additional monitoring to reduce obesity associated mortality. In this 
regard, large-scale, longitudinal analyses with matched samples from individuals who 
gain weight would be of considerable value. 
6.10 Summary 
In this study, I aimed to validate previously identified obesity-associated CpG sites in 
a novel cohort of 96 obese men compared with 96 lean men. This was performed by 
using a highly multiplexed bisulfite-PCR-sequencing microfluidics-based assay. No 
CpG sites met the assay-wide threshold for an association with BMI. The study 
identified strengths and weaknesses with the bisulfite-PCR-sequencing methodology 
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used for validating CpG methylation associated with obesity. These insights will 
inform a large-scale project aiming to generate a robust, replicable obesity associated 
DNA methylation profile in a cohort of 1000 lean and 1000 obese males. The study 
also brought forward two CpG sites as being suggestive of an association with BMI 
that are replicable across different cohorts and study settings.  
Elucidation of the epigenetic correlates of obesity has important implications for 
understanding disease pathogenesis and identifying biomarkers for disease 
progression. In a longer perspective, a more detailed understanding of how BMI-
related health complications develop may aid the development of targeted 





Chapter 7  
General Discussion and 
Future Directions  
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7.1 Summary of Key Findings and Conclusions 
I investigated the association between paternal metabolic health and offspring birth 
weight in a prospective cohort study of 500 mother-father-offspring trios (Chapter 
3). Three groups of fathers (lean, overweight and obese) were recruited and these 
had clear differences in metabolic parameters including insulin resistance, waist 
circumference, blood pressure and lipid profiles. I collected detailed health data on 
their partner (the mother). I followed up these couples with regards to pregnancy 
outcome, particularly focussing on the birth weight of their offspring. Contrary to 
previous retrospective studies, I did not identify a paternal metabolic risk factor that 
significantly increased the risk of fathering small for gestational offspring (68, 69, 224-
226). I did discover a non-significant trend towards higher insulin resistance in fathers 
of SGA infants. Due to limited numbers of SGA offspring and insulin-resistant fathers, 
I may have been under-powered to discover an association between paternal insulin 
resistance and growth restriction in his offspring. Such an association would be in line 
with results from studies of paternal monogenic diabetes, which is linked to a 
considerably reduced birth weight of his offspring (72). I did, however, find that 
paternal (own) birthweight was associated with his offspring’s birth weight, while 
maternal (own) birthweight was not. The association between paternal own birth 
weight and offspring birth weight has been recognised previously (67).  
My findings suggest that paternal genetic factors that influenced his own growth in 
utero, rather than factors acquired in his lifetime, are more likely to influence the 
intrauterine growth of his offspring. Conversely, maternal genetic factors that 
influenced her own growth in utero appear to have little effect on the in utero growth 
of her offspring, but rather the intra-uterine environment influences fetal growth. 
In a separate study, I performed a systematic review of studies analysing DNA 
methylation in human sperm (Chapter 4). I critically evaluated 124 articles relevant 
to the topic in accordance with PRISMA guidelines and objectively rated the quality 
of evidence for each publication (191). For each of the three main research 
methodologies (analyses of global DNA methylation, candidate gene analyses and 
genome-wide analyses), I summarised findings from studies where the quality of 
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evidence was rated as high. I concluded that the human sperm methylome has most 
frequently been studied in the context of sub- or infertility. In this, studies have 
typically assessed the association between fertility and promoter methylation of a 
small number of candidate genes, most commonly imprinted genes. Findings from 
such studies have been inconsistent. Indeed, I identified that there was little overlap 
between the findings from candidate gene analyses and the results from epigenome 
wide association studies (EWASs) of sub- and infertility. I also concluded that 
compared to readily available somatic tissues, there is limited evidence that the 
human sperm methylome can be dynamically remodelled in response to 
environmental influences. 
The systematic review also formed the basis of generating recommendations for 
future research. These included to shift research focus from candidate gene analyses 
and studies of global DNA methylation to well-powered genome wide approaches, 
e.g. by using microarrays (until whole-genome bisulfite sequencing becomes a cost-
effective option). There is also a need to widen the scope from an overwhelming 
focus on fertility to more focus on the impact of metabolism, ageing and toxins on 
the sperm methylome. Future research should present detailed phenotyping of 
participants, in particular their age and smoking status. Such covariates should also 
be taken into account when analysing results, e.g. by using multivariate regression 
analyses. I also recommended that research should include more longitudinal 
analyses, for example examining how changes in environmental or physiological 
factors impact the sperm methylome over time. I recommended that for studies of 
tissue specificity of DNA methylation, samples should be matched (i.e. come from the 
same individual) to avoid confounding of results due to genetic variation. These and 
other conclusions from the systematic review informed the comprehensive 
characterisation of the human sperm methylome described in Chapter 5. 
I performed the largest to date genome-wide characterisation of matched sperm and 
blood samples using the latest generation DNA methylation profiling array, the 
MethylationEPIC array (199) (Chapter 5). DNA methylation levels at > 850,000 CpG 
sites were measured in matched sperm and blood from a total of 92 individuals. I 
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found that, overall, sperm exhibited a highly polarised methylation profile towards 
the two extremes of DNA methylation levels, i.e. that both low (<20%) and high 
(>80%) levels of methylation were more commonly seen in sperm than in blood. 
I specifically sought to identify CpG sites where sperm and blood methylations co-
vary. This would allow blood to act as a proxy tissue in studies where sperm is 
unavailable. Significant correlation between sperm and blood methylation levels was 
identified at ~5,000 CpG sites. A high proportion of these sites displayed bi- and 
trimodal patterns of methylation (suggestive of a genetically driven effect) and that 
a high proportion had SNPs in the CpG site, as identified by cross-checking with the 
dbSNP Human Build 151 database (374). In other words, it is likely that methylation 
levels at the vast majority of these ~5,000 CpG sites was genetically driven. Indeed, 
there were only 10 CpG sites with significant methylation co-variation between the 
tissues and no known SNP in the probe sequence. These 10 CpG sites are likely to be 
too few to be of value in studies where blood is to be used as a surrogate tissue for 
sperm DNA methylation. It is, however, important to bear in mind that even at these 
10 CpG sites where no SNP included in the dbSNP database was identified as present 
at the CpG site itself, methylation levels at these sites could still be influenced by 
genetic polymorphisms. For example, local cis-regulatory elements and genetic 
effects on the methylome via transcription factors cannot be ruled out as influencing 
CpG methylation at these 10 sites (382). Indeed, we are likely to currently be 
underestimating the genetic influences on DNA methylation when interpreting the 
results of EWASs (400). It is probable that results from present-day EWASs assumed 
to reflect epigenetic alterations in response to various phenotypic changes will be 
revised with an improved understanding of the influence of genetic variation on DNA 
methylation, for example by continued identification of methylation quantitative 
trait loci (mQTLs) (400). 
I concluded that the DNA methylation profiles of sperm and blood are clearly distinct, 
driven by highly significant mean differences at multiple sites across the genome. 
There is little evidence of methylation co-variation between blood and sperm. 
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A comparison between methylation profiles of sperm and >6,000 somatic tissue 
samples available on the Gene Expression Omnibus was also performed. This analysis 
suggested that transcriptional regulation in spermatozoa is highly distinct from that 
of somatic tissue, most likely to repress overall transcription (265). My findings 
emphasise the importance of using disease-relevant tissues for epigenomic analyses, 
and question the validity of previous studies where blood has been used as a proxy 
tissue for sperm DNA methylation (153). 
In the above study, I found no evidence that obesity alters the methylation 
covariation between sperm and blood. I did, however, identify one CpG site that was 
differentially methylated in sperm and blood of overweight/obese men compared to 
lean men. It is interesting to note that this CpG site has not previously been identified 
as associated with obesity/BMI in EWASs using blood only. 
I validated previously identified obesity-associated CpG sites in a blood from a novel 
cohort of 96 obese and 96 lean males using a targeted bisulfite-PCR-sequencing 
approach (Chapter 6). This study constituted the first step in a large scale analysis 
aimed to identify a robust and replicable obesity associated DNA methylation profile. 
The larger study will include 1000 lean and 1000 obese males from the Norwegian 
Mother and Child cohort (MoBa) (401). Whilst I did not identify any CpG sites that 
were statistically associated with obesity at a genome-wide level, two CpG sites 
almost reached significance (FDR corrected p = 0.07). None of these CpG sites 
mapped to the 5’ promoter of their nearest gene, and any said mechanistic 
involvement in the pathogenesis of obesity ascribed to these sites should be 
investigated with functional or other analyses. These and other important caveats in 
the interpretation of these EWAS results are discussed further in section 7.4. Whilst 
being cautious to ascertain whether cg07037944 actually influences the gene to 
which it is nearest, this CpG site is annotated to the gene Death Associated Protein 
Kinase 2 (DAPK2) (104). This CpG site has been previously been associated with BMI 
in at least two large-scale EWASs of obesity (104, 106). The DAPK2 gene product has 
a role in mediating inflammatory reactions, and may therefore play a role in the 
chronic low-grade inflammation that is a feature of obesity (393). The second CpG 
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site, cg26651978, is annotated to the gene Lectin Galactoside-Binding Soluble 3-
binding Protein (LGALS3BP) (104). Several CpG sites annotated to LGALS3BP have 
previously been identified as associated with BMI (102, 104, 107). LGALS3BP has also 
been found to be differentially expressed in non-alcoholic fatty liver disease (NAFLD), 
which is commonly associated with high BMI (396).  
Importantly, this study also allowed evaluation of the bisulfite-PCR-sequencing 
method which will be used in the large-scale analysis. It identified strengths and 
limitations of the approach that will allow methodological refinement before the 
large study gets underway. This will improve our ability to generate a robust and 
replicable obesity associated DNA methylation profile, which has important 
implications for understanding disease pathogenesis, identifying biomarkers for 
disease, and identifying therapeutic targets. 
An overview of research questions, approaches to investigations, key findings and 
conclusions of my PhD project in presented in Figure 7-1. 
Figure 7-1. The following page: Summary of key findings in relation to the main hypotheses of 
my PhD project 
A summary of the main hypotheses guiding this work is presented, along with key research 
questions (grey boxes), methods of investigation (blue boxes) and key findings/conclusions from 
my research (green boxes). 







7.2 Implications of my Research Findings 
Over the course of my PhD, I employed a range of methods to interrogate whether, 
and how, paternal metabolic health influences sperm DNA methylation and the 
intrauterine growth of his offspring. In doing so, this thesis has contributed to the 
field of intergenerational inheritance and obesity associated epigenetic change in 
humans in a number of ways. 
First, this project has demonstrated that paternal BMI is associated with only a 
modest, if any, effect on offspring birth weight. A larger study or the study of extreme 
phenotypes would be necessary to identify an association (68, 69). It could be seen 
as encouraging that my research and a recent systematic review did not find evidence 
for paternal obesity at conception as associated with offspring birth weight (227). 
Instead, a meta-analysis of the association between paternal BMI at conception and 
offspring health outcomes showed that high paternal BMI around conception 
increased the risk of his offspring having a high BMI or high fat mass in childhood 
(227). This association could have arisen from factors in paternal spermatozoa that 
increase the risk of high adiposity in childhood, from lifestyle factors (an ‘obesogenic 
environment’), or from a combination of the two. In contrast to factors transferred 
via sperm during conception, an obesogenic environment is modifiable after 
conception has occurred. Further, pregnancy represents a period of increased 
motivation for parents to undertake lifestyle changes, and of coming into contact 
with health care providers (402). If it is the case that paternal BMI at conception is 
less influential than paternal BMI during a child’s early years, then intervening by 
encouraging healthy lifestyle habits (for both parents) during pregnancy could have 
considerable benefits for future offspring health. 
In line with previous research, I showed that paternal (own) birth weight is associated 
with the birth weight of his offspring (67). Antenatal prediction of estimated infant 
birth weight is important, as it guides both the timing and mode of delivery of a 
pregnancy (403). Although ultrasound based estimation of fetal weight has improved 
considerably in the last decades, it can still be inaccurate, especially if performed in 
late gestation (403). In a longer perspective, therefore, one could envisage that 
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paternal (own) birth weight is also taken into account to achieve a more accurate 
prediction of fetal weight. 
This thesis includes the first systematic review of studies of human sperm DNA 
methylation. The detailed overview of the field generated via the systematic review 
should be a useful resource for other researchers in the area, and for those interested 
in epigenetics of human germ cells. In this, I summarised findings from high-quality 
studies of global DNA methylation, candidate gene studies and genome-wide 
investigations of spermatozoal DNA methylation respectively. I found that few, if any, 
of the findings from candidate gene analyses of, typically, fertility correlated with 
findings from less biased genome-wide studies of the same phenotype. I also 
concluded that there are few, if any, robust and reproducible epigenetic correlates 
of subfertility from EWASs performed thus far. In this regard, it is interesting that 
there is already work underway to implement epigenetic testing of sperm as part of 
clinical semen analyses (404). It is possible that future, large-scale, DNA methylation 
analyses of spermatozoa will indeed identify specific CpG sites that can serve as 
reliable biomarkers of different types of subfertility that will be of clinical value. Until 
then, however, based on the inconsistent findings of studies of DNA methylation of 
fertility included in my systematic review, the clinical utility of designing a platform 
for measuring spermatozoal DNA methylation is likely to be limited. The critical 
evaluation of studies included in this systematic review allowed me to make specific 
and constructive recommendations for future research (summarised in section 7.1 
above). I hope that these recommendations will contribute towards refining research 
methodologies in this field, ultimately leading to clinically meaningful results 
regarding how paternal environmental and acquired traits can influence the next 
generation and beyond. 
Third, this project has empirically demonstrated the necessity of using disease 
relevant tissues, i.e. germ cells, in epigenomic investigations of intergenerational 
inheritance. Previous studies of intergenerational effects of metabolic phenotypes 
have used results from epigenetic analyses of blood and pancreatic tissue to infer 
transmission of specific DNA methylation signatures via spermatozoa (138, 153). My 
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findings strongly question the validity of this approach by showing little, if any, 
evidence of methylation co-variation between sperm and blood. 
I have demonstrated that a targeted bisulfite-PCR-Sequencing (Bis-PCR-Seq) 
approach can be a high-throughput, cost-effective alternative to microarray based 
methods of interrogating CpG methylation in large cohorts, e.g. in the context of 
validating previously identified CpG sites. Although Bis-PCR-Seq had drawbacks in my 
study, for example in that a large proportion of CpG sites could not be analysed due 
to low read coverage, we showed a high overall correlation of results between this 
method and using the MethylationEPIC array. After further refinement of the 
approach, in particular by improving strategies to reduce primer dimerisation, we aim 
to use this approach to generate a robust obesity associated DNA methylation profile 
in a cohort of 1,000 lean and 1,000 obese males. 
7.3 Strengths of my PhD Project 
Most previous studies analysing the impact of paternal BMI and insulin resistance on 
offspring birth weight have been retrospective (68, 69, 225, 226). The prospective 
nature of the Dad’s Health Study reduced potential selection bias and strengthened 
my ability to make results generalisable to a wider population. The Dad’s Health 
Study also included a more detailed phenotypic assessment of male participants than 
has often previous been the case. For example, fasting blood tests allowed us to 
reliably assess paternal insulin resistance, which is likely to be a more accurate 
measure of metabolic health compared to BMI alone (68). 
The analysis of genome-wide DNA methylation of matched sperm and blood samples 
(n = 92) had a considerably larger sample size compared to previous studies with a 
comparable methodology (n = 8) (168). In contrast to most previous investigations of 
spermatozoal DNA methylation, participants were not recruited from a reproductive 
medicine setting but were healthy, fertile volunteers. This makes findings from the 
analysis more generalisable to the male population as a whole. Another strength of 
this study was the use of the most recent DNA methylation profiling array, the 
MethylationEPIC array. This allowed characterisation of genomic regions that have 
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previously only been analysed in in human spermatozoa in small-scale studies (<10 
participants) using whole-genome bisulfite sequencing (341, 352). 
Another strength of the work presented in this thesis is that it includes novel methods 
of analysing epigenetic data. With co-workers, I used a recently developed data 
analysis pipeline designed for large methylation data sets to compare spermatozoal 
DNA methylation patterns to that of >6,000 somatic tissue samples (211). To my 
knowledge, this is the most extensive comparison between the DNA methylation 
profile of spermatozoa and that of somatic tissue samples. 
7.4 Limitations of my PhD Project 
I have discussed specific limitations of the studies described in each chapter 
separately. I will therefore limit the discussion below to more general and recurring 
limitations relevant to my PhD project. 
I had limited sample sizes that particularly affected the Dad’s Health Study described 
in Chapter 3. This likely made the study underpowered to detect modest effects of 
paternal influences on offspring birth weight. The power calculations used to 
determine a sample size for the Dad’s Health Study were based on effect sizes in 
previous studies which might have included confounding factors that influenced fetal 
growth by other mechanisms than acquired paternal traits, such as genetic influences 
or residual confounding not addressed in customised birthweight centiles (68, 176). 
Also, whilst previous studies in this area have been able to detect effects with sample 
sizes comparable to or smaller than the Dad’s Health Study cohort, they may have 
included more extreme phenotypes, e.g. severe growth restriction (69, 72). The Dad’s 
Health study mostly included healthy mother-father-offspring trios with most 
offspring appropriately grown for gestational age. Also, the Dad’s Health Study 
included relatively few obese fathers compared with lean and overweight fathers. 
Increasing the number of obese fathers would improve power and possibly unmask 
an association between paternal insulin resistance and fetal growth restriction. 
Including fathers with diabetes might also strengthen the link between paternal 
insulin resistance and fetal growth restriction. I identified a trend towards higher 
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insulin resistance in fathers of low birth weight infants that could be confirmed with 
a larger study size. Alternatively, studying offspring born to men with type 1 diabetes 
who have no insulin compared with men who have type 2 diabetes with generally 
high insulin levels could be revealing.  
Another potential source of imprecision applicable to the Dad’s Health study is lack 
of standardisation for weighing infants. For the Dad’s Health study, the birth weight 
of infants was obtained from UCLH discharge summaries. It is possible that some 
infants were less dry than others when the weighing was performed, and that there 
could have been differences in the time elapsed since the birth of an infant and the 
infant being weighed. It would have been prudent to standardise weighing of infants 
included in the study, for example weighing all infants at 30-45 minutes after birth 
and taking care that infants were dry when weighed. 
Additionally, in the context of sample sizes, the cohort of obese males (n = 24) who 
provided matched samples of blood and sperm was likely too limited to detect 
modest effects on how obesity may influence the covariation of DNA methylation 
between blood and sperm. The fact that I nevertheless identified one novel obesity 
associated CpG site in blood and sperm points towards the possibility that there is 
more to be explored in terms of gamete-specific epigenetic correlates of obesity that 
may not be detected in studies that only analyse blood. 
A further limitation is that while several strategies were used to minimise 
confounding of results in the analysis of how paternal metabolic health influences 
fetal growth, it is still possible that there were residual confounders not taken into 
account. One of these is socioeconomic status. There is a clear and consistent 
association between low socioeconomic status and low birth weight, even across 
more economically developed countries with state-funded healthcare systems such 
as the UK (405-407). Low socioeconomic status is also strongly linked to an increased 
risk of obesity and T2DM (408-410). In other words, low socioeconomic status 
increases the risk both of metabolic disease and of fathering low birth weight 
offspring. This could yield an association between paternal insulin resistance and low 
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birth weight offspring, without insulin resistance necessarily being the causal 
mechanism. It is possible that this factor may have influenced previous retrospective 
and case-control studies that identified an association between paternal obesity or 
insulin resistance and low offspring birth weight (69). In either case, it is a limitation 
of the Dad’s Health study that detailed information on household income and other 
determinants of socioeconomic status were not collected and taken into account. 
Another limitation of this project is the focus on DNA methylation as opposed to 
other epigenetic mechanisms and their integration. Early studies of intergenerational 
inheritance of acquired traits suggested that DNA methylation was a likely driver, or 
at least an important component of, mediating these effects (138, 140, 141). 
However, during the time of working on this project, the focus of analyses of 
intergenerational inheritance has increasingly shifted towards small RNA species 
(144, 145). Indeed, one study identified specific small RNA molecules capable of 
mediating effects of metabolic disease between generations (145). Epigenetic 
regulation by small RNA species and DNA methylation is of course not mutually 
exclusive, and there is extensive interaction between these mechanisms (411). 
Nevertheless, limiting my research to DNA methylation may have narrowed the 
potential for identifying biologically meaningful findings (145). 
Other limitations of the work presented in thesis relate to challenges in the 
interpretation of epigenome wide analyses of particular phenotypes more broadly. 
In this regard, one of the key issues is our yet incomplete understanding of, and 
methods for investigating, the association between sequence variation and DNA 
methylation. While estimates vary widely, it has been suggested that as much as 22% 
to 80% of the variability of DNA methylation van be accounted for by underlying 
genetic variation (412). In our studies, we accounted for genetic polymorphisms e.g. 
by removing probes from DNA methylation data using annotated lists of SNPs in the 
CpG site. In the study of methylation covariation between sperm and blood we 
further cross-checked results against the dbSNP database to investigate whether 
SNPs at the particular CpG sites investigated were likely to influence results (374). 
However, although these methods are among the currently most commonly used 
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methods to account for the influence of sequence variation on DNA methylation 
data, they are unlikely to be sufficient (412, 413). Indeed, including matched 
genotype information on participants along with information on methylation 
quantitative trait loci (mQTLs) will likely be required to achieve a more reliable 
understanding of whether phenotypic outcomes are associated with particular 
epigenetic signatures. 
It should be appreciated that regions of the genome that are involved in regulating 
the expression of a particular gene can be far away from the gene itself, for example 
in an enhancer (413). In this regard, the results from the validation study of obesity 
associated DNA methylation in blood should be interpreted with caution. Thus, none 
of the two CpG sites that were suggestive of being reproducibly associated with 
obesity (Chapter 6) were in the 5’ promoters of their nearest gene, where they would 
have been most likely to directly influence their expression. One of them 
(cg26651978) was 3’ of LGALS3BP, and could potentially be involved in regulating a 
distant gene, e.g. by being in an enhancer region. Therefore, although both DAPK2 
and LGALS3BP have plausible roles in the pathogenesis of obesity, it is far from clear 
that they are involved in the disease phenotype based on current EWAS findings. 
It is also worth reiterating that all large-scale EWASs of obesity and related traits thus 
far have been performed on the Illumina HM450. These include the studies from 
which we selected CpG sites for replication in the study of obesity associated DNA 
methylation in blood. Not only does this array interrogate less than 2% of the CpG 
sites in the human genome, but it is also heavily biased towards promoter regions, 
which may not be the most relevant sites for studies of phenotypic variation (414).  
As previously discussed (section 1.8.4), a major challenge in the interpretation of 
findings from EWASs is determining causality, i.e. whether particular epigenetic 
marks occur as a cause or a consequence of a particular phenotype (412, 413). This 
is less of a concern if the aim of a study is to, for example, identify biomarkers of a 
disease. However, if the aim is to appreciate if and how epigenetic alterations can 
influence a particular disease process, then methods of determining the causal 
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relationship between DNA methylation and phenotypic change should be employed. 
Such methods include two-step Mendelian randomisation, which aims to ascertain 
the causal relationships between exposure, DNA methylation and outcome (415). 
Using this method on large scale EWASs of obesity performed thus far indicate that 
a majority of DNA methylation signatures associated with obesity are a consequence 
rather than a cause of the disease process (106). This should be borne in mind when, 
for example, interpreting findings from the validation study of obesity associated CpG 
methylation in blood; that the two suggestive findings are potentially the 
consequence rather than the cause of a high BMI. In future studies, longitudinal 
analyses of individuals  recruited prior to the onset of a particular phenotypic change 
will also be key in avoiding issues around, for example, reverse causality in the 
context of epigenomic investigations (412, 414). 
As a consequence of the difficulties in interpreting results from EWASs, such as those 
described above, several researchers have argued that no EWAS performed to date 
can be said to be fully interpretable (400, 412). 
Lastly, the power calculations employed to determine an appropriate sample size for 
the Dad’s Health study (section 2.3.4) were problematic not only because they only 
took into account two groups of lean and obese males respectively, rather than three 
groups of lean, overweight and obese males. Indeed, one of the approaches for 
determining an appropriate sample size was based on a power of only 80% (rather 
than the more stringent 90% which was employed in the other approach). This may 
have limited our ability to identify clinically meaningful influences of paternal 
metabolic health on fetal growth. 
7.5 Future Directions 
As frequently is the case, the work presented in this thesis has opened up for several 
additional lines of enquiry, some of which are already underway. 
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7.5.1 Investigating the potential for reversibility of obesity associated epigenetic 
markers 
In the context of public health policy implications, it is of particular interest to explore 
whether obesity associated epigenetic signatures are reversible. If so, improvements 
in a man’s health before conception would make him less likely to impact on his 
offspring via epigenetic alterations passed via his sperm. I have therefore 
commenced recruitment for a prospective cohort study of obese males (BMI ≥ 35 
kg/m2) due to undergo bariatric surgery. The study analyses serial blood and semen 
samples from 15 obese men due to undergo bariatric surgery. In this, one set of blood 
and semen samples is collected approximately one month prior to surgery and 
constitutes the baseline, and a second set is collected three to four months after the 
surgery (when one full round of spermatogenesis has taken place). The third and final 
set is collected 9-12 months following bariatric surgery, when most of the weight loss 
has occurred (416). The study will also include a control cohort of 15 obese males not 
undergoing weight loss surgery, but providing samples at comparable times. This will 
help to reduce confounding by factors such as ageing. Such a control group has been 
lacking in previous research of weight loss related changes in spermatozoa (346). 
A previous small-scale study of six obese males undergoing bariatric surgery indicated 
that bariatric surgery could be associated with widespread epigenetic alterations in 
male germ cells. However, possibly due to the limited sample size, the study failed to 
identify any CpG sites that fulfilled the threshold for genome wide significance (147). 
Further, the study did not include a control cohort interrogated for spermatozoal 
DNA methylation changes occurring due to processes different from the bariatric 
surgery, such as ageing. 
Results from the bariatric surgery study will be a powerful way to inform public health 
policies directed towards improving preconception health. If obesity-associated 
epigenetic signatures present of spermatozoa are reversible with weight loss, then 
targeted intervention strategies that optimise a man’s health prior to conception 
have the potential to improve the health of the next generation and beyond. 
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7.5.2 Expanding sample sizes to detect modest effects of paternal insulin 
resistance on fetal growth 
The Dad’s Health study was likely underpowered to detect modest effects of paternal 
metabolic traits on offspring with birth weights across the normal birth weight 
spectrum. However, I did identify a non-significant trend of higher insulin resistance 
in fathers of low birth weight offspring, in spite of there being no similar trend in 
paternal BMI. This suggests the possibility that with an increased sample size, 
paternal insulin resistance might emerge as significantly associated with fathering 
low birth weight offspring. This association has clearly been demonstrated in the case 
of paternal monogenic diabetes (72). Several observational studies have also 
suggested an association between paternal insulin resistance and low offspring birth 
weight (69, 224, 225). To my knowledge, however, this has never been demonstrated 
in a prospective study. I therefore aim to expand the Dad’s Health study to further 
interrogate whether insulin resistance, rather than the more crude measure of 
paternal BMI, may be a modifiable risk factor for fathering low birth weight infants. 
7.5.3 Investigating longer-term effects of paternal metabolic disease 
Future work should also be focussed on longer term health consequences of paternal 
metabolic disease. It is possible that offspring born to males with metabolic disease 
may not display overt growth restriction or metabolic problems at birth, but instead 
do so later in life. For example, previous epidemiological studies have indicated that 
offspring born with a low weight at birth are particularly vulnerable to detrimental 
health consequences if they undergo rapid ‘catch-up growth’ in their first few years 
of life (66). Therefore, following up children born to fathers with metabolic disease 
by measuring e.g. BMI, waist circumference and insulin resistance could yield insights 
into intergenerational effects of metabolic disease that may not be obvious at birth. 
The challenge with this type of study in humans would be to account for the 
influences of a shared ‘obesogenic’ environment. Nevertheless, such research could 




7.5.4 Other avenues of investigating intergenerational effects in humans 
One could argue that paternal smoking and aging have more robust and replicable 
effects on offspring health than does paternal obesity (227). Paternal smoking has 
more consistently than paternal obesity been linked to low offspring birth weight (69, 
227). High paternal age at conception has consistently been linked to an increased 
risk of some psychiatric disorders in his offspring (227, 417). Both age and smoking 
are reliably known to influence DNA methylation signatures (195, 196). Age also 
appears to predictably influence DNA methylation signatures of spermatozoa (372). 
Therefore, investigating germline epigenetic signatures of smoking and aging could 
yield more consistent findings in terms of their potential to influence the next 
generation. This may be an interesting avenue for future research that could also 
become a proof of principle for intergenerational effects of epigenetic change in 
humans. 
7.5.5 Continued interrogation of spermatozoal regulation of gene expression 
The comprehensive characterisation of genome-wide CpG methylation in 
spermatozoa described in Chapter 5 identified a number of specific CpG sites that 
should be taken forward for continued investigation. For example, there were sites 
that showed a uniform level of methylation in one of the tissues, but a bimodal or 
trimodal pattern of methylation in the other. This begs the question of how tissue 
specific transcription factors regulate leukocyte- and spermatozoal gene expression 
at these sites. Also, we identified CpG sites with a negative correlation of methylation 
between sperm and blood, i.e. that higher methylation in blood is correlated to lower 
methylation in sperm. This suggests that there are physiological or environmental 
factors that increase methylation levels in one tissue but decreases them in the other. 
Characterisation of such factors could yield fascinating insights into tissue-specific, 
dynamic regulation of gene expression. 
Following publication of our findings of DNA methylation in matched sperm and 
blood samples, we will make our data publicly available in manner equivalent to what 
has been done for studies of e.g. methylation correlation of blood and brain tissue 
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(368). This should be a valuable resource for the interpretation of data from blood-
based EWAS analyses. 
It will also be interesting to see if the CpG site that we identified as significantly 
associated with obesity in sperm and blood replicates in other studies of obesity 
associated DNA methylation in sperm. If so, we may have identified a hint of an 
obesity associated epigenetic signature in a tissue that has the potential to influence 
the next generation. 
7.5.6 Large scale analysis of obesity associated DNA methylation profiles in 
blood 
The study described in Chapter 6, in which I validated previously identified obesity 
associated CpG sites in a novel cohort of 96 lean and 96 obese males, constituted the 
first step in a large-scale analysis aimed to identify a robust and replicable obesity 
associated DNA methylation profile. The larger study will include 1000 lean and 1000 
obese males from the Norwegian Mother and Child cohort (MoBa) (401) (MRC 
reference code MR/P011799/1; title ‘Paternal obesity-associated DNA methylation: 
an investigation into its reproducibility, reversibility and association with fetal growth 
restriction’). 
Results from this investigation will be of value in understanding the pathogenesis of 
obesity, developing biomarkers for disease and identifying therapeutic targets. In 
addition, we aim to use results from this study to investigate whether paternal 
obesity could influence his offspring in ways that were not obvious from the studying 
offspring birth weight alone. With this aim, I have collected cord blood samples from 
the majority of infants born to parents participating in the Dad’s Health Study. The 
CpG sites that emerge as robustly associated with obesity in the large scale validation 
study will be analysed for enrichment in cord blood of infants born to obese fathers 
compared to cord blood from infants born to lean fathers. Some previous studies 
have indicated that paternal obesity is indeed associated with altered offspring DNA 
methylation profiles, however these studies have employed a candidate gene 
approach and been relatively small scale (153, 418). 
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7.5.7 Distinguishing between genetic and acquired paternal effects on fetal 
growth 
A significant challenge in interpreting results from studies suggesting that paternal 
obesity or insulin resistance increases the risk of fathering low birth weight offspring 
has been to distinguish between what is an effect of paternal genetics versus 
acquired paternal traits. More specifically, two studies that informed my PhD project 
both showed that whilst obese or insulin resistant men were more likely to father 
low birth weight offspring, they were also more likely to have been small at birth 
themselves (68, 69). 
Interestingly, novel research methods coupled with considerably increased sample 
sizes (>550,000 participants in total) have begun to distinguish between effects on 
fetal growth that are genetically driven by the mother versus those that are 
genetically driven by the fetus and those driven by an interaction between the two 
(419). In a longer perspective, it would be interesting to develop this research 
strategy further to tease apart the relative contributions of paternal genetic and 
paternal non-genetic effects on fetal growth. Such a study would of course also need 
to account for maternal genetic and non-genetic effects. As indicated by the above 
study, a sample size of hundreds of thousands of DNA samples from mother-father-
offspring trios are likely to be required to achieve this aim. 
7.6 Summary and Concluding Remarks 
The concept of epigenetic markers as mediators of inter- and transgenerational 
effects of acquired traits is still controversial. Indeed, some researchers suggest that 
stochastic genetic and epigenetic variation have more influence on the sperm 
epigenome than, for example, dietary insults (143). The work presented in this thesis 
does not prove epigenetic change as underlying associations between acquired 
parental phenotypes and offspring health. It does, however, present a number of 
findings which advance the field of epigenetics in intergenerational inheritance. 
I have performed the largest to date genome-wide characterisation of matched 
human sperm and blood samples. From this, I have demonstrated that the highly 
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discordant and practically completely uncorrelated DNA methylation profiles of 
sperm and blood necessitates studying germ cells, rather than proxy tissues, in 
analyses of intergenerational effects. Such findings are in accordance with previous 
research that has analysed the methylation co-variation between blood and less 
readily available tissues such as brain (368). I have also identified specific CpG sites in 
spermatozoa that are of particular interest in understanding sperm-specific 
regulation of gene expression, and the factors that it may be influenced by. Further, 
I have identified a novel obesity associated CpG site in sperm and blood that has not 
previously been identified in EWASs of blood only. Interestingly, however, 
methylation at the same CpG site has previously been identified as associated with 
obesity in liver (377).  
Comparison of spermatozoal DNA methylation to the DNA methylation profiles of 
>6,000 somatic tissue samples available on the Gene Expression Omnibus database 
allowed us to confirm that spermatozoal transcriptional regulation is highly distinct, 
most likely due cause overall transcriptional repression (210, 265). 
Further, I have performed a comprehensive systematic review of studies of DNA 
methylation in human spermatozoa, and generated a number of concrete 
recommendations for future research based on my findings. 
In a prospective cohort study, I have shown that the impact of paternal metabolic 
health on offspring birth weight is limited, at least across the spectrum of normal 
birth weights. From this, I have suggested ways forward in further elucidating the role 
of paternal traits, in particular insulin resistance, on the fetal growth of his offspring. 
Continuing this work is of considerable importance from a public health perspective 
as fetal development represents a crucial time in which interventions could have 
enduring and powerful effects on adult health and disease. 
I have begun to validate previously identified CpG sites associated with obesity with 




Human obesity and birth weight are incredibly complex phenotypes influenced by a 
multitude of genetic, environmental, gene-environment, behavioural and social 
factors. Research in this area is subject to numerous challenges. There is, however, 
enormous potential gains from their continued elucidation, both scientifically and 
from a public health perspective. Research presented in this thesis constitutes an 
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Appendix 1. Questionnaire for Participating Fathers 
  
 
Questionnaire for Fathers 
The Dad’s Health Study- A Study of Paternal Health, Offspring Birth Weight and Intergenerational Inheritance of 
Epigenetic Marks 
The Dad’s Health Study 
(A Study to Investigate the Influence of Paternal Health on his Baby’s Birthweight) 
QUESTIONNAIRE FOR FATHERS V2 7/2/2016 
This questionnaire asks you some questions about your health and background. 
All answers you give are confidential and will only be seen by the research team. 
We would be grateful if you would help us by answering all the questions.  
If you have any queries about any of the questions or would like some help in 
completing this questionnaire, please contact Dr Fredrika Asenius on 07926668506 
or karin.asenius.12@ucl.ac.uk 
Thank you very much for your help. 
Name 
  
Date of Birth 
  




Length of gestation 
  

































Appendix 3. List of the 192 primers included in the study of 








1 cg01024458 Blood.B 100 5 - 
2 cg04162316 Blood.CD4 232 5 + 
3 cg09315878 BMI.EWAS 323 3 - 
4 cg09554443 BMI.EWAS 106 1 - 
5 cg09491962 BMI.EWAS 271 5 - 
6 cg26673975 Blood.Gran 348 4 + 
7 cg16395997 BMI.EWAS 196 4 + 
8 cg09935388 BMI.EWAS 325 3 - 
9 cg26257082 BMI.EWAS 222 3 - 
10 cg07504977 BMI.EWAS 171 5 - 
11 cg25131632 Blood.B 100 5 - 
12 cg10837404 Blood.CD4 286 3 - 
13 cg18990407 Blood.Mono 326 3 + 
14 cg24145109 BMI.EWAS 254 5 - 
15 cg03725309 BMI.EWAS 206 5 - 
16 cg23172671 BMI.EWAS 271 5 + 
17 cg00431050 BMI.EWAS 285 5 - 
18 cg13738327 Blood.B 333 5 - 
19 cg26166854 Blood.CD4 350 3 + 
20 cg26961332 Blood.Gran 323 3 - 
21 cg23244761 Blood.Mono 273 3 - 
22 cg09032544 Blood.CD8 317 5 - 
23 cg11130778 Blood.Gran 350 5 - 
24 cg03538296 Blood.NK 306 5 - 
25 cg11673687 BMI.EWAS 350 3 - 
26 cg01455178 BMI.EWAS 308 3 - 
27 cg27106643 Blood.B 112 3 - 
28 cg11067179 Blood.CD8 228 3 - 
29 cg15013257 Blood.Gran 120 3 - 
30 cg12484113 BMI.EWAS 201 2 - 
31 cg13997435 BMI.EWAS 260 4 - 
32 cg10717869 BMI.EWAS 161 3 - 
33 cg17768768 Blood.B 289 5 + 
34 cg06164961 Blood.CD8 272 5 + 
35 cg17822325 BMI.EWAS 115 3 - 
36 cg15323828 BMI.EWAS 288 3 + 
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37 cg00244001 BMI.EWAS 350 3 - 
38 cg13828440 Blood.NK 147 5 + 
39 cg12593793 BMI.EWAS 119 2 - 
40 cg01101459 BMI.EWAS 284 3 + 
41 cg13400249 Blood.CD4 350 5 + 
42 cg13430807 Blood.Mono 163 5 - 
43 cg00851028 BMI.EWAS 338 5 - 
44 cg18174654 Blood.CD8 121 4 - 
45 cg00701951 Blood.Mono 254 4 - 
46 cg25217710 BMI.EWAS 298 3 + 
47 cg02079413 BMI.EWAS 274 5 + 
48 cg07679948 Blood.CD4 348 4 - 
49 cg04468741 Blood.Mono 231 5 - 
50 cg10092518 BMI.EWAS 275 4 - 
51 cg11986385 BMI.EWAS 282 4 - 
52 cg08777095 Blood.CD8 133 4 - 
53 cg16636767 Blood.Mono 320 3 + 
54 cg25001190 BMI.EWAS 221 5 - 
55 cg04869770 BMI.EWAS 332 4 - 
56 cg07136133 BMI.EWAS 287 4 - 
57 cg17260706 BMI.EWAS 344 4 - 
58 cg15159104 BMI.EWAS 350 5 - 
59 cg02426464 BMI.EWAS 350 5 - 
60 cg24824917 BMI.EWAS 230 3 - 
61 cg00417304 BMI.EWAS 123 5 - 
62 cg26894079 BMI.EWAS 298 4 - 
63 cg21670987 BMI.EWAS 121 3 - 
64 cg01798813 BMI.EWAS 212 4 - 
65 cg24174557 BMI.EWAS 277 5 - 
66 cg11376147 BMI.EWAS 207 4 - 
67 cg07217499 BMI.EWAS 317 5 - 
68 cg03508235 BMI.EWAS 281 5 - 
69 cg07037944 BMI.EWAS 158 2 - 
70 cg08877257 BMI.EWAS 182 4 - 
71 cg19217955 BMI.EWAS 105 3 + 
72 cg13243168 BMI.EWAS 130 5 - 
73 cg12917475 BMI.EWAS 234 3 - 
74 cg02119938 BMI.EWAS 322 1 - 
75 cg22695339 BMI.EWAS 282 3 + 
76 cg18772573 BMI.EWAS 282 4 + 
77 cg03433986 BMI.EWAS 168 5 - 
78 cg03523676 BMI.EWAS 347 5 - 
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79 cg07728579 BMI.EWAS 245 4 - 
80 cg14020176 BMI.EWAS 223 5 - 
81 cg00994936 BMI.EWAS 193 3 - 
82 cg27117792 BMI.EWAS 297 5 - 
83 cg26357885 BMI.EWAS 191 5 - 
84 cg20507228 BMI.EWAS 215 5 - 
85 cg11024682 BMI.EWAS 291 1 + 
86 cg10508317 BMI.EWAS 280 5 - 
87 cg11152384 BMI.EWAS 292 4 - 
88 cg27614723 BMI.EWAS 124 2 - 
89 cg00863378 BMI.EWAS 350 2 - 
90 cg16611584 BMI.EWAS 261 3 - 
91 cg22950899 BMI.EWAS 215 3 + 
92 cg11660018 BMI.EWAS 316 4 - 
93 cg00973118 BMI.EWAS 267 4 + 
94 cg24457403 BMI.EWAS 310 4 - 
95 cg26651978 BMI.EWAS 219 5 - 
96 cg19574327 BMI.EWAS 226 5 - 
97 cg25096107 BMI.EWAS 153 3 - 
98 cg08857797 BMI.EWAS 303 2 - 
99 cg02008402 BMI.EWAS 267 5 + 
100 cg10734665 BMI.EWAS 209 4 - 
101 cg03078551 BMI.EWAS 249 5 - 
102 cg09777883 BMI.EWAS 349 4 - 
103 cg19750657 BMI.EWAS 164 5 + 
104 cg01419914 BMI.EWAS 136 5 - 
105 cg07814318 BMI.EWAS 339 5 - 
106 cg09109383 BMI.EWAS 206 4 + 
107 cg27050612 BMI.EWAS 339 4 + 
108 cg20981127 BMI.EWAS 348 5 - 
109 cg06876354 BMI.EWAS 218 4 - 
110 cg00916899 BMI.EWAS 213 5 - 
111 cg04924511 BMI.EWAS 288 5 - 
112 cg19266387 BMI.EWAS 146 5 - 
113 cg15442888 BMI.EWAS 244 5 - 
114 cg13305415 BMI.EWAS 233 5 - 
115 cg15835542 BMI.EWAS 229 5 - 
116 cg04557677 BMI.EWAS 188 5 - 
117 cg15357118 BMI.EWAS 287 5 - 
118 cg18217136 BMI.EWAS 241 4 - 
119 cg13010621 BMI.EWAS 159 5 - 
120 cg03327570 BMI.EWAS 232 5 - 
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121 cg05628049 BMI.EWAS 227 5 - 
122 cg23576855 BMI.EWAS 190 4 + 
123 cg16721489 BMI.EWAS 189 4 + 
124 cg08309687 BMI.EWAS 349 5 - 
125 cg02286155 BMI.EWAS 311 1 - 
126 cg17178175 BMI.EWAS 236 5 - 
127 cg01881899 BMI.EWAS 268 1 + 
128 cg04816311 BMI.EWAS 160 4 + 
129 cg02560388 BMI.EWAS 345 5 + 
130 cg00108715 BMI.EWAS 334 5 - 
131 cg22143698 BMI.EWAS 276 5 - 
132 cg09222732 BMI.EWAS 276 5 - 
133 cg23647610 BMI.EWAS 344 5 - 
134 cg08548559 BMI.EWAS 350 2 - 
135 cg10179300 BMI.EWAS 331 1 - 
136 cg09956615 BMI.EWAS 158 4 - 
137 cg19017142 BMI.EWAS 132 4 - 
138 cg27115863 BMI.EWAS 269 2 - 
139 cg13084458 BMI.EWAS 259 5 - 
140 cg08215255 BMI.EWAS 210 5 - 
141 cg24776142 BMI.EWAS 299 2 + 
142 cg00634542 BMI.EWAS 196 4 - 
143 cg07730360 BMI.EWAS 255 5 - 
144 cg06690548 BMI.EWAS 336 1 + 
145 cg03957124 BMI.EWAS 257 5 - 
146 cg26804423 BMI.EWAS 262 4 - 
147 cg23417875 BMI.EWAS 218 5 - 
148 cg03318904 BMI.EWAS 168 4 - 
149 cg01671681 BMI.EWAS 122 5 - 
150 cg01300684 BMI.EWAS 226 4 - 
151 cg25570328 BMI.EWAS 281 5 + 
152 cg09349128 BMI.EWAS 269 1 + 
153 cg00673344 BMI.EWAS 265 5 + 
154 cg00850073 BMI.EWAS 329 4 - 
155 cg00585790 BMI.EWAS 305 4 + 
156 cg26361535 BMI.EWAS 277 1 - 
157 cg02650017 CRP/BMI 250 4 + 
158 cg08118908 Smoking 299 5 + 
159 cg25197194 Smoking/BMI 280 5 - 
160 cg01677628 Obesity SNP associated 180 4 + 
161 cg26545918 Obesity SNP associated 277 5 - 
162 cg10062919 Smoking 344 4 - 
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163 cg09363892 Obesity SNP associated 153 5 - 
164 cg10639395 Obesity SNP associated 304 5 - 
165 cg00834536 Obesity SNP associated 267 5 - 
166 cg13591783 BMI.EWAS 316 4 - 
167 cg22304262 CRP/BMI 286 5 - 
168 cg27269962 BMI.EWAS 213 5 - 
169 cg13840239 BMI.EWAS 163 5 - 
170 cg12992827 CRP/BMI 260 5 + 
171 cg00073090 Smoking 159 5 - 
172 cg01844514 BMI.EWAS 317 4 - 
173 cg14264316 BMI.EWAS 199 4 - 
174 cg17560136 BMI.EWAS 191 4 - 
175 cg19406367 Smoking 320 4 - 
176 cg02571142 BMI.EWAS 330 5 - 
177 cg19589396 BMI.EWAS 127 5 - 
178 cg14476101 CRP 349 4 - 
179 cg11028075 Smoking 290 4 - 
180 cg26077378 Smoking 295 5 + 
181 cg22864340 Obesity SNP associated 257 4 + 
182 cg00489954 Obesity SNP associated 240 4 + 
183 cg23078228 Obesity SNP associated 219 4 - 
184 cg07960624 BMI.EWAS 181 4 - 
185 cg12054453 CRP 186 4 + 
186 cg19821297 CRP 261 4 + 
187 cg11700584 Smoking 291 4 + 
188 cg26952928 BMI.EWAS 308 4 + 
189 cg17592360 Obesity SNP associated 127 5 - 
190 cg25392060 BMI.EWAS 195 1 - 
191 cg15497724 Obesity SNP associated 177 4 - 
192 cg05149343 Obesity SNP associated 253 5 + 
Appendix 3 Table 1. List of primers included in the profiling of obesity associated CpG methylation 
in blood. 
‘Marker’ refers to the reason of primer inclusion where BMI.EWAS = identified from EWASs of BMI, 
smoking = control probes for smoking, obesity SNP associated = sites previously identified as 
influenced by obesity associated SNPs, and CRP = control probes for inflammation. Blood.Mono, 




Appendix 4. FDR corrected p-values for the t-test of DNA 
methylation differences between the lean and obese participants 













































































Appendix 5.  Example of a FastQC quality control report of the 
Illumina MiSeq data in the study of obesity associated CpG 
methylation in blood 
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